[
    "The sample is a clinical trial for the treatment of schizophrenia using the drug dronabinol. The trial is in phase 1/phase 2 and the disease being studied is schizophrenia. The icd-10 codes associated with the disease are listed as [\"F20.0\", \"F20.1\", \"F20.2\", \"F20.3\", \"F20.5\", \"F20.89\", \"F20.9\"]. The eligibility criteria for participants include being between 18 and 50 years old, diagnosed with schizophrenia, chronic cannabis users who have used for at least 1 year, using cannabis at least once weekly, currently being treated with antipsychotic medication, and must be on the same dose of antipsychotic medication for at least 3 months. Females of childbearing potential must use an adequate form of birth control while participating and participants will be required to have blood pressures greater than 90/60 and less than 140/90. Exclusion criteria include use of illicit drugs other than cannabis, any psychiatric hospitalizations within 3 months, pregnancy in females, and taking clozapine.",
    "The sample is a clinical trial for a drug called fx005, which is being tested for its effectiveness in treating osteoarthritis of the knee. The trial is in phase 1/phase 2 and the participants must be at least 40 years old and have been diagnosed with unilateral or bilateral osteoarthritis of the knee for at least 6 months. The trial has specific inclusion and exclusion criteria, including Kellgren-Lawrence grades II or III, a specific score for the WOMAC A subscale (pain), and a body mass index of \u2264 40 kg/m2. Participants must also be willing to comply with the study procedures and visit schedule and abstain from using restricted medications during the study. Women who are pregnant, nursing, or likely to become pregnant during the study are excluded from participating.",
    "The sample is a clinical trial for patients with advanced lung adenocarcinoma in either stage IIIB or stage IV. The trial is in phase 1/phase 2 and involves the drugs erlotinib hydrochloride and hsp90 inhibitor auy922. The eligibility criteria include having a previous response to an EGFR-TKI or a documented mutation in the EGFR gene, radiographic progression by RECIST during treatment with erlotinib/gefitinib, and measurable (RECIST) indicator lesion not previously irradiated. Patients must also have undergone a biopsy after the development of acquired resistance and have a Karnofsky Performance Status >= 70% OR ECOG/WHO Performance Status 0-1. The exclusion criteria include symptomatic CNS metastases, prior treatment with any HSP90 inhibitor compounds, and other concurrent severe and/or uncontrolled medical conditions that could cause unacceptable safety risks or compromise compliance with the protocol.",
    "The sample is a clinical trial with a combination of phase 1 and phase 2. The trial is focused on treating esophageal and gastric adenocarcinoma using a combination of drugs including panitumumab, epirubicin, oxaliplatin, and xeloda. The eligibility criteria for the trial includes patients with histologically or cytologically confirmed diagnosis of adenocarcinoma of the stomach, gastroesophageal junction, or lower third of the esophagus, AJCC stage II-IIIB (gastric) or IIA-IVA (esophageal). Patients must not have had prior radiation or chemotherapy including anti-EGFR or vascular endothelial growth factor (VEGF) antibody or tyrosine kinase inhibitor treatments. Patients must also have normal organ, metabolic and marrow function. The trial has a list of exclusion criteria including evidence of distant metastatic disease, T4 tumor on initial staging studies, and history of interstitial lung disease. Women who test positive for serum or urine pregnancy test < 72 hours before randomization or are breast feeding are also excluded. The trial requires patients to have the ability to understand and the willingness to sign and date a written IEC/IRB approved informed consent form.",
    "The sample is a clinical trial for patients with lymphoma, specifically diffuse large cell B-cell NHL, who have failed prior systemic chemotherapy with or without monoclonal antibody-based therapies. The trial is in phase 1/phase 2 and the drug being tested is clofarabine. The eligibility criteria include being at least 18 years old, having measurable disease, having an ECOG performance status of 0, 1, or 2, and having a life expectancy greater than 12 weeks. The exclusion criteria include previously untreated NHL, history of T-cell lymphoma, and any significant concurrent disease or illness that would compromise patient safety or compliance.",
    "The sample is a clinical trial for patients with certain types of cancer, including brain and central nervous system tumors, extragonadal germ cell tumor, ovarian cancer, and testicular germ cell tumor. The trial is in phase 1/phase 2 and involves the use of drugs such as cisplatin, gemcitabine hydrochloride, ifosfamide, and paclitaxel. The eligibility criteria include having unresectable metastatic disease, rising serum markers, and being in first relapse after a single prior cisplatin-containing combination chemotherapy. Patients must also meet certain medical and psychological requirements and have no prior malignancy except successfully treated nonmelanoma skin cancer or superficial bladder cancer. The trial is designed to test the effectiveness of the chemotherapy schedule on patients who meet these criteria.",
    "The sample is a clinical trial for breast cancer patients in phase 1/phase 2. The trial is testing the effectiveness of three drugs - fulvestrant, mk-0646, and dasatinib - on hormone receptor-positive HER2-negative metastatic breast cancer. The trial has eligibility criteria that include having received up to one line of endocrine therapy for metastatic disease, having measurable or evaluable disease, being postmenopausal, and having certain laboratory values within normal ranges. Patients must also consent to biopsies. Exclusion criteria include having certain medical conditions or medications, having active or untreated brain metastasis, and having bone-only metastases.",
    "The sample is a clinical trial with a phase 1/phase 2 design, aimed at testing the efficacy of various drugs in treating a range of diseases, including acute and chronic leukemia, myelodysplastic syndrome, non-Hodgkin lymphoma, and chronic lymphocytic leukemia. The trial involves patients who meet specific eligibility criteria, including being under 60 years old, having a related donor who is genotypically HLA-matched, and having adequate cardiac and pulmonary function. The trial also has exclusion criteria, such as being seropositive for HIV or hepatitis B or C, having active infections, or having uncontrolled central nervous system disease involvement. The trial involves a range of drugs, including regulatory T-cells, conventional T-cells, melphalan, thiotepa, and anti-thymocyte globulin, rabbit, among others. The trial aims to determine the safety and efficacy of these drugs in treating the specified diseases.",
    "The sample is a clinical trial with a combination of phase 1 and phase 2. The trial is focused on two types of cancer, esophageal neoplasms and stomach neoplasms, and their corresponding ICD-10 codes. The trial is testing the effectiveness of two drugs, docetaxel and oxaliplatin. The eligibility criteria for the trial includes having adenocarcinoma of gastric-esophagal junction, being in stage II to III, and having unidimensional measurable disease. The exclusion criteria includes having had surgery of primary tumor, metastasis, or prior chemo- or radiotherapy.",
    "The sample is a record of a clinical trial with a phase 1/phase 2 designation. The trial is focused on sickle cell disease and pulmonary hypertension, with a list of corresponding ICD-10 codes. The only drug being tested is hydroxyurea. The eligibility criteria for the trial includes age between 10 and 25 years old, confirmed diagnosis of sickle cell disease with hemoglobin SS, SC or S-B^0 thalassemia, and a tricuspid regurgitant jet velocity (TRJV) equal to or greater than 2.5 m/sec on 2 baseline Doppler echocardiograms at least 3 months apart. Exclusion criteria includes patients already being treated with hydroxyurea, patients on a chronic transfusion protocol, patients with evidence of hepatic or renal dysfunction, pregnant patients, and patients with documented causes of severe pulmonary hypertension other than from SCD.",
    "The sample is a clinical trial with a combination of F16IL2 and doxorubicin for patients with advanced solid tumors or breast cancer. The trial has both Phase I and Phase II cohorts. Patients in Phase I cohort 1 must not be suitable for doxorubicin/anthracycline therapy but must be considered suitable for F16IL2 therapy alone. Patients in Phase II must have histologically or cytologically confirmed breast cancer and must not have received a cumulative anthracycline dose of more than 300 mg/m2 of doxorubicin or of more than 600 mg/m2 of epirubicin or pegylated or non-pegylated liposomal doxorubicin, prior to study entry, in order to avoid anthracycline-associated cardiotoxicity. The eligibility criteria include age, previous treatments, measurable lesions, hematologic, liver and renal function, life expectancy, negative test for human immunodeficiency virus, negative serum pregnancy test for females of childbearing potential, and willingness to comply with the scheduled visits, treatment plan, laboratory tests and other study procedures. The exclusion criteria include active infections, known brain metastases, chronic active hepatitis or active autoimmune diseases, history of acute or subacute coronary syndromes, heart insufficiency, irreversible cardiac arrhythmias, LVEF \u2264 50%, uncontrolled hypertension, ischemic peripheral vascular disease, severe rheumatoid arthritis, severe diabetic retinopathy, recovery from major trauma including surgery within 4 weeks of administration of study treatment, known history of allergy to IL-2, doxorubicin, or other intravenously administered human proteins/peptides/antibodies, pregnancy or breast feeding, chemotherapy or radiation therapy within 4-6 weeks of the administration of study treatment, cumulative exposure to anthracycline-containing chemotherapy prior to study entry precluding the application of at least an additional 150 mg/m2 doxorubicin, treatment with an investigational study drug within 6 weeks before beginning of treatment with F16-IL2, previous in vivo exposure to monoclonal antibodies for biological therapy in the 6 weeks before administration of study treatment, growth factors or immunomodulatory agents within 7 days of the administration of study treatment, neuropathy > Grade 1, and patient requires or is taking corticosteroids or other immunosuppressant drugs on a long-term basis.",
    "The sample is a clinical trial for patients with non-small-cell lung carcinoma in phase 1/phase 2. The trial requires patients to have a histologic or cytologic diagnosis of NSCLC, Stage IV or selected stage IIIB, and to have been previously treated with at least one platinum-based chemotherapy. Patients must also meet various other eligibility criteria, including having a performance status of 0-2 on the ECOG criteria, having at least one unidimensionally measurable lesion meeting Response Evaluation Criteria in Solid Tumors, and having an estimated life expectancy of at least 8 weeks. The trial excludes patients with small-cell lung cancer alone or with NSCLC, unresolved chronic toxic effects from previous anticancer therapy, and various other conditions.",
    "The sample is a record from a clinical trial table that includes information about the phase of the trial, the diseases being studied, the corresponding ICD-10 codes, the drugs being used, and the eligibility criteria for participants. In this particular sample, the trial is in phase 1/phase 2 and is focused on end stage renal disease and renal transplant. The ICD-10 codes associated with these diseases are listed. The drugs being used in the trial include anti-thymocyte globulin, tol101, steroids, tacrolimus, and mycophenolate mofetil (mmf). The eligibility criteria for participants are also listed, including age, previous medical history, and other factors that may exclude someone from participating in the trial.",
    "The sample is a clinical trial for patients with recurrent or metastatic squamous cell carcinoma of the head and neck. The trial is in phase 1/phase 2 and involves the use of drugs such as rad001, cetuximab, cisplatin, and carboplatin. The eligibility criteria include having measurable disease, no prior monoclonal antibodies or small molecule tyrosine-kinase inhibitors for the treatment of recurrent or metastatic SCCHN, and normal organ and marrow function. Exclusion criteria include patients with known brain metastases, history of allergic reactions to compounds of similar chemical or biologic composition to RAD001, and impairment of gastrointestinal function or gastrointestinal disease that may significantly alter the absorption of RAD001. The trial requires patients to be able to receive adequate enteral nutrition by mouth or through a G-tube device and to use adequate contraception if they are of child-bearing potential.",
    "The sample is a record from a clinical trial table that includes information about the phase of the trial, diseases being studied, icd-10 codes of the diseases, drugs being tested, and eligibility criteria for participants. In this particular sample, the trial is in phase 1/phase 2 and is focused on studying solid tumors and stage IV gastric cancer. The drug being tested is paclitaxel. The eligibility criteria for participants include being between 18 and 70 years old, having advanced or metastatic solid cancer with no available standard therapy or having failed at least once with standard therapy, having adequate bone marrow, liver, and kidney function, having an Eastern Cooperative Oncology Group performance status of \u2264 2, having a life expectancy of 3 months or more, and providing written informed consent. Exclusion criteria include having major infectious or neurological disease, brain metastasis or hematologic malignancy, having undergone surgery, radiation therapy, hormone or chemotherapy within 4 weeks prior to the beginning of investigational drug administration, having a history of failure to the taxane line of chemotherapy, and having other severe internal diseases or heart disease. Pregnant women, nursing mothers, or patients of childbearing age who did not agree to contraception are also excluded.",
    "The sample is a record from a clinical trial table that includes information about the phase of the trial, the diseases being studied, the ICD-10 codes associated with those diseases, the drugs being used in the trial, and the eligibility criteria for participants. In this particular sample, the trial is a combination of phase 1 and phase 2, and is focused on multiple myeloma and plasma cell neoplasm. The drugs being used in the trial are bortezomib, melphalan, and pegylated liposomal doxorubicin hydrochloride. The eligibility criteria include a diagnosis of multiple myeloma, specific disease characteristics, and patient characteristics such as ECOG performance status, life expectancy, and blood counts. The sample also includes information about prior concurrent therapy and restrictions on concurrent treatment during the trial.",
    "The sample is a clinical trial for breast cancer patients in phase 1/phase 2. The trial is testing the effectiveness of three drugs: xl147 (sar245408), xl765 (sar245409), and letrozole (femara). The eligibility criteria for the trial include having histologically confirmed breast cancer that is ER+ and/or PGR+, negative for HER2, and refractory to a nonsteroidal aromatase inhibitor. The subject must also have either disease progression or disease recurrence. In addition, the subject must be a postmenopausal female, have an ECOG performance status of \u2264 1, and have adequate organ and marrow function. The trial also has exclusion criteria, such as having received prior treatment with a selective inhibitor of PI3K, AKT, and/or mTOR, or having untreated, symptomatic, or progressive brain metastases. The subject must be able to understand and comply with the protocol requirements and have signed the informed consent document.",
    "The sample is a record of a clinical trial with a phase 1/phase 2 designation. The trial is focused on urinary incontinence as the disease being studied. The icd-10 codes associated with the disease are listed as [\"['N39.492', 'R32', 'R39.81', 'N39.498', 'L24.A2']\"]. The trial involves two drugs, uish001 and a matching placebo. The eligibility criteria for the trial include women who have moderate to severe urge, stress or mixed Urinary Incontinence, while exclusion criteria include medical history of migraines, neurologic problems, swallowing disorder, stroke or severe depression, medical history of heart failure, peripheral edema or moderate to severe asthma or chronic obstructive pulmonary disease (COPD), certain restricted medications, and any other condition that would interfere with the safety of the subject.",
    "The sample is a clinical trial for postmenopausal women with histology-confirmed invasive primary breast cancer who have completed primary surgical or radiotherapy with or without adjuvant chemotherapy and are candidates to receive adjuvant therapy with aromatase inhibitors. The trial is in phase 1/phase 2 and includes patients with breast cancer and bone diseases. The trial will test the effectiveness of vitamin D as a treatment option. The eligibility criteria include having a life expectancy of at least 5 years, Eastern Clinical Oncology Group (ECOG) performance status 0-2, and the ability to understand and sign a written informed consent document. Exclusion criteria include the use of medications affecting bone metabolism, recent history of excessive alcohol or drug use, and pregnancy or nursing. Survivors of previous cancers and HIV-positive subjects will not be excluded.",
    "The sample is a clinical trial for lung adenocarcinoma patients in phase 1/phase 2. The trial involves the use of erlotinib with cetuximab as a treatment. The eligibility criteria include having pathologic evidence of lung adenocarcinoma confirmed at MSKCC, measurable indicator lesions not previously irradiated, radiographic progression by RECIST during treatment with erlotinib, and having received treatment with erlotinib for more than 3 months. Other criteria include having a documented mutation in EGFR exons 19 or 21, Karnofsky performance status \u2265 or = to 70%, and meeting certain medical requirements such as normal bilirubin levels and negative pregnancy tests. Exclusion criteria include having symptomatic CNS lesions, uncontrolled intercurrent illness, prior cetuximab or panitumumab treatment, and current grade 2 or greater skin toxicity on erlotinib therapy.",
    "The sample is a clinical trial for a drug called \"xoma 052\" and its placebo for the treatment of type 2 diabetes. The trial is a combination of phase 1 and phase 2. The eligibility criteria for the trial include having a fasting blood glucose concentration of at least 126 mg/dL or symptoms of hyperglycemia with a casual/random plasma glucose value of at least 200 mg/dL, having HbA1c levels between 7.5% and 12%, having stable type 2 diabetes for more than 6 months, being between the ages of 18 and 70, having a weight between 80 lbs and 325 lbs, having a BMI between 23 and 40 kg/m2, and agreeing not to change diet and exercise regimen during the trial. Exclusion criteria include the use of certain medications, recent changes in diabetes medication, certain medical conditions, and pregnancy or breastfeeding.",
    "The sample is a record from a clinical trial table that includes information about the trial phase, diseases being studied, ICD-10 codes for those diseases, drugs being tested, and eligibility criteria for participants. In this particular sample, the trial is in phase 1/phase 2 and is studying several types of colorectal cancer. The drugs being tested are panitumumab and conatumumab. The eligibility criteria include having metastatic adenocarcinoma of the colon or rectum, documented disease progression, and meeting certain hematologic, renal, and hepatic function limits. There are also exclusion criteria, such as having a history of other primary cancer or known presence of central nervous system metastases.",
    "The sample is a record of a clinical trial with a phase 1/phase 2 designation. The trial is focused on the treatment of renal cell carcinoma, and the table includes a list of disease names and ICD-10 codes, as well as a list of drug names. The eligibility criteria for the trial are also included, with specific requirements for the diagnosis of RCC, prior treatment regimens, and disease measurability. The exclusion criteria are also listed, including the presence of acute infection or other significant systemic illness, central nervous system involvement by malignancy, history of other cancer within 5 years, and previous receipt of rIL-21 or sorafenib.",
    "The sample is a clinical trial for a vaccine enhancement patch for the A/H5N1 antigen. The trial is in phase 1/phase 2 and is looking for healthy adult males or females between the ages of 18-49 to participate. The eligibility criteria includes signing an informed consent, having no clinically significant laboratory abnormalities or physical examination abnormalities, and not having any known allergies to the A/H5N1 antigen or adhesives. Participants must also not have any coagulation disorders or be taking any anticoagulant medication within 30 days prior to vaccination. They must not have participated in any research involving investigational product within 30 days before planned date of vaccination or planned participation during study period. Additionally, they must not have donated or received blood or blood products such as plasma within the three months before planned date of vaccination or planned donation or use during the study period. Participants must not have received or planned to receive any licensed vaccines within 2 weeks (inactivated vaccines) or 4 weeks (live vaccines) prior to planned date of vaccination or planned receipt of any licensed vaccine during the first 42 days on study. They must not have previous or planned vaccination with any vaccine containing an oil in water emulsion adjuvant or previous or planned vaccination with pandemic vaccine against A/H5N1 or previous proven contact with A/H5N1 wild type virus. Participants must not have ever received investigational enterotoxigenic E. coli LT, or LT (R192G) or NasalFlu, Berna Biotech, Ltd. Ever received cholera toxin or vaccine. They must not have recent or regular use of oral, topical or injected steroid medications within 30 days prior to vaccination or planned use during the study period. Use of immunosuppressive systemic steroid medications including inhaled steroids within three months prior to vaccination or planned use during the study period is also not allowed. Comorbid conditions or treatments that are immunosuppressive, including cancer, diabetes, and end-stage renal disease, as determined by the Investigator, are also not allowed. Participants must not have positive serology for HIV-1, HIV-2, HBsAg, or HCV, history of severe atopy, medical history of acute or chronic skin disease at vaccination area, active skin allergy, signs of acute skin infection, sunburn or skin abnormalities at the vaccination area including fungal infections, severe acne, active contact dermatitis, or a history of keloid formation, hirsute at vaccination area, artificial tanning over the duration of the study including the screening period, visible tattoos or marks at the vaccination area that would prevent appropriate dermatologic monitoring of the vaccination site, fever greater than or equal to 38.0\u00b0C at the time of planned vaccination, suspicion of or recent history of alcohol or substance abuse, women who are pregnant or breastfeeding, acute illness at screening or at the time of planned vaccination, ever had a serious reaction to prior influenza vaccination, developed a neurological disorder following a previous influenza vaccination or have any acute and evolving neurological disorder, employee of the investigational site or sponsor, and history of employment in bird or poultry industries or considerable exposure to birds.",
    "The sample is a record of a clinical trial with a phase 1/phase 2 designation. The trial is focused on the treatment of rectal carcinoma, with a list of associated ICD-10 codes. The trial involves the use of two drugs, s-1 and oxaliplatin. The eligibility criteria for the trial include having locally advanced and non-metastatic rectal adenocarcinoma, being able to undergo R0 resection, having no prior therapy, having a performance status of 0-1 on the ECOG scale, having normal organ and marrow function, and having sufficient oral intake. The exclusion criteria include a history of serious allergic reaction, complications such as sensory neurotoxicity or serious diarrhea, pregnancy or lactation in females, and having another malignancy in the past 5 years except for early stage cancer that was cured by local treatment.",
    "The sample is a record from a clinical trial table that includes information about the phase of the trial, diseases being studied, icd-10 codes of the diseases, drugs being tested, and eligibility criteria for participants. In this particular sample, the trial is in phase 1/phase 2 and is studying the effects of levonorgestrel on healthy individuals. The eligibility criteria include having a BMI greater than or equal to 18, refraining from excessive alcohol use, and not being pregnant or lactating. There are also several exclusion criteria, such as having a history of drug or alcohol abuse, known or suspected breast or endometrial carcinoma, and using certain medications that may interfere with the efficacy of hormone contraceptives.",
    "The sample is a clinical trial for Hodgkin's disease, in which patients with clinical stage IIB, III, or IV and no prior antitumor therapy are eligible to participate. The trial is a combination of phase 1 and phase 2. The trial involves the use of drugs such as prednisone, vinblastine, doxorubicin (adriamycin), and gemcitabine. The eligibility criteria include age between 60 to 75 years, WHO performance status 0-2, normal pulmonary function, and written informed consent. However, patients with certain histologies, leukocytes less than 2,500/microL, and platelets less than 100,000/microL are excluded from the trial.",
    "The sample is a record from a clinical trial table that includes information about the phase of the trial (phase 1/phase 2), a list of diseases (hematologic malignancies, acute leukemia, myelodysplastic syndromes, Hodgkin's lymphoma, non-Hodgkin's lymphoma, myeloma, and chronic myelogenous leukemia), a list of corresponding ICD-10 codes, a list of drugs (fludarabine, thiotepa, and melphalan), and eligibility criteria for patients to participate in the trial. The eligibility criteria include having a high-risk hematologic or oncologic diagnosis, having already received front-line therapy, having a related donor who is a 4 antigen match at the HLA-A, B, C, and DR loci, and meeting certain organ function and performance status requirements. There are also exclusion criteria, such as having a low performance status, a high HCT-CI score, being HIV positive, or having active involvement of the central nervous system with malignancy. Donor selection is also described in compliance with certain regulations and program SOPs.",
    "The sample is a clinical trial for non-small cell lung cancer patients, with a combination of pemetrexed and cisplatin drugs in both phase 1 and phase 2. The trial has eligibility criteria for patients, including being at least 18 years old, having adequate blood, liver, lungs, and kidney function, and being able to visit the doctor's office once a week. Female patients of child-bearing potential must test negative for pregnancy and both male and female patients must agree to use a reliable method of birth control during and for 3 months following the last dose of study drug. The trial also has exclusion criteria, including previous chemotherapy or thoracic radiation therapy, recent treatment with an unapproved drug, pregnancy or breastfeeding, and unsuitability or unwillingness to take certain supplements.",
    "The sample is a clinical trial for patients with moderate to severe plaque psoriasis. The trial is in phase 1/phase 2 and involves the use of the drug Humira, followed by Humira plus three B vitamins. The eligibility criteria include being 18 years or older, having a negative pregnancy test, and agreeing to use medically acceptable contraception. Patients must also be willing and able to self-administer subcutaneous injections or have a qualified person available to administer them. Exclusion criteria include having erythrodermic, pustular, or guttate psoriasis, a history of drug or alcohol abuse, and being pregnant or nursing. The trial requires patients to attend all study visits and comply with protocol requirements.",
    "The sample is a clinical trial with a combination of phase 1 and phase 2. The trial is focused on testing the effectiveness of d-methadone and placebo drugs on patients suffering from chronic pain caused by various types of cancer. The trial includes patients with diseases such as bladder cancer, breast cancer, colon cancer, and others. The eligibility criteria include being 18 years or older, having chronic pain with an average intensity of at least 3 on a scale of 0-10, and having a Karnofsky Performance Score (KPS) of at least 80. Patients must also give informed consent to participate in the study and have a negative urine pregnancy test. The exclusion criteria include known hypersensitivity to methadone, hepatic function tests greater than 2 times the upper limit of normal, and neurologic or psychiatric disease that could compromise data collection.",
    "The sample is a clinical trial for patients with multiple myeloma in phase 1/phase 2. The trial involves the use of drugs such as doxil, melphalan, and bortezomib. The eligibility criteria include being previously diagnosed with multiple myeloma, having progressive disease, being 18 years or older, having a life expectancy of at least 3 months, and meeting certain medical requirements such as having a certain level of platelets and bilirubin. The exclusion criteria include being pregnant or breastfeeding, having a history of allergic reactions to certain compounds, having certain medical conditions such as severe heart failure or uncontrolled arrhythmias, and having received certain types of chemotherapy or corticosteroids.",
    "The sample is a clinical trial for patients with advanced stage IV non-small cell lung cancer who have evidence of inoperable local recurrence or metastasis. The trial is in phase 1/phase 2 and the drug being tested is abi-007. The eligibility criteria include being 18 years or older, having no other active malignancy, having measurable disease documented radiographically, and having received no prior chemotherapies for the treatment of metastatic disease. Patients must also have certain levels of blood counts, liver function tests, and alkaline phosphatase levels. They must have an expected survival of greater than 12 weeks and an ECOG performance status of 0-1. Patients or their legally authorized representative or guardian must have agreed to participate in the study and signed the Informed Consent form prior to participation in any study-related activities.",
    "The sample is a clinical trial for phase 1/phase 2, which involves patients with various types of tumors such as brain and central nervous system tumors, extragonadal germ cell tumor, ovarian cancer, teratoma, and testicular germ cell tumor. The trial uses drugs such as carboplatin, ifosfamide, and paclitaxel. The eligibility criteria for patients include having a confirmed germ cell tumor, measurable disease or elevated serum tumor markers, advanced disease resistant to cisplatin-based chemotherapy, and adequate medical condition for general anesthesia. Patients must also meet certain medical requirements such as platelet count, WBC count, and creatinine clearance. Prior concurrent therapy is also taken into consideration.",
    "The sample is a clinical trial for patients with hepatocellular carcinoma, a type of liver cancer. The trial is in phase 1/phase 2 and involves the drug sorafenib. The eligibility criteria include having unresectable HCC with or without systemic metastases, being mentally competent to provide written informed consent, having measurable disease, and meeting certain blood test results. Exclusion criteria include having had previous external beam radiation therapy to the liver, abnormal liver function tests, and having had prior chemotherapy or other medical agents used to treat hepatocellular carcinoma. The trial also has specific requirements for hepatic arterial anatomy and lung shunt fraction.",
    "The sample is a clinical trial with a combination of phase 1 and phase 2. The trial is focused on two diseases, postural orthostatic tachycardia syndrome and orthostatic intolerance, and their associated ICD-10 codes. The trial involves the use of three drugs, droxidopa, atenolol, and placebos. The eligibility criteria for the trial include meeting the CDC criteria for chronic fatigue syndrome and having evidence of postural tachycardia syndrome with symptoms of orthostatic intolerance. Exclusion criteria include being pregnant or lactating, having certain medical conditions such as coronary artery disease or glaucoma, and being enrolled in other studies using investigational products.",
    "The sample is a clinical trial for rheumatoid arthritis, with a combination of phase 1 and phase 2. The trial involves the use of abatacept or placebo, administered both intravenously and subcutaneously. The eligibility criteria for participants include a diagnosis of RA with active disease for at least one year, a certain number of swollen and tender joints, and stable use of methotrexate or methotrexate plus one other oral DMARD for at least three months. Exclusion criteria include recent bacterial infections, certain lab test abnormalities, a history of cancer within the past five years, and exposure to certain drugs or biologics. Participants must also not have been exposed to live vaccines.",
    "The sample is a record from a clinical trial table that includes information about the trial's phase, diseases being studied, ICD-10 codes associated with those diseases, drugs being used in the trial, and eligibility criteria for participants. In this particular sample, the trial is in phase 1/phase 2 and is focused on hematologic malignancies. The ICD-10 codes associated with these malignancies are listed, as well as the drugs being used in the trial. The eligibility criteria for participants are also listed, including age, performance status, life expectancy, and other medical conditions that would exclude someone from participating in the trial.",
    "The sample is a clinical trial for patients with metastatic or recurrent gastric cancer who have received prior treatment for advanced disease. The trial is in phase 1/phase 2 and involves the use of the drugs taxol, campt, and topotesin. The eligibility criteria include having at least one measurable lesion, being between the ages of 20 and 75, having a performance status of 0 to 2, and meeting certain hematologic and serum level requirements. Exclusion criteria include having active multiple cancers, serious concurrent infections or illnesses, liver cirrhosis, brain metastasis, and prior treatment with Taxan or CPT-11. Patients must also provide written informed consent to participate in the study.",
    "The sample is a record of a clinical trial with a phase 1/phase 2 designation. The trial is focused on the disease asthma, with a list of icd-10 codes associated with it. The trial involves two drugs, qax576 and placebo. The eligibility criteria for the trial includes a history of asthma attacks, taking inhaled corticosteroids, and being a non-smoker. The exclusion criteria includes being a woman of child-bearing potential, having a history of respiratory disease other than asthma, having a history of severe allergy to food or drugs, previous use of monoclonal antibodies, and having a very low or high body weight. There may be other protocol-defined inclusion/exclusion criteria that apply.",
    "The sample is a record from a clinical trial table that includes information about the phase of the trial (phase 1/phase 2), the diseases being studied (brain and central nervous system tumors, prostate cancer), the corresponding ICD-10 codes for the diseases, the drugs being tested (everolimus, gefitinib), and the eligibility criteria for participants. The eligibility criteria include disease characteristics such as confirmed diagnosis and disease progression, as well as patient characteristics such as age, performance status, and medical history. The criteria also specify prior concurrent therapies that are not allowed during the trial.",
    "The sample is a clinical trial for rheumatoid arthritis in phase 1/phase 2. The trial is testing the effectiveness of two drugs, belatacept and abatacept, on patients who have been diagnosed with RA for less than 5 years and have failed at least one Disease Modifying Antirheumatic Drug (DMARD). The trial requires patients to have a joint count of 10 or more swollen and 12 or more tender, and an Erythrocyte Sedimentation Rate (ESR) greater than -28mm/rr or morning stiffness greater than -45 minutes. Women and men who are not willing to use an accepted form of contraception, those with active vasculitis, those who have been treated with another investigational drug within 30 days, and those with a history of asthma, angioedema, or anaphylaxis are excluded from the trial.",
    "The sample is a record from a clinical trial table that includes information about the trial's phase, diseases being studied, icd-10 codes of the diseases, drugs being used, and eligibility criteria for participants. In this particular sample, the trial is in phase 1/phase 2 and is studying metastatic melanoma. The icd-10 codes associated with the disease are listed, as well as the drug being used, which is a combination of dasatinib and dacarbazine (dtic). The eligibility criteria for participants are also listed, including requirements for organ function, previous treatments, and medical history. Exclusion criteria are also listed, such as recent major surgery or radiation therapy, ongoing cardiac dysrhythmias, and ongoing treatment with therapeutic doses of warfarin.",
    "The sample is a record from a clinical trial table that includes information about the phase of the trial, diseases being studied, ICD-10 codes associated with those diseases, drugs being tested, and eligibility criteria for participants. In this particular sample, the trial is in phase 1/phase 2 and is focused on primary open-angle glaucoma and ocular hypertension. The ICD-10 codes associated with these diseases are listed as \"H40.053\", \"H40.051\", \"H40.052\", and \"H40.059\". The drugs being tested are \"lx7101 (0.125%)\", \"lx7101 (0.25%)\", and \"lx7101 vehicle\". The eligibility criteria for participants include being over 18 years old, having a documented diagnosis of POAG or OHT in both eyes, and being willing and able to provide written informed consent. There are also exclusion criteria listed, such as having a history of any form of glaucoma other than POAG, being unable to discontinue contact lens wear, and having a history of ocular trauma or infection within a certain timeframe.",
    "The sample is a clinical trial for pancreatic adenocarcinoma, in which the phase is a combination of phase 1 and phase 2. The trial involves the use of drugs such as pimasertib, gemcitabine, and placebo. The eligibility criteria for the trial include having a confirmed diagnosis of metastatic adenocarcinoma of the pancreas, being at least 18 years old, and having a complete tumor assessment within 28 days prior to trial entry. Exclusion criteria include bone marrow impairment, renal impairment, liver function abnormality, and history of central nervous system metastases. The trial also requires female subjects of childbearing potential and male subjects with female partners of childbearing potential to use adequate contraception during the trial.",
    "The sample is a record from a clinical trial database. It includes information about the phase of the trial, which is either phase I, phase II, or phase III. The diseases being studied are listed as 'melanoma', and the corresponding ICD-10 codes are also provided. The drugs being tested are 'intetumumab', 'dacarbazine', and 'placebo'. The eligibility criteria for the trial are listed under 'criteria', including inclusion criteria such as confirmed melanoma, measurable disease, and prior chemotherapy, as well as exclusion criteria such as bone metastases, prior radiation to target lesions, and concurrent use of certain therapies.",
    "The sample is a phase 2 clinical trial for breast cancer. The trial is testing the effectiveness of a combination of drugs, including trastuzumab, docetaxel, and carboplatin, in a dose-dense regimen. The trial has specific eligibility criteria, including having HER-2 overexpressing breast cancer, being in clinical stage 2-3B, and having a normal ejection fraction. The exclusion criteria include having metastatic disease and a low ejection fraction. The diseases are listed as breast cancer, and the icd-10 codes associated with the disease are also provided.",
    "The sample is a phase 2 clinical trial for gastroesophageal reflux disease. The trial includes patients who are 18-70 years old and have at least one of the two symptoms, heartburn and reflux. Patients must also have photographically documented erosive esophagitis confirmed by esophagogastroduodenoscopy (EGD) and graded according to the Los Angeles (LA) Classification (A-D), within 5 days before randomization to treatment. Female patients must be nonpregnant, nonlactating, postmenopausal, surgically sterilized, or using a medically acceptable form of birth control. Patients with cancerous or peptic ulcers, Zollinger-Ellison syndrome, varices of esophagus or fundus of stomach, a known history of gastric acid suppression operation, esophageal operation or peptic operation other than simple closure of perforation, severe complications, severe other diseases of digestive tract such as Crohn's disease and ulcerative colitis, and severe other systemic diseases are ineligible. Patients who have taken proton pump inhibitors within the 5 days or for more than three consecutive days within the two weeks immediately preceding start of study drug, participated in a clinical trial with an investigational drug or device within the past three months, have hypersensitivity or idiosyncratic reaction to ilaprazole, esomeprazole or any other benzimidazole, have alcoholic intemperance, drug addiction or any other improper habits are also ineligible.",
    "The sample is a phase 2 clinical trial for patients with peritoneal carcinomatosis or adenomucinosis secondary to colorectal or appendiceal cancer who have undergone cytoreductive surgery and intraperitoneal hyperthermic chemotherapy within the past 12 weeks. The trial is testing the effectiveness of thalidomide as a treatment option. The eligibility criteria include various patient characteristics such as ECOG performance status, blood counts, liver function, and medical history. Patients must also not be pregnant or nursing, and must use effective contraception during and after treatment. Prior concurrent therapy is limited to IPHC, and patients cannot use high level sedatives, recreational drugs, or alcohol during the trial.",
    "The sample is a phase 2 clinical trial for peripheral arterial disease. The eligibility criteria include being between 35 and 85 years old, having a history of PAD confirmed by medical chart or ankle brachial pressure index at rest \u22640.90, and having stable lower extremity symptoms for at least 1 month prior to screening. Inclusion criteria also require the subject to be using suitable birth control or be post-menopausal or sterilized, and to have been on a stable treatment for cardiac risk factors for at least 1 month prior to screening. Exclusion criteria include non-atherosclerotic PAD, recent hospitalization for acute coronary syndrome or stroke, and chronic use of certain medications. The drug being tested is sodium nitrite.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on treating advanced/metastatic scirrhous gastric carcinoma using the drug tki258. The trial includes patients who have previously received one or two systemic lines of treatment and have evidence of diffusely infiltrating gastric lesions and/or at least one measurable extra-gastric lesion. Patients must also have an ECOG performance status of 0 to 2 and adequate liver, renal, and hematologic function. Exclusion criteria include patients who have received prior treatment with an FGFR inhibitor, have known brain metastases or signs/symptoms attributable to brain metastases, or have another primary malignancy within 3 years prior to starting study treatment. Other protocol-defined inclusion/exclusion criteria may also apply. The record includes information on the diseases being treated, the icd-10 codes associated with those diseases, and the eligibility criteria for the trial.",
    "The sample is a phase 2 clinical trial for the treatment of female sexual arousal disorder and hypoactive sexual desire disorder. The trial involves the drug bremelanotide and has eligibility criteria for female participants who are at least 21 years old, premenopausal, and have previously experienced sexual arousal during sexual activity and/or normal level of desire in the past for at least 2 years. Participants must also be willing to engage in sexual activities and be in a stable relationship with a partner (male or female) for at least 6 months. The trial has exclusion criteria for participants with certain medical conditions, unresolved sexual trauma or abuse, and certain gynecologic conditions. Participants must also have a negative serum pregnancy test and use a medically acceptable form of contraception for the duration of the trial and 1 month following the last dose of trial drug. The trial involves necessary questionnaire scores and has a normal pelvic examination requirement.",
    "The sample is a phase 2 clinical trial for the treatment of opioid-induced constipation. The trial involves the use of methylnaltrexone bromide and a placebo as drugs. The eligibility criteria include participants who are 18 years or older, have undergone an orthopedic procedure, are receiving opioid analgesics, and are acutely constipated. Exclusion criteria include participants with known hypersensitivity to the drugs, those who have received any investigational new drug in the previous 30 days, and those with constipation not attributed to post-procedure opioids. The trial also requires participants to sign an informed consent form and use appropriate birth control if they are females of childbearing potential.",
    "The sample is a phase 2 clinical trial for asthma patients. The trial includes patients who are homozygous for arginine at the 16th amino acid position of the beta2 adrenergic receptor, have a documented history of asthma, are non-smokers or ex-smokers with a cigarette smoking history of less than 10 pack-years, and are on a maintenance treatment with inhaled corticosteroids. The trial excludes patients with significant diseases other than asthma, recent history of myocardial infarction, hospitalized for heart failure within the past year, any unstable or life-threatening cardiac arrhythmia, malignancy for which the patient has undergone resection, radiation therapy or chemotherapy within the last five years, diagnosis of chronic obstructive pulmonary disease, history of life-threatening pulmonary obstruction, known active tuberculosis, undergone thoracotomy with pulmonary resection, or completed a pulmonary rehabilitation program in the six weeks prior to visit 1 or currently in a pulmonary rehabilitation program that will not be maintained throughout the duration of the study. The trial will test the efficacy of tiotropium bromide and salmeterol xinafoate compared to a placebo.",
    "The sample is a phase 2 clinical trial for the treatment of hormone-resistant prostate cancer, recurrent prostate cancer, and stage IV prostate cancer. The trial involves the drug saracatinib and has specific eligibility criteria, including previous treatment with docetaxel, ECOG performance status 0-1, and various medical requirements such as ANC \u2265 1,500/mm\u00b3 and total bilirubin < 2.0 x institutional ULN. Patients must also not have any conditions that impair their ability to swallow AZD0530 tablets, have a history of uncontrolled or unstable cardiac dysrhythmia, or evidence of interstitial lung disease. The trial has various other requirements and restrictions, including the discontinuation of certain drugs and the use of contraception for fertile patients.",
    "The sample is a phase 2 clinical trial for patients with cancer-related pain that is controlled with baseline pain medication but experience breakthrough pain episodes that are at least 4/10 in severity and last for at least 10 minutes. The trial is testing the effectiveness of sublingual methadone as a treatment for these breakthrough pain episodes. Patients must be able to hold 1.0cc of water under their tongue for 5 minutes and provide written informed consent. Patients with severe respiratory disease, prior sensitivity to methadone, currently taking methadone, or expected to have changes in their pain within the next 7 days are excluded from the trial. Patients who are clinically unstable or have a life expectancy of less than one month are also excluded.",
    "The sample is a phase 2 clinical trial for non-small cell lung cancer. The trial involves two interventions: intervention a with irinotecan, oxaliplatin, and neulasta, and intervention b with etoposide, carboplatin, and neulasta. The eligibility criteria include having a histologic or cytologic diagnosis of SCLC, measurable or assessable tumor parameters, ECOG Performance Status 0-2, and adequate bone marrow, liver, and renal function. Participants must also have fully recovered from any previous surgery and radiation therapy, agree to practice approved methods of birth control, and provide written informed consent. Exclusion criteria include concurrent cancer chemotherapy, biologic therapy, or radiotherapy, administration of any investigational drug within 28 days prior to administration of the current therapy, and concurrent serious infection.",
    "The sample is a phase 2 clinical trial for patients with non-small cell lung cancer. The trial includes patients with stage IIIB with pleural effusion or stage IV disease, who have measurable disease and meet certain eligibility criteria. The trial involves the drug sorafenib tosylate and patients must not have received prior immunotherapy, biologic therapy, or gene therapy. The trial also has various exclusion criteria, such as no uncontrolled hypertension, no concurrent chemotherapy, and no other concurrent anticancer agents or therapies.",
    "The sample is a phase 2 clinical trial for patients with non-small cell lung cancer. The trial is testing the effectiveness of the drug cetuximab in combination with chemotherapy. The eligibility criteria include having a confirmed diagnosis of non-small cell lung cancer, measurable disease, and normal organ and marrow function. Patients must also have an ECOG performance status of 0-1 and be over 18 years old. Exclusion criteria include prior chest radiation therapy, history of pulmonary fibrosis, and receiving any other investigational agents. Patients must also not have a history of severe allergic reactions to monoclonal antibodies and must not have peripheral neuropathy of more than grade 1 in severity. The trial requires patients to sign an informed consent form and agree to use adequate contraception if they are of child-bearing potential.",
    "The sample is a phase 2 clinical trial for patients with kidney cancer that has spread or cannot be surgically removed. The trial is testing the effectiveness of the drug gefitinib. The eligibility criteria include having confirmed renal cell carcinoma, a Karnofsky performance status of 60-100%, and meeting certain laboratory values. Patients must not have uncontrolled brain metastases or evidence of severe or uncontrolled systemic disease. Prior treatment with certain drugs is allowed, but not with gefitinib or agents specifically designed to inhibit the epidermal growth factor receptor. Patients must not be taking certain medications and must not have evidence of clinically active interstitial lung disease. The trial is looking for patients who meet these criteria and have not had certain treatments within a certain timeframe.",
    "The sample is a clinical trial for esophageal cancer patients in phase 1/phase 2. The trial includes patients with histologically confirmed epidermoid or glandular carcinoma of the thoracic esophagus, who have invasive disease and are resectable. The trial excludes patients with inoperable disease, invasion of the tracheo-bronchial tree, recurring esophageal paralysis, esopho-tracheal fistula, cervical esophageal carcinoma, multifocal esophageal carcinoma, superficial esophageal carcinoma, proven metastatic disease, known liver cirrhosis, renal insufficiency, respiratory insufficiency, progressive coronary insufficiency, myocardial infarction in the past 6 months, legally incapacitated, impossible to receive study therapy due to geographical, social, or psychological reasons, noncompliant within constraints of the study, hematologic malignancy or other cancer except carcinoma in situ of the uterine cervix, treated nonmelanoma skin cancer, or intramucous disease treated within the past 3 years. The trial also has eligibility criteria for patient characteristics, including WHO performance status, weight loss, absolute neutrophil count, platelet count, creatinine, PTT, albumin, FEV1, pregnancy or nursing status, and effective contraception use for fertile patients. The trial excludes patients who have had prior anticancer chemotherapy or radiotherapy, treatment with endoprosthesis, or surgery (esophagectomy) planned without thoracotomy. The trial involves the use of cisplatin and fluorouracil drugs.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on the disease of smoking and includes a list of ICD-10 codes associated with the disease. The drug being tested is taranabant. The eligibility criteria for the trial includes smoking at least 10 cigarettes per day for at least 1 year, meeting certain laboratory test criteria, and being in overall good health as determined by the investigator. The exclusion criteria includes patients with certain psychiatric diagnoses or cancers, patients using nicotine replacement therapy, and patients on a diet regimen.",
    "The sample is a record of a clinical trial in phase 2, focused on pulmonary disease, chronic obstructive. The trial includes a list of icd-10 codes for the disease and a list of drugs being tested, including various doses of different medications and placebos. The eligibility criteria for the trial include a diagnosis of chronic obstructive pulmonary disease and a smoking history of more than 10-pack years, while exclusion criteria include a history of asthma, allergic rhinitis, myocardial infarction, or unstable or life-threatening cardiac arrhythmias, as well as marked baseline prolongation of QT/QTc interval.",
    "The sample is a phase 2 clinical trial for the treatment of non-Hodgkin's lymphoma. The trial requires patients to have no previous chemotherapy or radiotherapy, and to meet certain eligibility criteria such as having measurable or evaluable disease, being HBsAg-positive, and having certain blood counts and liver function tests within normal limits. Patients must also sign an informed consent form. Exclusion criteria include age over 75 or under 15, pregnancy or breastfeeding, history of brain metastasis or CNS involvement, impaired cardiac function, and concurrent use of glucocorticoids for other reasons. The trial will use a combination of cyclophosphamide, epirubicin, etoposide, and prednisolone as the treatment regimen.",
    "The sample is a phase 2 clinical trial for breast cancer. The trial is looking at the effectiveness of three drugs, pd 0332991 and two doses of letrozole, in treating inoperable estrogen receptor positive and HER2 negative breast cancer in postmenopausal women. The trial requires tumor tissue for biomarker studies and acceptable bone marrow, liver, and kidney function. The exclusion criteria include prior or concomitant treatment for advanced breast cancer, other major cancer in the past 3 years, and important cardiovascular events in the past 6 months.",
    "The sample is a record of a clinical trial in phase 2 for breast cancer. The trial involves the drugs pemetrexed and gemcitabine. The eligibility criteria for the trial include having a performance status of 0 to 2 on the ECOG performance status schedule, having measurable disease as defined by RECIST criteria, and having adequate organ function. Patients may have had up to one prior systemic chemotherapy for metastatic disease, and prior adjuvant therapy is allowed if it has been more than one year since the end of therapy. Patients with serious concomitant systemic disorders that would compromise their safety or ability to complete the study are excluded. The icd-10 codes for the disease are also provided.",
    "The sample is a phase 2 clinical trial for patients with ovarian, breast, prostate, pancreatic, and advanced tumors. The trial is testing the drug olaparib for patients with confirmed documented deleterious or suspected deleterious BRCA mutation and confirmed malignant solid tumors for which no standard treatment exists. Patients must have at least one lesion that can be accurately assessed by CT/MRI and is suitable for repeated assessment at follow-up visits. Patients who have previously been treated with a PARP inhibitor, including olaparib, or who are unable to swallow orally administered medication are excluded from the trial. Additionally, patients who have received any systematic chemotherapy or radiotherapy within 2 weeks from the last dose prior to study treatment are also excluded.",
    "The sample is a phase 2 clinical trial for psoriasis vulgaris, a skin condition. The trial involves testing four different products, including daivobet\u00ae gel, on lesions located on the arms, legs, and/or trunk. The eligibility criteria include being 18 years or older, having a stable psoriasis diagnosis, and having lesions with a Total Clinical Score of 4 to 9. Exclusion criteria include being pregnant or breastfeeding, using certain topical or systemic treatments, and having certain medical conditions. The trial requires subjects to follow all study procedures and complete the entire study.",
    "The sample is a phase 2 clinical trial for Alzheimer's disease. The trial includes patients between the ages of 50 and 85 with a clinical diagnosis of probable Alzheimer's disease based on DSM-IV and NINCDS-ADRDA criteria. The patients must have mild to moderate Alzheimer's disease with a MMSE score between 11 and 25 for those with a middle school education or above, between 8 and 20 for those with an elementary school education, and between 5 and 16 for illiterate patients. The trial also requires a CT or MRI scan to exclude other structural brain diseases, and a neurologic examination with no significant abnormalities. Patients must have a Hachinski Ischemic Score of less than 4 and a Hamilton Depression Scale of less than or equal to 10. They must also have a stable chaperone for more than 2 hours a day or accumulated fewer than 14 hours per week. Patients must provide informed consent, and their caregivers must agree to participate in the study. Exclusion criteria include other types of dementia, sudden onset of early dementia with gait disorders, seizures, and behavioral changes, clinical manifestations of focal neurological signs, history of cerebrovascular disease and stroke, serious lack of folic acid and VitB12, syphilis antibody positive or thyroid dysfunction, mechanical intestinal obstruction, resting pulse less than 60, severe liver or renal disease, history of bone marrow transplantation, mental illness such as severe depression, cognitive damage caused by alcohol or drug abuse, critical condition, use of any agent for the treatment of dementia within 4 weeks of randomization, sensitivity to ACHEI, sensitivity to two or more foods/drugs, and use of another investigational agent within one month of screening.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on diabetes, specifically type 1 diabetes mellitus. The trial includes a list of icd-10 codes associated with the disease. The trial involves two drugs, liraglutide and placebo. The eligibility criteria for the trial includes having type 1 diabetes mellitus for at least 5 years, being a candidate for islet cell transplantation, and having reduced awareness of hypoglycemia. The exclusion criteria includes not having been treated with any anti-diabetic medication other than insulin within 4 weeks of the trial start, not having had any previous organ transplantation, not having a history of acute idiopathic or chronic pancreatitis, and not having a family or personal history of multiple endocrine neoplasia type 2 (MEN2) or familial medullary thyroid carcinoma (FMTC).",
    "The sample is a phase 2 clinical trial for patients with malignant diseases who experience nausea, vomiting, and chemotherapy. The trial involves the use of two drugs, palonosetron and granisetron, and has specific eligibility criteria for patients, including age, Karnofsky score, and predicted life expectancy. The trial also has exclusion criteria, such as ongoing emesis, CNS malignancy, and contraindications to chemotherapy. The table includes information on the diseases being studied, their corresponding ICD-10 codes, and the eligibility criteria for the trial.",
    "This sample is for a phase 2 clinical trial for patients with metastatic or unresectable colon cancer who have previously progressed on cetuximab plus irinotecan based combination. The trial involves the use of cetuximab with irinotecan as the treatment. The eligibility criteria include having a confirmed wild type KRAS mutation, an ECOG score of less than or equal to 1, adequate organ and marrow function, and measurable disease. Patients must have failed or been deemed intolerant to other standard chemotherapy treatments such as oxaliplatin and fluoropyrimidines. The exclusion criteria include receiving any other investigational agents not included in the study, having known brain metastases, and having a history of other invasive cancers with current evidence of disease. Patients must be off chemotherapy or other targeted therapies for at least 3 weeks before study treatment. The trial also has other exclusion criteria related to allergies, skin toxicity, intercurrent illness, and pregnancy or breastfeeding.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on the treatment of hepatocellular carcinoma, a type of liver cancer. The trial includes a list of ICDCodes, which are codes used to classify diseases and medical conditions. The trial also includes a list of drugs being used in the treatment, including etoposide, oxaliplatin, and capecitabine. The eligibility criteria for the trial are listed, including age range, disease criteria, and medical history. The sample also includes exclusion criteria, such as prior malignancy and uncontrolled medical conditions.",
    "The sample is a phase 2 clinical trial for mild persistent asthma. The trial includes male and female patients between the ages of 18-50 who have signed an informed consent form and have clinical evidence of asthma. The patients must be steroid na\u00efve and have an FEV1 at the screening visit that is greater than 70% of the predicted value and at least 2.0 L. The trial also requires patients to have a body mass index between 18 and 35, sensitivity to AMP at the screening visit, and FENO levels greater than 25 ppb at the screening visit. The trial has exclusion criteria, including patients who have received an investigational product within 2 months of the screening visit, inability to comply with study procedures or treatment intake, any significant lung disease, chronic obstructive pulmonary disease (COPD), previous or current smokers with a smoking history greater than 5 pack years, uncontrolled disease that may place the patient at undue risk, QTc greater than 450msec at the screening visit, serum potassium less than 3.5 mEq/L or greater than 6 mEq/L, intolerance/hypersensitivity or any contra-indication to treatment with beta2-agonists and/or inhaled corticosteroids, history of alcohol or substance abuse, major surgery in the previous 3 months, exacerbation of asthma requiring treatment with oral steroids during the last month prior to screening visit, treatment with slow-release corticosteroids 2 months prior to screening visit, currently treated with anti-IgE antibodies, respiratory tract infection within 4-weeks prior to screening visit, females not willing to use effective contraceptive measures, and females who are pregnant, lactating, or planning to become pregnant.",
    "The sample is a phase 2 clinical trial for patients with advanced metastatic or unresectable soft tissue sarcoma, excluding osteosarcoma. The trial is testing the effectiveness of the drug lbh589 (panobinostat\u00ae). The eligibility criteria include being at least 18 years old, having measurable nodal disease, having an ECOG performance status of 2 or less, and having adequate haematological, liver, and renal function. Patients must also have prior treatment with a doxorubicin containing regimen and have a life expectancy of at least 12 weeks. The trial excludes patients with certain medical conditions, unresolved toxicities from prior therapy, and those who are pregnant or breastfeeding. Patients must also be able to comply with the protocol and follow instructions given by the clinic staff.",
    "The sample is a phase 2 clinical trial for patients with schizophrenia and cognitive dysfunction. The trial is testing the effectiveness of the drugs tc-5619 and placebo. The eligibility criteria include a diagnosis of schizophrenia, stable symptoms, and controlled medication use. Exclusion criteria include a history of alcohol or drug abuse, significant medical conditions, and pregnancy or lactation. The trial is also excluding patients who have participated in another clinical trial within the last 3 months or who are involved in planning or conducting the study.",
    "The sample is a phase 2 trial for psoriasis. The icd-10 codes associated with the disease are listed as well as the drugs being tested, which include a placebo and two different doses of rg3421. The eligibility criteria for the trial include being an adult between the ages of 18 and 70 with moderate to severe chronic plaque psoriasis and being medically stable. Exclusion criteria include having any other skin condition that may interfere with the evaluation of the study medication on plaque lesions, as well as any confounding or concomitant condition or treatment.",
    "The sample is a phase 2 clinical trial for patients with advanced or recurrent cancer who have refractory neuropathic pain rated 4 or greater on a 0-10 scale and have failed to respond to two commonly used treatments. The trial is testing the effectiveness of the drug krn5500 compared to a placebo. Inclusion criteria include being 18 years or older, having a Karnofsky performance status of 40 or more, and if taking opioids for pain, having a stable regimen over the past week before enrolling. Exclusion criteria include having had radiation to the site of neuropathic pain within the past 4 weeks, major surgery within the past 2 weeks, and a history of severe allergic reaction to drugs containing polysorbate 80, among others.",
    "The sample is a phase 2 clinical trial for the treatment of schizophrenia. The trial is testing the effectiveness of two drugs, vabicaserin and risperidone, on patients with a diagnosis of schizophrenia established greater than 1 year. The trial is looking for generally healthy men and women aged 18 to 65 who are able to remain hospitalized for the duration of the screening period and for 4 weeks of double-blind treatment. The trial has exclusion criteria, including current Axis I primary psychiatric diagnosis other than schizophrenia, current diagnosis or history of substance abuse or dependence, and subjects taking high or chronic doses of benzodiazepine at the screening evaluation who would be likely to have severe withdrawal symptoms upon discontinuation.",
    "The sample is a phase 2 clinical trial for patients with non-small cell lung cancer. The trial includes patients who have had complete surgical resection and have no evidence of metastatic disease. The eligibility criteria include age over 18, ability to take oral medication, and ability to start treatment between 8 and 12 weeks following surgery. The trial excludes patients with preoperative radiologic evidence of N2 disease, mixed small cell and non-small cell histologies, and pulmonary carcinoid tumors. The trial also excludes patients with a history of prior malignancy within 5 years, women who are pregnant or breastfeeding, and patients with active infection requiring parenteral antibiotics. The trial requires patients to understand the nature of the study and give written informed consent.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on ovarian neoplasms and includes a list of associated ICD-10 codes. The drug being tested is a combination of sagopilone (zk 219477) and carboplatin. The eligibility criteria for the trial includes having evidence of ovarian cancer measurable by CT scan or CA125 blood levels, no recent radiation or chemotherapy, and a good response to previous treatment with carboplatin or cisplatin. The exclusion criteria includes having had more than one treatment regimen with carboplatin or cisplatin, prior treatment with other epothilones, and use of any investigational drug in the last 4 weeks. Additional criteria will be determined at the screening visit.",
    "The sample is a phase 2 clinical trial for the treatment of primary central nervous system lymphoma. The trial involves the drug pemetrexed and has eligibility criteria that include confirmation of the disease, age over 18, certain blood counts, and adequate medical health. Exclusion criteria include poor performance status, low blood counts, and inability to undergo MRI scans. The sample also includes a list of ICD-10 codes for the disease and detailed inclusion and exclusion criteria.",
    "The sample is a phase 2 clinical trial for psoriasis vulgaris, a skin disease. The trial is testing the effectiveness of two drugs, leo 22811 and placebo. The eligibility criteria for participants include having a clinical diagnosis of psoriasis vulgaris for at least 6 months, covering at least 10% of the body surface area, and having a Psoriasis Area and Severity Index (PASI) score of at least 10. Participants must also be aged 18 or above, attending a hospital outpatient clinic or the private practice of a dermatologist, and not have any major diseases or conditions that would put them at risk. Exclusion criteria include recent treatment with certain medications or therapies, current diagnosis with certain types of psoriasis or other skin conditions, and known hypersensitivity to the investigational product. The sample also includes detailed inclusion and exclusion criteria for participants.",
    "The sample is a phase 2 clinical trial for patients with pancreatic cancer. The trial is testing the effectiveness of three drugs - docetaxel, liposomal doxorubicin, and enoxaparin. The eligibility criteria for the trial include having histologically-confirmed pancreatic carcinoma with at least one measurable lesion, being 18 years or older, having certain blood levels within normal ranges, having an ECOG performance status of 2 or less, and having an expected survival of at least 3 months. Exclusion criteria include having undergone chemotherapy or radiation therapy within the preceding 4 weeks, having certain medical conditions such as congestive heart failure or duodenal erosion, and having a history of severe hypersensitivity reaction to docetaxel or other drugs formulated with polysorbate 80.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on the disease of functional dyspepsia, which is identified by the Rome II criteria. The trial is testing the drug z-338. The eligibility criteria for the trial include subjects who have postprandial fullness and/or early satiety as their most bothersome symptom. The exclusion criteria are not specified in this sample.",
    "The sample is a phase 2 trial for diabetes. The icd-10 codes for the disease are listed as \"E23.2\", \"N25.1\", \"P70.2\", \"O24.92\", \"Z83.3\", \"Z86.32\", and \"E10.65\". The trial involves two drugs, phentermine/topiramate and placebo. The eligibility criteria for the trial include completing a qualifying OB-202 trial, using adequate contraception for females of child-bearing potential, providing written informed consent, and being willing and able to comply with scheduled study visits, treatment plan, lab tests, and other study procedures. The exclusion criteria include subjects who have developed one or more morbidities during the OB-202 trial that would pose a safety concern.",
    "The sample is a phase 2 clinical trial for patients with epithelial ovarian cancer. The trial includes the drugs gemcitabine, carboplatin, and paclitaxel. The eligibility criteria for the trial include having histologically verified epithelial ovarian cancer, being in FIGO stage III-IV, having measurable disease, and meeting certain size requirements for lesions. Exclusion criteria include having ovarian tumors with low malignant potential, non-epithelial ovarian or mixed epithelial tumors, and having received previous chemotherapy or radiotherapy. The trial also has a time limit of 6 weeks between definitive surgery and enrollment.",
    "The sample is a phase 2 trial for diabetic neuropathies. The table includes information on the diseases, icd-10 codes, drugs, and eligibility criteria for the trial. The inclusion criteria require patients to be at least 18 years old, have a diagnosis of painful, distal, symmetrical, sensory-motor polyneuropathy due to diabetes for at least 1 year, and have a score of at least 40 mm on the Pain Visual Analogue Scale. The exclusion criteria include significant hepatic impairment, neurological disorders unrelated to diabetic neuropathy, any pain or condition that may confound assessment or self-evaluation of the pain due to diabetic neuropathy, amputations other than toes, a current or recent diagnosis or episode of major depressive disorder and/or uncontrolled depression, history of transient ischemic attack or stroke, and myocardial infarction or unstable angina within the past three months.",
    "The sample is a phase 2 clinical trial for cancer patients with moderate to severe chronic pain that requires around-the-clock opioid therapy. The trial is testing the effectiveness of oxycodone and oxycodone/naloxone in treating constipation induced or worsened by opioid medication. The trial includes patients who are at least 18 years old and willing to discontinue their current opioid analgesic routine. The eligibility criteria also include having a negative urine pregnancy test for females less than one year post-menopausal, and having a documented history of moderate to severe chronic cancer pain. The trial excludes patients with a history of hypersensitivity to oxycodone, naloxone, bisacodyl, related products, and other ingredients, as well as those with evidence of clinically significant cardiovascular, renal, hepatic or psychiatric disease.",
    "The sample is a record from a clinical trial table. It includes information about the phase of the trial, which is phase 2, and the disease being studied, which is type 2 diabetes mellitus. The icd-10 codes associated with the disease are also listed. The drugs being tested in the trial are mk-0893, sitagliptin, metformin, and placebos for each of these drugs. The eligibility criteria for participants are also included, such as having suboptimal glucose control and not being on certain types of medication. Exclusion criteria are also listed, such as having a history of type 1 diabetes or contraindications to certain medications.",
    "The sample is a record from a clinical trial table that includes information about the trial's phase, diseases being studied, icd-10 codes of the diseases, drugs being tested, and eligibility criteria for participants. In this particular sample, the trial is in phase 2/phase 3 and is focused on metastatic breast cancer. The drug being tested is capecitabine. The eligibility criteria include having a functional ECOG status of less than 2, having at least one measurable lesion according to RECIST criteria, and having a life expectancy of at least 3 months. There are also exclusion criteria, such as having previously shown severe reactions to therapy with fluoropyrimidines or having severe intellectual impairment.",
    "The sample is a phase 2 clinical trial for the treatment of relapsing-remitting multiple sclerosis and multiple sclerosis. The trial involves the drug dimethyl fumarate and has specific eligibility criteria for participants, including a confirmed diagnosis of RRMS, a prior brain MRI demonstrating lesions consistent with MS, and an EDSS score between 0.0 and 5.0. Participants must also be taking the same dose of a prescribed IFN\u03b2 or GA for at least 12 months consecutively at the time of enrollment and remain on this treatment for the duration of the study. There are also exclusion criteria, such as having other chronic diseases of the immune system or malignancies, being pregnant or nursing, or having participated in any other drug, biologic, or device study within 6 months prior to study enrollment.",
    "The sample is a phase 2 clinical trial for the treatment of symptomatic multiple myeloma. The trial includes participants who have measurable disease and have received at least one prior line of chemotherapy for multiple myeloma, but are refractory to or have relapsed after the last therapy. The trial also includes participants with a Karnofsky performance status greater than 60 or Eastern Cooperative Oncology Group (ECOG) performance status of 0-2, and a calculated or measured creatinine clearance of less than or equal to 30 mililiter per minute (ml/min). However, participants who had received bortezomib in previous clinical trials and best response was progressive disease or experienced one or more serious events, or received nitrosoureas within 6 weeks, or 2 consecutive weeks of intense corticosteroids, or immunotherapy or antibody therapy within 4 weeks before enrolment, or have a history of allergic reaction attributable to compounds containing boron or mannitol, or have peripheral neuropathy of Grade 2 or greater intensity at the time of signing informed consent form, or are pregnant or breast-feeding females are excluded from the trial.",
    "The sample is a phase 2 clinical trial for the treatment of metastatic or advanced gastric cancer using the drug trastuzumab. The trial is open to adult patients between the ages of 18 and 75 who have previously undergone platinum-based or 5-fluoropyrimidine-based chemotherapy for metastatic disease and have experienced disease progression. Patients must also have at least one measurable lesion and HER2 overexpression (IHC [2+] or [3+]). The trial has exclusion criteria, including concurrent chemotherapy or immunotherapy, brain or meningeal metastases, clinically significant cardiac disease, advanced pulmonary disease or severe dyspnoea, co-existing malignancies or malignancies diagnosed within the last 5 years (except basal cell cancer or cervical cancer in situ), and women who are pregnant or breastfeeding.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on the disease of allergic rhinitis and includes a list of ICD-10 codes associated with the disease. The trial involves several drugs, including placebo, allegra, allegra-d, and pf-03654746. The eligibility criteria for the trial include being between the ages of 19-55 and having experienced allergic rhinitis within the past 2 years. Additionally, subjects must respond to a ragweed nasal allergen challenge during screening. Exclusion criteria include a history of asthma or FEV1 < 80% predicted, significant concomitant disease or medications, and symptoms of allergic rhinitis within 2 weeks prior to screening.",
    "This is a sample of a clinical trial in phase 2 for the disease polycythemia vera. The trial is looking at the drug erlotinib. The eligibility criteria for the trial includes having a WHO 2008 diagnosis of polycythemia vera, a hemoglobin level above 18.5 g/dl for men (16.5 g/dl for women), and the presence of the JAK2V617F mutation. Patients may be on active treatment such as phlebotomy or aspirin. The trial also requires an ECOG performance status of 0, 1, 2, or 3, adequate hepatic and renal function, and excludes patients with active malignancy or clinically significant cardiac disease within the past year. Concurrent cytoreductive therapy is not allowed.",
    "The sample is a phase 2 trial for patients with breast or gynecological cancer who are receiving AC-like or CT MEC chemotherapy and have experienced at least one episode of vomiting or retching during the first 5 days following Cycle 1 of chemotherapy. The trial is testing the effectiveness of a combination of drugs including fosaprepitant dimeglumine, 5-ht3 ra, dexamethasone, and rescue medication in preventing chemotherapy-induced nausea and vomiting (CINV). The trial has inclusion and exclusion criteria, such as ECOG status 0-1 and no recent use of benzodiazepines or opiates. The trial does not allow participation for pregnant or breastfeeding individuals or those with symptomatic central nervous system metastasis or a history of other malignancies in the last 2 years.",
    "The sample is a phase 2 clinical trial for the treatment of melanoma. The trial includes patients with recurrent or unresectable stage III disease, stage IV disease, or non-choroidal origin. The trial drugs are sorafenib tosylate and temsirolimus. The eligibility criteria include various medical conditions, such as normal bilirubin and creatinine levels, no uncontrolled hypertension, and no evidence of bleeding diathesis or coagulopathy. Patients must also meet certain requirements related to their medical history, such as no more than one prior systemic chemotherapy regimen for metastatic melanoma. The trial also has specific requirements related to the timing of prior treatments and surgeries. Patients must have measurable disease and meet certain laboratory values, such as a white blood count of at least 3,000/mm\u00b3. The trial excludes patients with certain medical conditions, such as traumatic injury within the past 3 weeks and concurrent full-dose anticoagulation.",
    "The sample is for a phase 2 clinical trial for the treatment of various autism spectrum disorders using memantine hydrochloride (HCL) and placebo capsules. The eligibility criteria include having completed at least 12 weeks of exposure to the study drug in a lead-in study, meeting responder criteria at two consecutive visits, having a knowledgeable caregiver, being able to speak and understand English, having normal physical examination and laboratory test results, and having a family that can guarantee adequate safety monitoring and attendance to clinic visits. Exclusion criteria include having a concurrent medical condition that might interfere with the study, having a significant risk of suicidality, having evidence or history of malignancy or any significant disease, not using or willing to use a conventional method of contraception, requiring treatment with prohibited concomitant medications, and not being suitable for the study.",
    "The sample is a phase 2 clinical trial for non-small cell lung cancer. The trial includes patients with confirmed metastatic NSCLC who have measurable disease according to RECIST v.1.0 2009 and are KRAS, BRAF, and PI3K wild type in primary tumor or metastatic tissue. Patients must be over 18 years old with a PS score of less than 2 and adequate organ function. The trial also requires patients to have certain levels of neutrophil, platelet, and leucocyte counts, as well as specific levels of total bilirubin, serum transaminases, creatinine clearance, magnesium, and calcium. Patients must also consent to translational research studies and provide written informed consent. Exclusion criteria include clinically significant cardiovascular disease, known CNS metastasis, prior chemotherapy for metastatic disease, indication for radiation therapy or prior radiotherapy within 30 days before treatment start, other malignant diseases within 5 years prior to inclusion in the study, and other experimental therapy within 30 days prior to treatment initiation. Patients who have a history of interstitial lung disease, are pregnant or breastfeeding, or are not willing to use highly effective methods of contraception during treatment and for 6 months after the end of treatment are also excluded.",
    "The sample is a phase 2 trial for patients with stable coronary artery disease. The trial involves the use of ticagrelor, clopidogrel, and aspirin as drugs. The eligibility criteria for the trial include having documented stable coronary artery disease, being a female of childbearing potential with a negative pregnancy test and willing to use contraception, and not having a history of acute coronary syndromes within the past 12 months or needing revascularization. Exclusion criteria include having an unstable condition in the past 30 days, having an increased bleeding risk, and having a history of intolerance or allergy to aspirin or clopidogrel.",
    "The sample is a phase 2 clinical trial for the treatment of bacterial infections. The trial includes male and female subjects between the ages of 18 and 65 who meet certain eligibility criteria, such as having a negative nasal culture for S. aureus and being able to understand and comply with the requirements of the study. The trial involves the use of the drugs retapamulin and placebo, and subjects must abstain from sexual intercourse or use non-hormonal contraception during the study period. Exclusion criteria include a history of alcohol or substance abuse, positive urine drug or alcohol screen, and a history of illicit drug abuse.",
    "This is a sample of a clinical trial for phase 2, focusing on chronic lymphocytic leukemia. The trial is testing the effectiveness of the drugs bendamustine and rituximab. The eligibility criteria for participants include having confirmed chronic lymphocytic leukemia, experiencing certain disease-related symptoms, and not having received prior therapy for CLL. Participants must also meet certain age and health requirements, and be willing to sign a consent form. Exclusion criteria include previous chemotherapy or radiotherapy for CLL, ongoing or active infections, and certain allergies or medical conditions.",
    "The sample is a phase 2 clinical trial for patients with aggressive non-Hodgkin's lymphoma who have either relapsed or are refractory to first-line chemotherapy. The trial involves the use of rituximab, etoposide, methylprednisolone, cytarabine, and cisplatin. The eligibility criteria include a clinical diagnosis of aggressive non-Hodgkin's lymphoma, expression of CD20 on lymphoma cells, measurable lesions on imaging studies, and meeting certain blood cell count requirements. Exclusion criteria include hepatic dysfunction, renal insufficiency, cardiac dysfunction or arrhythmia, severe infection, CNS involvement, other malignancies, and pregnancy or breastfeeding.",
    "The sample is a phase 2 clinical trial for lung cancer patients who have had previous treatment with platinum-based chemotherapy and surgery. The trial is testing the effectiveness of the drugs oxaliplatin and pemetrexed. The eligibility criteria include having measurable disease, a good performance score, adequate bone marrow, renal, and hepatic function, and a life expectancy of more than 12 weeks. Patients must also have recovered from any prior treatments and provide informed consent. Exclusion criteria include having an active infection, CNS metastases, or a history of allogeneic transplant, HIV, or Hepatitis B or C infection. Patients must not be pregnant or lactating and must not have any medical conditions that could interfere with their ability to participate in the study.",
    "The sample is a phase 2 clinical trial for rheumatoid arthritis. The trial includes patients with active disease, defined as having at least 4 swollen joints and 6 tender/painful joints, and either elevated ESR or CRP levels. Patients must also have a positive rheumatoid factor, radiographic erosion, or serum anti-cyclic citrullinated peptide antibodies. They must have been receiving oral or subcutaneous methotrexate for at least 6 months prior to randomization. Patients with other inflammatory diseases or chronic pain disorders are excluded from the trial. The trial involves the use of drugs such as azd5672, etanercept, and placebo.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on two diseases, atrial fibrillation and thromboembolism, and includes a list of corresponding ICD-10 codes. The trial involves the use of several drugs, including edoxaban and warfarin. The eligibility criteria for the trial include being between 18 and 80 years old, having persistent non-valvular AF supported by abnormal ECG, and having a CHADS2 index score of at least 2. The exclusion criteria include having mitral valve disease or previous valvular heart surgery, known contraindication to any anticoagulant including warfarin, and known or suspected hereditary or acquired bleeding or coagulation disorder.",
    "The sample is a record from a clinical trial table that includes information about the phase of the trial, a list of diseases being studied, their corresponding ICD-10 codes, a list of drugs being used, and eligibility criteria for participants. In this particular sample, the trial is in phase 1/phase 2 and is studying various hematological malignancies such as chronic myeloproliferative disorders, leukemia, lymphoma, and myelodysplastic syndromes. The trial is specifically looking at patients who are scheduled for hematopoietic stem cell transplantation from unrelated donors and are currently receiving a conditioning regimen comprising cyclosporine and total body radiotherapy or busulfan and cyclosporine. The eligibility criteria include various medical and health-related factors such as age, performance status, life expectancy, and renal function. The sample also includes information about prior concurrent therapies and restrictions on certain foods and medications during the trial.",
    "The sample is a phase 2 clinical trial for hypertension. The trial includes subjects who have been diagnosed with essential hypertension for at least 1 year and are on a stable dose of at least one, but not more than 3 antihypertensive medications for at least 3 months. The inclusion criteria also require the subject to have a systolic blood pressure at screening between 100 and 150 mmHg, and diastolic blood pressure must not exceed 105 mmHg. The exclusion criteria include subjects with a weight greater than 100 kg or less than 50 kg, and any significant medical condition or abnormal safety laboratory results which, in the judgement of the Investigator would place the subject at significant risk. The trial will test the effectiveness of the drug pl3994 compared to a placebo.",
    "The sample is a clinical trial for gastroesophageal reflux disease, with a phase 2/phase 3 designation. The trial involves testing the effectiveness of different doses and combinations of the drug rabeprazole, along with a placebo, for treating GERD symptoms. The trial has specific eligibility criteria for participants, including currently being treated with a PPI but still experiencing GERD symptoms at least twice a week. There are also exclusion criteria, such as a history of serious arrhythmia or drug abuse, and women who are pregnant or not using contraception. The trial aims to determine the safety and efficacy of the drug for treating GERD symptoms.",
    "The sample is a phase 2 clinical trial for patients with esophageal cancer. The trial is testing the effectiveness of the drugs carboplatin and pemetrexed. The eligibility criteria include having histologically or cytologically confirmed squamous cell carcinoma or adenocarcinoma of the esophagus or gastroesophageal junction, no evidence of distant metastases, and a tumor that is considered surgically resectable. Patients must also meet certain patient characteristics such as having an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 and no other severe underlying disease that would preclude study entry. Prior concurrent therapy is also restricted, with no prior chemotherapy for esophageal cancer and no prior radiotherapy field that overlapped the anticipated fields of study radiotherapy.",
    "The sample is a phase 2 clinical trial for patients with ovarian epithelial, fallopian tube, or primary peritoneal cavity cancer that has recurred or metastasized. The trial requires patients to have measurable disease and to have received a platinum-containing chemotherapy regimen for their primary disease. Patients must also meet various eligibility criteria, including having a performance status of ECOG 0-2, no evidence of CNS disease, and meeting certain blood count and liver function requirements. Patients must not have a history of bleeding diathesis, esophageal varices, or arterial thromboembolic events within the past 6 months. They must also not have any other active malignancy within the past 5 years except nonmelanoma skin cancer or carcinoma in situ of the cervix. Patients must not have any gastrointestinal tract disease resulting in an inability to take oral medication, and they must not have known HIV positivity. The trial involves treatment with erlotinib hydrochloride and requires patients to meet various other criteria related to their medical history and current health status.",
    "The sample is a record of a clinical trial with a combination of phase 1 and phase 2. The trial is focused on amyotrophic lateral sclerosis, and the icd-10 code associated with it is G12.21. The drug being tested is a combination of zinc and copper. The eligibility criteria for the trial include being between the ages of 18-85, having clinically definite or probable ALS by El Escorial criteria, having an ALS-FRS score greater than 25, and being capable of providing informed consent and complying with trial procedures. The exclusion criteria include having a forced vital capacity (FVC) below 50%, a history of liver disease, severe renal failure, creatinine greater than or equal to 1.5 mg/dL, intolerance to zinc or copper, evidence of motor neuron disease for greater than 5 years, any other co-morbid condition which would make completion of the trial unlikely, being pregnant or breastfeeding if female, unwillingness to use birth control if of childbearing age, taking any other trial medications, having a history of significant anemia, and having elevated levels of zinc or copper below normal at baseline.",
    "The sample is a phase 2 trial for breast cancer patients with involvement of at least one axillary or internal mammary lymph node. The trial includes patients who have completed definitive breast surgery and have histologically free margins of lumpectomy or mastectomy. The trial also includes patients who have not received prior cytotoxic chemotherapy, hormonal therapy or radiation for this breast cancer. The trial involves the use of drugs such as doxorubicin hydrochloride, cyclophosphamide, paclitaxel, tamoxifen citrate, and aromatase inhibition therapy. The eligibility criteria include various medical conditions such as ECOG performance status of 0-2, absolute neutrophil count >= 1000/mm^3, platelet count >= 100,000/mm^3, and LVEF >= institutional limits of normal by MUGA or ECHO. The trial excludes patients with HER2+ breast cancer, clinical evidence of inflammatory disease or fixed axillary nodes, and those who require therapeutic anticoagulation. Women must not be pregnant or breast-feeding due to the potential harmful effects of bevacizumab on the developing fetus.",
    "The sample is a record of a clinical trial in phase 2, which involves patients with asthma and GERD. The trial includes a list of ICD-10 codes for the diseases, a list of drug names, and eligibility criteria for the patients. The inclusion criteria require that patients have a diagnosis of asthma for at least 6 months, symptoms of asthma during the run-in period, and a history of acid reflux symptoms. The exclusion criteria include patients with clinically relevant abnormalities, a smoking history of \u226510 pack-year, and those who have had previous surgery on the esophagus or stomach.",
    "The sample is a phase 2 clinical trial for hypertension. The trial includes subjects aged 20 to 75 years with essential hypertension, measured to have a sitting diastolic blood pressure (SiDBP) between 90mmHg and 114mmHg at baseline. The trial excludes patients with severe hypertension, secondary hypertension, abnormal renal or liver function, hypokalemia or hyperkalemia, depleted sodium ion or body fluid, hypotension, severe insulin dependent or uncontrolled diabetes mellitus, severe heart disease, significant arrhythmia, hypertrophic obstructive cardiomyopathy, severe cerebrovascular disease, wasting disease, autoimmune disease, connective tissue disease, known severe or malignancy retinopathy, hepatitis B or C or HIV positive reaction, history of alcohol or drug abuse within 2 years, allergic reaction to any angiotensin II antagonist, any chronic inflammation disease, medical histories of malignant tumor within 5 years, childbearing and breastfeeding women, female who plan to become pregnancy or have a possibility of pregnancy but don't prevent conception with acknowledged methods, patients who took medicine within 12 weeks from screening visit or is going on the progress of other clinical trial, and subjects who are judged unsuitable to participate in this study by the investigator. The drugs used in the trial are fimasartan, amlodipine, and placebo.",
    "The sample is a phase 2 clinical trial for type 2 diabetes. The trial involves the use of a drug called mci-196 and a placebo of the same tablet. The eligibility criteria for the trial include patients with fasting blood glucose levels between 130mg/dL and 200mg/dL and HbA1c levels of 7.0% or above. Patients with serious cardiac, hepatic or renal complications, serious diabetic complications, complete biliary obstruction or ileus, pregnant, lactating, and probably pregnant patients, and patients who cannot agree to contraception are excluded from the trial. The diseases are listed as 'type 2 diabetes', and the icd-10 codes associated with the disease are also provided.",
    "The sample is a phase 2 clinical trial for patients with proliferative diabetic retinopathy and macular edema. The trial involves the use of the drug ranibizumab. The eligibility criteria include having previously untreated PDR with high risk characteristics and developing edema within 7-14 days post PRP therapy. Exclusion criteria include pregnancy, neovascularization of the iris or neovascular glaucoma, and prior treatment with certain intravitreal injections. The trial requires participants to provide written informed consent and comply with study assessments for the full duration of the study.",
    "The sample is a phase 2 clinical trial for the treatment of metastatic adenocarcinoma of the pancreas using a combination of drugs including gsk1120212, gemcitabine, and placebo. The trial is open to patients who are 18 years or older, have a confirmed diagnosis of metastatic adenocarcinoma of the pancreas, and have a performance status score of 0 or 1 according to the Eastern Cooperative Oncology Group (ECOG) scale. Patients must also have adequate baseline organ function and be able to swallow and retain orally administered medication. The trial has a list of inclusion and exclusion criteria that patients must meet to be eligible for participation.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on treating several types of prostate cancer, including hormone-refractory and recurrent prostate cancer. The trial is testing the effectiveness of a drug called eribulin mesylate. The record includes a list of eligibility criteria for patients to participate in the trial, such as having a confirmed diagnosis of adenocarcinoma of the prostate, evidence of treatment failure with previous hormonal therapy, and an ECOG performance status of 0-2. The record also includes a list of exclusion criteria, such as having serious concurrent medical illness or active infection that would preclude study treatment, and having prior strontium chloride Sr 89, samarium 153 lexidronam pentasodium, or other radioisotopes.",
    "The sample is a clinical trial for a drug called tak-700, which is being tested on male subjects over the age of 18 with metastatic prostate adenocarcinoma that has progressed while on androgen deprivation therapy. The trial is in phase 1/phase 2 and the eligibility criteria include having radiograph-documented metastatic disease, a prostate-specific antigen level of at least 5 ng/mL, and meeting all screening laboratory values as specified in the protocol. The exclusion criteria include having a history of myocardial infarction, uncontrolled hypertension, or any other serious medical condition or psychiatric illness that might affect life expectancy or make it difficult to successfully manage and follow the subject according to protocol. The sample also includes a list of diseases, icd-10 codes, and eligibility criteria.",
    "The sample is a phase 2 clinical trial for various hematologic diseases, including acute-graft-versus-host disease, leukemia, non-hodgkin lymphoma, and hodgkin lymphoma. The trial involves the use of drugs such as sirolimus, mycophenolate mofetil, carmustine, etoposide, cyclophosphamide, and ftbi. The eligibility criteria include age range, specific types of leukemia and lymphoma, and performance status. Exclusion criteria include prior stem cell transplant, HIV infection, pregnancy, and certain medical conditions. The trial requires patients to take oral medications during the transplantation period and sign a written informed consent document.",
    "The sample is a phase 2 clinical trial for patients with locally advanced, non-metastatic primary T3 or T4 adenocarcinoma of the rectum. The trial is testing the effectiveness of a combination of drugs including capecitabine, fluorouracil, leucovorin calcium, and oxaliplatin. The eligibility criteria for the trial include having a confirmed diagnosis of rectal adenocarcinoma, not having evidence of tumor outside of the pelvis, and having a distal border of the tumor at or below the peritoneal reflection. Patients must also have Eastern Cooperative Oncology Group (ECOG) performance status 0-1 and be able to tolerate the proposed surgical procedure. Additionally, patients must meet certain laboratory and medical criteria, such as having a caloric intake > 1500 kilocalories/day and having no active inflammatory bowel disease or other serious medical illness or disease that might limit the patient's ability to receive protocol therapy.",
    "The sample is a phase 2 clinical trial for lupus nephritis, a disease affecting the kidneys in patients with systemic lupus erythematosus. The trial involves the use of mycophenolate sodium, prednisone, and methylprednisolone as drugs. The eligibility criteria for the trial include having at least 4 classification criteria for SLE, being aged 18 or older, having proliferative lupus nephritis classified as ISN/RPS class III or IV, having had a renal biopsy within the last 24 months, and having proteinuria defined as >0.5 gram urine protein per gram urine creatinine at screening and baseline, among other criteria. Exclusion criteria include having a calculated creatinine clearance <30 ml/min, having received certain medications within the last 3 months, being pregnant or nursing, and having a history of hypersensitivity to any of the study drugs or drugs with similar chemical structures, among other criteria.",
    "The sample is a phase 2 trial for gastroesophageal reflux disease (GERD) and related symptoms such as heartburn and regurgitation. The trial includes patients who have a history of GERD for at least 6 months and have been continuously treated with daily optimized unchanged PPI therapy for any GERD indication for the last 4 weeks before enrollment. The trial excludes patients who have not experienced any GERD symptom improvement during PPI treatment, have had prior surgery of the upper gastrointestinal tract, or have certain conditions or diseases such as heart disease, angina, seizure disorders, congestive heart failure, liver disease, kidney disease, lung disease, or cancer. The trial involves the use of the drug lesogaberan (azd3355) and a placebo. The eligibility criteria include providing informed consent prior to any study-specific procedures.",
    "The sample is a record of a clinical trial that is in phase 2/phase 3. The trial is focused on treating neuralgia and neuropathic peripheral pain using the drug sodium valproate. The diseases are identified by their ICD-10 codes, which are listed as ['G50.0', 'M54.81', 'B02.22', 'M79.2']. The eligibility criteria for the trial include having peripheral neuropathic pain and providing signed written informed consent. The exclusion criteria include having central neuropathic pain or a current or past hepatic disease.",
    "The sample is a phase 2 clinical trial for patients with anaplastic thyroid carcinoma, a type of thyroid cancer. The trial is testing the effectiveness of the drug imatinib. The eligibility criteria include having measurable disease, a Karnofsky performance status of >70%, and a life expectancy of at least 12 weeks. Patients must also meet certain hematologic and hepatic function requirements, have a normal serum calcium level, and have a serum creatinine less than 1.5 x the institutional upper limits of normal. Women of childbearing potential must have a negative pregnancy test and patients of reproductive potential must practice effective contraception. Patients must have completed prior chemotherapy, chemoradiation, radiation therapy, or surgery at least 28 days prior to registration, and all toxicities must have resolved. The exclusion criteria include certain medical or psychiatric illnesses, concurrent radiotherapy or chemotherapy, pregnancy or lactation, malabsorption syndromes, serious concurrent infections, previous organ allografts, chronic liver disease, a known diagnosis of HIV infection, major surgery within 2 weeks of study entry, and grade III/IV cardiac problems.",
    "The sample is a phase 2 clinical trial for the treatment of chronic hepatitis C. The trial includes patients who are at least 18 years old, have had hepatitis C for at least 6 months, and have a specific genotype of the virus. Patients must not have previously been treated with interferon and must meet certain BMI and weight requirements. Female patients of child-bearing potential and male patients with female partners of child-bearing potential must use two forms of effective non-hormonal contraception. The trial excludes patients who are pregnant or lactating, have liver disease or impaired liver function, have cirrhosis or incomplete/transition to cirrhosis, have hepatitis B or HIV infection, have a history of neoplastic disease within the last 5 years (except for localized or in situ carcinoma of the skin), have pre-existing renal disease or severe cardiac disease, or have a history of drug or alcohol abuse within the last year (except for cannabinoid use). The trial involves the use of several drugs, including copegus placebo, ro5024048, danoprevir, peginterferon alfa-2a [pegasys], ribavirin [copegus], and ritonavir.",
    "The sample is a clinical trial for pancreatic cancer patients in phase 1/phase 2. The trial includes patients with non-metastatic, unresectable disease and those who cannot undergo resection due to underlying medical problems. The trial drug is vorinostat. The eligibility criteria include having an ECOG performance status of 0 or 1, being at least 18 years old, having cytologic or histologic proof of adenocarcinoma of the pancreas, and meeting certain physical exam and CT criteria. Patients must not have received prior radiation therapy to the upper abdomen and must meet certain bone marrow, hepatic, and renal function requirements. Exclusion criteria include prior abdominal radiotherapy, participation in any other experimental drug study in the 30 days preceding initiation of treatment on the current study, and prior treatment with HDAC inhibitors (except valproic acid with a 30-day washout period). Pregnant or lactating women, those with serious, uncontrolled, concurrent infections, and those with certain medical illnesses or psychiatric disorders are also excluded.",
    "The sample is a phase 2 clinical trial for patients with Sj\u00f6gren's syndrome and dry mouth. The trial is testing the effectiveness of the drug rebamipide. The eligibility criteria include being 20 years or older, having dry mouth and decreased salivation, and not having received rebamipide or any other investigational drug within 3 months prior to obtaining informed consent. Exclusion criteria include having dry mouth due to a cause other than Sj\u00f6gren's syndrome, being pregnant or lactating, having a history of hypersensitivity to rebamipide, and being judged inappropriate for inclusion in the study by the investigator or subinvestigator.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on prostate cancer and includes a list of ICD-10 codes associated with the disease. The trial involves the use of two drugs, docetaxel and zd1839. The eligibility criteria for the trial include specific clinical stage requirements, performance status, and adequate hematological, liver, and renal function. The exclusion criteria include prior treatment with radiation or biologic therapy for prostate cancer, major surgery within four weeks, and prior hormonal therapy. The sample also includes detailed inclusion and exclusion criteria for the trial.",
    "The sample is a phase 2 clinical trial for ovarian cancer. The trial includes two different drugs, genexol\u00ae-pm 260mg/m2 plus carboplatin 5 auc and genexol\u00ae 175mg/m2 plus carboplatin 5 auc. The eligibility criteria for the trial includes subjects who are 18 years or older, have confirmed unresectable or metastatic epithelial cancer of the exocrine pancreas, and have not received prior radiation therapy or systemic treatment such as chemotherapy or immunotherapy for pancreatic cancer. However, prior use of chemotherapy for radiation sensitization is allowed. Subjects who have had a major surgery within 2 weeks prior to the screening/baseline visit are excluded from the trial.",
    "The sample is a phase 2 clinical trial for postherpetic neuralgia, a condition where pain persists after the healing of herpes zoster skin rash. The trial involves the drugs retigabine and placebo. The eligibility criteria include being able to provide informed consent, being between 18-85 years old, having PHN for more than 6 months, and having a pain score that qualifies. Exclusion criteria include having other significant pain that may confound PHN pain assessment, previous neurolytic or neurosurgical therapy for PHN, evidence of a progressive CNS disease, significant psychiatric or neuropsychiatric disorders, and clinically significant abnormalities on physical examination, vital signs, ECG, or laboratory tests at the screening visit.",
    "The sample is a phase 2 clinical trial for patients with prostate cancer that is unresponsive or refractory to hormone therapy. The trial includes patients who have received prior hormonal therapy and have documented progression detected by PSA increase, physical examination, and/or imaging. Patients must have achieved stable pain control for a minimum of seven consecutive days prior to study entry. The trial allows for prior radiation therapy (to < 25% of the bone marrow only) and surgery. Patients must have a life expectancy of more than 3 months and an ECOG Performance score of < 2. The trial includes eligibility criteria related to blood counts, liver function, kidney function, and other medical conditions. Patients must have voluntarily given written informed consent to participate in the study and be willing to comply with the scheduled visit, treatment plans, laboratory tests, and other study procedures. The trial has exclusion criteria related to prior cytotoxic chemotherapy, prior isotope therapy, prior radiotherapy to >25% of bone marrow, prior treatment with biological response modifiers within the previous 4 weeks, and other medical conditions that do not permit adequate follow-up and compliance with the study protocol. The trial also has exclusion criteria related to the use of drugs that may inhibit the metabolism of docetaxel, concurrent treatment with other experimental drugs, and treatment with any other anti-cancer therapy (except LHRH agonists) including any prescribed compounds and/or over-the-counter (OTC) products for the treatment of prostate cancer must be stopped prior to day of enrolment.",
    "The sample is a record of a clinical trial in phase 2 for Alzheimer's disease. The trial involves the use of drugs such as pf-04494700 and placebo. The eligibility criteria for participants include having a Mini Mental State Exam (MMSE) score between 14-26 and receiving acetylcholinesterase inhibitors on a stable dose for at least 4 months prior to randomization. Exclusion criteria include having a history of neurological, psychiatric, or any other illness that could contribute to non-Alzheimer's dementia, a known history of familial AD or any evidence for early onset AD known or possibly associated with genetic mutations, evidence or history of diabetes mellitus Type 1 or Type 2, and history or symptoms of autoimmune disorders. The icd-10 codes associated with Alzheimer's disease are also included in the record.",
    "The sample is a phase 2 clinical trial for patients with stage IIIB or IV non-small cell lung cancer who have progressed after at least 12 weeks of treatment with single-agent erlotinib. The trial involves a combination of erlotinib hydrochloride, pemetrexed disodium, and docetaxel. The eligibility criteria include having a measurable lesion, an ECOG performance status of 0-2, and a life expectancy of at least 12 weeks. Patients must also meet certain laboratory criteria and provide informed consent. The trial has exclusion criteria, such as active CNS disease, prior treatment with pemetrexed and docetaxel, and pregnancy or breastfeeding.",
    "The sample is a phase 2 clinical trial for the treatment of gout, hyperuricemia, arthritis, joint disease, and renal insufficiency. The trial involves the use of two different doses of ulodesine (bcx4208) and a placebo. The eligibility criteria include being between the ages of 18 and 70, having a documented diagnosis of gout and moderate renal insufficiency, and being willing and able to take allopurinol 200 mg every day for the duration of the treatment. There are also exclusion criteria, such as being unable to tolerate allopurinol, having a history of severe renal insufficiency, or being pregnant or breastfeeding. The trial requires participants to provide authorization for the use and disclosure of personal health information in accordance with HIPAA.",
    "The sample is a phase 2 clinical trial for patients with extensive stage small cell lung cancer. The trial involves the use of three drugs - carboplatin, etoposide, and topotecan hydrochloride. The eligibility criteria include confirmation of the disease, measurable or evaluable disease, ECOG performance status of 0-2, and a life expectancy of more than 2 months. Patients must also meet certain hematopoietic, hepatic, and renal requirements, and must not have any other serious medical or psychiatric illnesses that would prevent them from complying with the study. Prior chemotherapy is not allowed, but prior radiotherapy for brain metastasis is allowed. Other prior or concurrent therapies are not specified.",
    "The sample is a record of a clinical trial in phase 2, focused on the disease of severe sepsis. The trial involves the use of two drugs, talactoferrin alfa and placebo. The eligibility criteria for the trial include being over 18 years old, having onset of severe sepsis within the previous 24 hours, receiving antibiotic therapy, and being able to take medication by mouth or feeding tube. Exclusion criteria include having received investigational medication within 4 weeks prior to participation, being pregnant or breastfeeding, having severe congestive heart failure, known severe HIV infection, presence of severe burns, being on high dose immunosuppressants, having a life expectancy for concurrent illness of less than 6 months, and more. The trial requires the patient, legal next-of-kin, or legal guardian to sign an informed consent form and be committed to providing full, aggressive life support.",
    "The sample is a phase 2 trial for attention deficit hyperactivity disorder. The trial includes children between the ages of 6-12 who have been diagnosed with ADHD and have age-appropriate cognitive functioning. The treatment involves extended release methylphenidate (ritalin la) plus behavior therapy. The eligibility criteria include written informed consent from the parent and patient (over 7), and exclusion criteria include a history of malignant neoplasm, seizures (except childhood febrile seizures), hyperthyroidism, and concurrent medical conditions that may interfere with the study. Other protocol-defined inclusion/exclusion criteria may also apply.",
    "The sample is a phase 2 clinical trial for the treatment of acute, uncomplicated human influenza. The trial involves testing the effectiveness of the drugs peramivir and placebo. The eligibility criteria for participants include being male or non-pregnant female over the age of 18, having a positive Influenza A or B Rapid Antigen Test, having a fever and at least one respiratory symptom and one constitutional symptom of at least moderate severity, and providing written informed consent. Exclusion criteria include pregnancy or breastfeeding, clinically significant signs of acute respiratory distress, history of severe chronic obstructive pulmonary disease or severe persistent asthma, and current treatment for viral hepatitis B or C. Participants must not have received certain medications or vaccines within a certain timeframe prior to the trial.",
    "The sample is a phase 2 trial for nicotine dependence. The inclusion criteria require written informed consent, female participants aged 18-65 who smoke at least 10 cigarettes per day, and meet DSM-IV criteria for current nicotine dependence. Participants must be willing to take the study medication and motivated to quit smoking. Women of childbearing potential must have a negative urine pregnancy test and agree to use an approved form of contraception. Exclusion criteria include severe unstable medical illness, life-threatening arrhythmia or cardiovascular event within six months of enrollment, and abuse or dependence of any substance other than nicotine or caffeine in the past 6 months. Participants must not have a history of non-response to an adequate trial of nicotine replacement therapy, and must not be using an investigational drug or device within 4 weeks of enrollment. The use of statins during the period of the investigation is also prohibited.",
    "The sample is a record of a clinical trial for a drug called mp-214, which is being tested on patients diagnosed with schizophrenia. The trial is in phase 2/phase 3 and the table includes information on the diseases being treated, the icd-10 codes associated with those diseases, the drugs being tested, and the eligibility criteria for patients to participate in the trial. The inclusion criteria include obtaining written informed consent from the patient, a diagnosis of schizophrenia according to the DSM-IV-TR criteria, and normal physical examination, laboratory, vital signs, and/or electrocardiogram (ECG). The exclusion criteria include patients with a diagnosis of schizoaffective disorder, schizophreniform disorder, other psychotic disorders other than schizophrenia, or bipolar I or II disorder.",
    "The sample is a record of a clinical trial that is in phase 2/phase 3. The trial is focused on the treatment of unipolar depression using drugs such as escitalopram and pindolol. The eligibility criteria for the trial include patients aged between 18 and 65 years old, suffering from major depression according to DSM-IV with a MADRS score of at least 25, and not currently being treated with an antidepressant except for non-responders or those who cannot tolerate their current medication. The trial also requires informed consent from the patients. Exclusion criteria include any other Axis I disorder, non-responders to escitalopram in the past, pregnancy and breastfeeding, contraindications to the treatments, significant somatic comorbidity, high risk of suicidality, and women of childbearing age without a safe means of contraception. The diseases being studied are limited to unipolar depression, and the icd-10 codes associated with the disease are listed as well.",
    "The sample is a phase 2 clinical trial for the treatment of anal cancer using the drugs fluorouracil and mitomycin c. The eligibility criteria for patients include having histologically confirmed carcinoma of the anal canal, being in primary invasive disease stage, and having T2-4, N0-3 disease. Patients must also have a Zubrod performance status of 0-1, meet certain laboratory values, and not have any severe, active comorbidities. Prior radiation therapy to the pelvis, systemic chemotherapy for cancer of the anus, and surgery for cancer of the anus that removed all macroscopic anal cancer are not allowed. Patients must not be pregnant or nursing, and fertile patients must use effective contraception. The trial does not allow concurrent use of sargramostim (GM-CSF) or amifostine.",
    "The sample is a phase 2 clinical trial for Parkinson's disease. The trial includes patients aged 30 to 80 years who meet the criteria for \"Diagnosis of idiopathic Parkinson's disease\" according to the UKPDS Brain Bank criteria. Patients must have a modified Hoehn and Yahr stage 1-2.5 and cannot have undergone surgery for the treatment of Parkinson's disease or have any other brain surgery at any time. Patients must also not have dyskinesias, motor fluctuations, swallowing difficulties, or loss of postural reflexes. The trial includes a list of drugs, including azd3241 300 mg bid, azd3241 600 mg bid, and placebo. The eligibility criteria for the trial are also listed.",
    "The sample is a phase 2 clinical trial for non-small cell lung cancer. The trial involves the use of the drugs pemetrexed and gemcitabine plus bevacizumab. The eligibility criteria include being at least 65 years old with an ECOG of 0 to 1, having histologically/cytologically confirmed Stage IIIB/IV NSCLC, having measurable disease, and not having received radiotherapy within 2 weeks of initial chemotherapy dosing for this study. The exclusion criteria include prior systemic or other concurrent chemo for metastatic NSCLC, ongoing treatment with full-dose warfarin or its equivalent, and hypersensitivity to any component of Alimta, gemcitabine &/or bevacizumab, &/or cannot tolerate folic acid, corticosteroids or Vitamin B12 supplements.",
    "The sample is a phase 2 clinical trial for colorectal cancer. The trial is testing the effectiveness of three drugs, bevacizumab (also known as Avastin), capecitabine (also known as Xeloda), and oxaliplatin, on patients with unresectable liver metastasis. The trial is open to adult patients who are 75 years old or younger and have not received chemotherapy before. Patients must have at least one measurable lesion and an ECOG status of 0-2. Patients who have previously been exposed to Avastin, have clinical or radiological evidence of CNS metastases, have uncontrolled hypertension or clinically significant cardiovascular disease, or are currently taking aspirin or other medications known to predispose to gastrointestinal ulceration are excluded from the trial.",
    "The sample is a phase 2 clinical trial for patients with recurrent or metastatic gastric cancer that has progressed following first-line therapy. The trial is testing the effectiveness of a combination of olaparib, paclitaxel, and placebo drugs. The eligibility criteria include confirmed ATM protein status, at least one measurable or non-measurable lesion that can be assessed by imaging, and no more than one prior chemotherapy regimen for the treatment of gastric cancer in the metastatic or recurrent setting. Exclusion criteria include previous treatment with a PARP inhibitor, more than one prior chemotherapy regimen, and the presence of a second primary cancer, except for certain types of adequately treated cancers.",
    "The sample is a phase 2 clinical trial for patients with unresectable metastatic colorectal cancer. The trial involves the use of drugs such as capecitabine, fluorouracil, irinotecan hydrochloride, and leucovorin calcium. The eligibility criteria include confirmation of colorectal cancer, measurable disease, and a WHO performance status of 0-2. Patients must also meet certain medical criteria such as having a life expectancy of more than 3 months, certain blood counts, and no contraindications to study therapy. Prior chemotherapy for metastatic disease is not allowed, but prior adjuvant chemotherapy is allowed if it was at least 6 months ago and did not include irinotecan hydrochloride with or without bevacizumab. Other concurrent anticancer therapy is not allowed.",
    "The sample is a phase 2 clinical trial for the treatment of moderate chronic obstructive pulmonary disease (COPD). The trial includes patients between the ages of 40 and 80 who meet certain criteria for GOLD stage II disease, have a BMI of less than 35.5 kg/m2, and are current or former smokers. The trial excludes patients who have had more than 2 exacerbations requiring treatment with oral steroids or hospitalization for COPD in the previous year, or who have had a lower respiratory tract infection or significant disease instability in the month preceding screening or during the period between screening and randomization. The trial involves testing the effectiveness of different doses of pf-03635659 compared to a placebo and an active comparator. The diseases and icd-10 codes associated with the trial include pulmonary disease, chronic obstructive, lung diseases, respiratory tract diseases, chronic obstructive airway disease, and COPD.",
    "The sample is a phase 2 clinical trial for the treatment of various types of cancer, including colorectal neoplasm, head and neck neoplasm, carcinoma, non-small-cell lung, and esophageal neoplasm. The trial involves the drug temozolomide and requires participants to meet certain eligibility criteria, such as having a positive biomarker test, having measurable lesions, and having adequate hematologic, renal, and liver functions. Participants must also be at least 18 years old and able to take the medication orally or through a feeding tube. Exclusion criteria include having received treatment for a second malignancy within the past year and having unstable or progressing central nervous system metastasis.",
    "The sample is a phase 2 trial for patients with metastatic squamous cell carcinoma or adenocarcinoma of the esophagus or gastroesophageal junction. Patients must have at least one paraffin block available or at least 15 unstained slides for analysis of tumor EGFR status. They must also have measurable disease and no prior chemotherapy or radiotherapy. Patients must have completed any major surgery \u2265 4 weeks or any minor surgery \u2265 2 weeks before registration. Patients must have fully recovered from the procedure. The trial requires patients to have an ECOG Performance Status of 0-2, be \u2265 18 years of age, and have a stable weight for at least one week prior to registration. Patients must not be pregnant or breastfeeding. The trial also has several exclusion criteria, including no evidence of Gilbert's Syndrome, no myocardial infarction < 6 months prior to registration, and no \u2265 grade 2 diarrhea within 7 days prior to registration.",
    "The sample is a phase 2 clinical trial for knee osteoarthritis. The trial involves testing the effectiveness of several drugs, including crx-102, prednisolone, and placebo. The eligibility criteria for participants include being at least 40 years old, having knee pain for at least 6 months, having a radiographic evidence of knee OA, and meeting certain WOMAC pain score requirements. There are also several exclusion criteria, such as a history of certain diseases or surgeries, drug or alcohol abuse, and pregnancy or lactation. The trial requires participants to comply with certain requirements, including taking a multivitamin or vitamin D and calcium supplements daily.",
    "The sample is a phase 2 clinical trial for the treatment of systemic sclerosis using the drug imatinib mesylate. The trial includes patients who are at least 18 years old and have a clinical diagnosis of diffuse systemic sclerosis with a stable modified Rodnan skin score. The trial excludes patients with certain medical conditions, ongoing treatment with other immunosuppressive therapies, and those who have used other anti-fibrotic agents in the past three months. Patients with severe lung disease or a positive pregnancy test are also excluded. The trial requires men and women with reproductive potential to use effective contraception throughout the study.",
    "The sample is a clinical trial for kidney transplantation, kidney disease, and kidney failure. The trial is in phase 1/phase 2 and involves the use of drugs such as alemtuzumab, mycophenolate mofetil, sirolimus, and tacrolimus. The eligibility criteria for the trial include having a weight greater than 40 kg, receiving a living-related primary kidney allograft, having a negative B-cell and T-cell cytotoxic and flow cytometry crossmatch, having a normal echocardiogram, and having received a full course of vaccination for hepatitis B virus. Exclusion criteria include having previously received or currently receiving an organ transplant other than a kidney, being HIV infected, having a positive antibody for hepatitis C virus, having a current cancer or a history of cancer within the 5 years prior to study entry, and having any form of substance abuse or psychiatric disorder that may interfere with the study.",
    "The sample is a phase 2 clinical trial for HIV infections. The trial includes patients who have a screening plasma HIV-1 RNA value between 2,000 - 250,000 copies/ml, have documented evidence of genotypic resistance, and are receiving an antiretroviral therapy regimen containing at least 3 drugs. The trial aims to test the efficacy of the drugs matching placebo and bevirimat. The eligibility criteria include being free from any acute infection or serious medical illness within 14 days prior to study entry, having a negative pregnancy test for females of child-bearing potential, and being willing to comply with the meal requirements described in the protocol. The exclusion criteria include patients with malabsorption syndromes affecting drug absorption, abnormal Hemoglobin, and recent use of any recreational drugs (except marijuana).",
    "The sample is a phase 2 trial for patients with atherosclerosis. The trial involves the use of drugs such as mldl1278a, placebo, and stable doses of statin therapy. The eligibility criteria include having evidence of qualifying vessel plaque inflammation, documented atherosclerotic vascular disease, and the use of a stable dose of statin therapy for at least 6 weeks prior to screening. Patients must also be capable of maintaining statin therapy at a current dose level from screening until the last follow-up visit. The exclusion criteria include recent cardiovascular events, pregnancy or breastfeeding, abnormal laboratory values or ECG, history of anaphylactic reactions, impaired renal function, and exposure to substantial radiation within 12 months prior to screening.",
    "The sample is a phase 2 clinical trial for multiple sclerosis. The trial includes patients with clinically confirmed MS and an EDSS score less than or equal to 6, who have had two documented relapses in the previous 3 years and one clinical relapse during the preceding year. The trial involves the use of teriflunomide and a placebo for teriflunomide. The eligibility criteria include exclusion of patients with relevant cardiovascular, hepatic, hematologic, neurological, endocrine or other major systemic diseases, pregnant or nursing women, and those who wish to parent children during or after the trial. Patients who have been treated with interferon, gamma-globulin, glatiramer acetate, or other noncorticosteroid immunomodulatory therapies in the 4 months prior to the trial are also excluded. The trial also excludes patients who have used cladribine, mitoxantrone, or other immunosuppressant agents such as azathioprine, cyclophosphamide, cyclosporin, methotrexate or mycophenolate before enrollment. Any known condition or circumstance that would prevent compliance or completion of the study is also excluded.",
    "The sample is a phase 2 clinical trial for hypertension. The trial is testing the effectiveness of the drugs mk8141 and enalapril compared to a placebo. The eligibility criteria include being between 35 and 65 years old, not having been treated for hypertension in the past 14 days, and not taking more than 2 medications to treat high blood pressure in the past 14 days. Women who are unable to have children or do not use birth control are also eligible. Exclusion criteria include taking more than 2 medications to treat high blood pressure, having a history of stroke, heart attack, or certain diseases, being HIV positive, abusing drugs or alcohol, and having participated in another clinical study in the last 4 weeks.",
    "The sample is a phase 2 clinical trial that involves testing the effectiveness of two doses of a drug called mk-8237 in treating allergic rhinitis. The trial includes patients who have a history of allergic rhinitis/rhinoconjunctivitis to house dust of 1 year duration or more (with or without asthma). The trial excludes patients who are sensitized and regularly exposed to animal dander and molds, sensitized and regularly exposed to seasonal allergens, have undergone immunosuppressive treatment within 3 months prior to screening (except steroids for allergic and asthma symptoms), have a history of chronic urticaria and/or angioedema within 2 years prior to screening, have undergone previous immunotherapy treatment with any HDM allergen for more than 1 month within 3 years prior to screening, have ongoing treatment with any specific immunotherapy, have a history of anaphylaxis with cardiorespiratory symptoms with prior immunotherapy, due to an unknown cause or to an inhalant allergen, have unstable uncontrolled/partially controlled or severe asthma, or life-threatening asthma attack or an occurrence of any clinical deterioration of asthma that resulted in emergency treatment, hospitalization due to asthma, or treatment with systemic corticosteroids (but allowing short-acting beta agonists [SABA]) within 3 months prior to screening, have asthma requiring medium- or high-dose inhaled corticosteroid (ICS) within 12 months prior to screening, have chronic sinusitis within 2 years prior to screening, have a nasal condition that could confound the efficacy or safety assessments (e.g., nasal polyps), are pregnant, breastfeeding or planning to become pregnant during the study, or have participated in a different investigational study at any site during the same time frame of this study. The trial includes a placebo group and two groups receiving different doses of the drug.",
    "The sample is a clinical trial for phase 2 of a drug called AZD2171, which is being tested on patients with various types of ovarian and peritoneal cancers. The trial includes a list of eligibility criteria, such as having a life expectancy of at least 6 months, having normal lab values, and not having received certain types of prior treatments. The trial also has exclusion criteria, such as having had chemotherapy or major surgery within the past 3 weeks, having known brain metastases, or having a history of allergic reactions to similar compounds. The sample includes detailed information about the inclusion and exclusion criteria, as well as the diseases, icd-10 codes, and drugs involved in the trial.",
    "The sample is a phase 2 clinical trial for patients with metastatic colorectal cancer. The trial involves the use of three drugs - capecitabine, bevacizumab, and irinotecan. The eligibility criteria for the trial include confirmation of locally advanced or metastatic colorectal cancer, measurable or evaluable disease, ECOG performance status of 2 or less, age between 18 and 72 years, progression after 1st line therapy with FOLFOX/AVASTIN, adequate liver, renal, and bone marrow function, ability to understand the nature of the study, and written informed consent. Exclusion criteria include a history of serious cardiac disease, recent myocardial infarction or stroke, clinically significant peripheral vascular disease, recent abdominal fistula or gastrointestinal perforation, recent major surgical procedure or significant traumatic injury, presence of central nervous system or brain metastasis, evidence of bleeding diathesis or coagulopathy, high blood pressure, pregnancy or lactation, life expectancy less than 3 months, recent radiotherapy or metastatic infiltration of the liver, chronic diarrhea or partial bowel obstruction, active infection requiring antibiotics, second primary malignancy (except for non-melanoma skin cancer and in situ cervical cancer), and psychiatric illness or social situation that would preclude study compliance.",
    "The sample is a phase 2 clinical trial for the treatment of myelofibrosis, a type of blood cancer. The trial is testing the drug aplidin (plitidepsin) on patients who meet certain eligibility criteria, such as having a diagnosis of primary myelofibrosis or post polycythemia vera/essential thrombocythemia myelofibrosis, being at least 18 years old, and having acceptable organ function. The trial also has exclusion criteria, such as previous treatment with plitidepsin, recent chemotherapy or immunomodulatory drug therapy, and incomplete recovery from major surgery. The sample includes a list of diseases and their corresponding ICD-10 codes, as well as the eligibility criteria for the trial.",
    "The sample is a phase 2 clinical trial for patients with incurable colorectal cancer that has metastasized or recurred and is accessible to biopsy. The trial is testing the drug bortezomib. Patients must have at least one measurable lesion that is at least 20mm by conventional techniques or 10mm by spiral CT scan. Patients must also meet certain eligibility criteria, including age over 18, ECOG performance status of 0-1 or Karnofsky score of 70-100%, and a life expectancy of more than 3 months. Patients must also meet certain hematopoietic, hepatic, renal, and cardiovascular criteria, and cannot have certain concurrent illnesses or treatments. Prior chemotherapy is allowed, but no more than one line of prior chemotherapy is allowed for metastatic disease. Prior radiotherapy is allowed, but not to the sole site of measurable disease. No other concurrent investigational agents are allowed.",
    "The sample is a phase 2 clinical trial for the treatment of glaucoma, ocular hypertension, and eye disease. The trial involves the use of two drugs, ama0076 and placebo. The eligibility criteria for the trial include being an adult between the ages of 30-85 with a diagnosis of ocular hypertension or primary open-angle glaucoma in both eyes, not currently receiving medication for intraocular pressure (IOP), and having elevated IOP levels. The exclusion criteria include uncontrolled intraocular hypertension, receiving more than one medication for IOP, having a central corneal thickness outside of a certain range, having poor visual acuity or significant visual field loss, and having acute angle-closure glaucoma or a narrow anterior chamber angle.",
    "The sample is a phase 2 clinical trial for the treatment of acute myeloid leukemia. The trial is looking for participants who are at least 60 years old and fit for intensive chemotherapy, with no significant co-morbidities, and have a life expectancy of more than 1 month. The trial is also looking for participants with high-risk features such as blasts > 20% in bone marrow and poor risk cytogenetics. The trial is testing the effectiveness of two drugs, azacitidine and lenalidomide. The eligibility criteria include various medical conditions and factors that would exclude participants from the trial, such as total bilirubin levels, congestive heart failure, and prior therapy with azacitidine or lenalidomide. Women who are pregnant or breastfeeding and men who are unwilling or unable to use an acceptable method of birth control are also excluded from the trial.",
    "The sample is a phase 2 clinical trial for the treatment of metastatic or relapsed breast cancer using a combination of endotag-1 and paclitaxel. The trial is open to female patients who are at least 18 years old and have a histologically proven triple-receptor-negative breast cancer. The patients must have completed any previous taxane-containing chemotherapy regimen at least 6 months prior to enrollment and have at least one measurable tumor lesion according to RECIST criteria. The patients must also have an ECOG performance status of 0, 1, or 2 and be willing to perform double-barrier contraception during the study and for 6 months post-chemotherapy treatment. The trial has exclusion criteria such as more than 1 previous chemotherapeutic treatment for metastatic or relapsed disease, major surgery < 4 weeks prior to enrollment, and clinically significant cardiac disease (NYHA stadium > 2). The patients must also sign an informed consent form to participate in the trial.",
    "The sample is a phase 2 clinical trial for the treatment of advanced or metastatic gastric carcinoma, or adenocarcinoma of the gastroesophageal junction or of the distal esophagus. The trial is testing the drug GSK1363089 (formerly xl880). The eligibility criteria include having a confirmed diagnosis of the specified cancers, measurable disease, an ECOG performance status \u22642, and the ability to ingest the drug. Exclusion criteria include having received more than two lines of prior cytotoxic chemotherapy, having received an investigational drug within 14 days of the first dose of study drug, and having known brain metastases. The trial also requires paired tumor biopsies and subjects must be able to understand and comply with the protocol and have signed the informed consent document.",
    "The sample is a phase 2 clinical trial for patients with high-grade glioma, including glioblastoma multiforme, anaplastic astrocytoma, anaplastic oligodendroglioma, and high-grade astrocytoma not otherwise specified. The trial is for patients with recurrent or progressive disease that is refractory to standard therapy. The trial requires radiographically documented measurable disease, and patients must meet certain eligibility criteria, including having a Karnofsky performance status of 50-100%, a life expectancy of at least 8 weeks, and certain laboratory values within normal limits. The trial involves the use of the drug cilengitide and excludes patients who have undergone certain prior treatments or who are receiving other concurrent anticancer therapy or experimental agents.",
    "This is a sample from a table that contains information about clinical trials. The trial is in phase 2 and is focused on treating non-small-cell lung carcinoma. The trial is looking at the drug xl647 and the eligibility criteria includes having a confirmed diagnosis of unresectable Stage IIIB or Stage IV relapsed or recurrent NSCLC, documented progressive disease following a prior response to monotherapy with erlotinib or gefitinib, or a documented T790M EGFR mutation. The trial also requires measurable disease defined according to RECIST, an ECOG performance status of 0 or 1, and the use of an accepted method of contraception during the course of the study. The sample also includes exclusion criteria such as having received radiation to \u226525% of bone marrow within 30 days of XL647 treatment, having received erlotinib or gefitinib within 14 days of the first dose of study drug, and having a corrected QT interval (QTc) of >0.45 seconds.",
    "The sample is a phase 2 clinical trial for the treatment of hypercholesterolemia. The trial includes eligibility criteria for participants, such as age range, specific LDL-C levels, and fasting mean TGs. There are also exclusion criteria, such as pregnancy, uncontrolled hypertension, and a history of liver disease or malignancy. Participants must understand and comply with the protocol and sign consent. The trial will test the effectiveness of two drugs, atorvastatin and aegr-733, and participants cannot be using other lipid-lowering medications during the trial.",
    "The sample is a phase 2 clinical trial for the treatment of plaque-type psoriasis with or without psoriatic arthritis. The trial involves the use of various drugs, including cnto 1959, adalimumab, and placebo. The eligibility criteria include a diagnosis of psoriasis for at least 6 months, being a candidate for phototherapy or systemic treatment, and being considered a suitable candidate for adalimumab therapy. There are also specific requirements for birth control for female and male participants. The exclusion criteria include a history of severe or uncontrolled diseases, contra-indication to anti-TNF therapy, chronic or recurrent infectious disease, nonplaque form of psoriasis, previous treatment with adalimumab, and recent use of therapeutic agents targeted to IL-12, IL-17, or IL-23.",
    "The sample is a clinical trial for a drug called RP-1127 (glyburide for injection) for the treatment of acute ischemic stroke in the MCA or MCA/ACA territory. The trial is a combination of phase 1 and phase 2. The eligibility criteria for the trial include having a clinical diagnosis of acute ischemic stroke, a pre-morbid mRS score of 0-1, a baseline DWI lesion between 82 cm3 and 210 cm3 on MRI, and being treated with IV rtPA within the established criteria. The trial also has exclusion criteria, such as evidence of any diagnosis other than acute ischemic stroke likely to cause the presenting symptoms and signs, commitment to decompressive craniectomy (DC) prior to enrollment, or treatment with IA rtPA or by mechanical means for clot disruption or with hypothermia. The sample also includes a list of diseases, icd-10 codes, and drugs related to the trial.",
    "The sample is a phase 2 clinical trial for pancreatic cancer. The trial includes adult patients who are 18 years or older and have locally advanced and/or metastatic pancreatic cancer (stage III or IV) with a Karnofsky performance status of 60% or higher. The trial excludes patients with local pancreatic cancer (stage IA to IIB), those who have had adjuvant chemotherapy within the last 6 months, those who have had previous systemic therapy for metastatic pancreatic cancer, those with other primary tumors within the last 5 years (except for adequately treated cancer in situ of cervix or basal cell skin cancer), and those with clinically significant cardiovascular disease. The trial will test the effectiveness of erlotinib and gemcitabine as treatments for pancreatic cancer.",
    "The sample is a phase 2 clinical trial for metastatic colorectal cancer. The trial involves the use of chemotherapy drugs such as capecitabine, oxaliplatin, 5-fu, and leucovorin. The eligibility criteria for the trial include having no prior treatment for metastatic disease, a PS score of 0-2, and measurable disease. However, patients with neuropathy greater than or equal to grade 2, concomitant radiation therapy or other systemic cancer therapies, and brain metastases are excluded from the trial. The icd-10 codes associated with the disease are also provided.",
    "The sample is a phase 2 clinical trial for rheumatoid arthritis. The trial involves testing multiple drugs, including a placebo, and the eligibility criteria includes having an inadequate response to Methotrexate, taking Methotrexate for at least 3 months at a minimal weekly dose of 15 mg, having an ACR global function status class of 1-3, having a minimum of 6 swollen and 6 tender joints with evidence of synovitis in at least 1 hand or wrist, and having a high sensitivity C-reactive protein (hsCRP) level of at least 0.8 mg/dL. The exclusion criteria includes having previously received or currently receiving concomitant biologic therapy.",
    "The sample is a phase 2 clinical trial for patients with non-small-cell lung carcinoma or adenocarcinoma with BAC features. The trial is testing the drug Velcade and has specific eligibility criteria for patients to participate. These criteria include having progressed on or after receipt of 1 to 2 prior lines of chemotherapy, having measurable disease by RECIST, and having an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2. The trial also has exclusion criteria, such as having had chemotherapy or an EGFR TKI 4 weeks prior to enrollment and having poorly controlled hypertension, diabetes mellitus, or another serious medical or psychiatric illness that could potentially interfere with the completion of treatment according to the protocol.",
    "The sample is a phase 2 clinical trial for the treatment of multiple myeloma and plasma cell neoplasm. The trial involves the use of three drugs - dexamethasone, lenalidomide, and melphalan. The eligibility criteria for the trial include confirmed multiple myeloma, measurable serum M-component or urinary excretion of light-chain protein, and being ineligible for stem cell transplantation due to advanced age, comorbid illness, or patient preference. Patients must also meet certain patient characteristics such as having an ECOG performance status of 0-2, life expectancy of at least 12 months, and meeting certain blood count and liver function tests. Patients must not have any other malignancies within the past 5 years, except for adequately treated nonmelanoma skin cancer or curatively treated in situ cancer of the cervix. Patients must not have any serious illness or medical condition that would preclude study participation, and must not have a history of significant neurologic or psychiatric disorder that would preclude informed consent. Prior chemotherapy or corticosteroids for the treatment of multiple myeloma is not allowed, but prior radiotherapy to single sites for pain control or local plasmacytoma is allowed. Concurrent bisphosphonates are allowed, but concurrent corticosteroids above physiologic replacement doses and other concurrent anticancer therapy are not allowed.",
    "This sample is from a clinical trial in phase 2 for the treatment of human immunodeficiency virus (HIV) infection. The trial involves the use of several drugs, including BMS-663068, raltegravir, tenofovir, and ritonavir, among others. The eligibility criteria for the trial include having a plasma HIV-1 RNA level of at least 1000 copies/ml, prior treatment with antiretroviral therapies (excluding integrase inhibitors), and a CD4+ T-cell count of more than 50 cells/mm3. However, individuals with a history of genotypic resistance to any component of the study regimen or certain laboratory and electrocardiogram (ECG) values are excluded from the trial.",
    "The sample is a phase 2 clinical trial for patients with advanced and/or metastatic malignant soft tissue sarcoma of high or intermediate grade. The trial includes patients with various types of sarcoma, excluding certain types such as embryonal rhabdomyosarcoma and chondrosarcoma. Patients must have evidence of objective progression within the last 6 months and presence of measurable disease. They must have received no more than one combination or two single agent chemotherapy regimens for advanced disease. Patients must also meet certain eligibility criteria such as having adequate bone marrow, hepatic, and renal function, absence of brain or subdural metastases, and absence of pre-existing neuropathy > Grade 2. Women of childbearing potential must agree to use contraceptive methods while on treatment and during a period of 3 months after the end of treatment. The trial has exclusion criteria such as prior history of malignancies other than sarcoma, significant cardiovascular impairment, and severe/uncontrolled intercurrent illness/infection.",
    "The sample is a record from a clinical trial table that includes information about the phase of the trial (phase 1/phase 2), the diseases being studied (hematologic malignancies and AML), the ICD-10 codes associated with those diseases, the drugs being tested (cp-4055), and the eligibility criteria for patients to participate in the trial. The eligibility criteria include factors such as age, performance status, laboratory values, and previous treatments. The sample also includes exclusion criteria, such as allergies to the drug being tested, positive HIV or hepatitis status, and uncontrolled illness. The record provides detailed information about the trial and the patients who are eligible to participate.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on prostate cancer and includes a list of ICD-10 codes associated with the disease. The trial involves the use of three drugs: docetaxel, ly2181308 sodium, and prednisone. The eligibility criteria for the trial include confirmation of adenocarcinoma of the prostate that is metastatic and/or unresectable, hormone refractory prostate cancer, Eastern Cooperative Oncology Group (ECOG) status 0-2, and adequate hematological, liver, and renal functions. The exclusion criteria include known hypersensitivity to docetaxel or taxane therapy, documented central nervous system or leptomeningeal metastasis, prior treatment with chemotherapy or bone-seeking radionuclides in the past 6 weeks, evidence of painful and/or destructive bone metastases, and recent treatment with a drug that has not received regulatory approval.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on the treatment of metastatic breast cancer. The icd-10 codes associated with the disease are listed as C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, and D48.60. The trial is testing the effectiveness of two drugs, bevacizumab and paclitaxel. The eligibility criteria for participants include being at least 20 years old, having advanced or inoperable metastatic breast cancer, being HER2 negative, having at least one measurable lesion based on RECIST criteria, and not having received previous chemotherapy for metastatic breast cancer.",
    "The sample is a phase 2 trial for head and neck cancer and squamous cell carcinoma. The trial involves the drug lapatinib and has specific eligibility criteria for participants, including being newly diagnosed with stage III-IV HNSCC, having no evidence of distant metastasis, and not having prior radiation therapy to the head and neck sites. Participants must also meet certain health requirements, such as having a left ventricular ejection fraction within the institutional normal range and not having certain medical conditions that would preclude the use of concurrent CRT. The trial has exclusion criteria as well, such as known hypersensitivity to lapatinib or any of its excipients and a history of myocardial infarction within 6 months of study entry.",
    "This is a sample from a clinical trial table that includes information about the trial's phase, diseases being studied, associated ICD-10 codes, drugs being tested, and eligibility criteria for participants. In this particular sample, the trial is in phase 2 and is focused on chronic obstructive pulmonary disease (COPD). The ICD-10 codes associated with COPD are listed, along with the drugs being tested (indacaterol/glycopyrrolate, indacaterol, and placebo). The eligibility criteria for participants are also listed, including age, smoking history, lung function, and exclusion criteria such as pregnancy, certain medical conditions, and medication allergies.",
    "The sample is a phase 2 clinical trial for the treatment of insomnia. The trial is testing the effectiveness of the drug \"pd 0200390\" and a placebo. The trial is looking for participants who have a 3-month history of primary insomnia, are between the ages of 18 and 64, and have difficulty initiating and maintaining sleep for at least 3 nights a week for the past month. Participants with a history of an Axis 1 psychiatric diagnosis, breathing related sleep disorder, or any medical or neurological condition that could interfere with sleep are excluded from the trial. Additionally, participants who use alcohol as a sleep aid or consume more than 2 standard drinks per day or more than 14 per week are also excluded.",
    "The sample is a phase 2 clinical trial for major depressive disorder. The trial involves the use of quetiapine extended release (xr) and a placebo. The eligibility criteria for the trial include a diagnosis of major depressive disorder, appropriate treatment history, and a Hamilton Depression Rating Scale (HAM-D17) total score of 20 points or more. Exclusion criteria include concurrent or previous history of DSM-IV-TR Axis I disorders, except major depressive disorder, within the last 6 months before informed consent, and concurrence of DSM-IV-TR Axis II disorder that is considered to greatly affect patient's current mental status. Other exclusion criteria include history of dependence of substances other than caffeine and nicotine or history of abuse or dependence of alcohol, and concurrent or previous history of diabetes mellitus. The sample also includes a list of icd-10 codes of diseases.",
    "The sample is a phase 2 clinical trial for the treatment of type 2 diabetes mellitus. The trial includes adult male and female subjects between 18 and 65 years of age with a BMI between 27 and 40 kg/m2. The inclusion criteria require subjects to have established type 2 diabetes mellitus for at least 3 months and inadequate glycemic control defined by an HbA1c level of \u2265 7.5% and \u226510% at screening. Subjects must also be on a stable dose of metformin and/or sulfonylurea for \u2264 2 months prior to the screening visit. The exclusion criteria include subjects with type 1 diabetes mellitus, maturity-onset diabetes of the young, or any rare form of diabetes, as well as those who have had more than 4 episodes of severe hypoglycemia in the 6 months prior to screening. Subjects who have been treated with certain medications in the 3 months prior to screening or who are receiving systemic glucocorticoids for \u226514 days are also excluded.",
    "The sample is a phase 2 clinical trial for the treatment of eosinophilic esophagitis. The trial is open to both male and female participants aged 18-50 who have tried an elimination diet and have been on treatment with a protocol pump inhibitor for at least two months prior to enrollment. Female participants must be of non-childbearing potential and appropriate contraception must be used by male participants. The trial requires good communication skills and understanding of the study requirements. Exclusion criteria include recent use of corticosteroids, other eosinophilic disorders, history of immunodeficiency diseases, and drug or alcohol abuse within the past 12 months. Other protocol-defined inclusion/exclusion criteria may also apply.",
    "The sample is a phase 2 clinical trial for advanced or metastatic adenocarcinoma of the breast using the drug MKC-1. The trial includes patients who have failed both a taxane and an anthracycline, given sequentially or in combination, either in an adjuvant or metastatic setting. The eligibility criteria include age 18 or older, Karnofsky performance status greater than or equal to 70%, and radiographic or physical examination evidence of at least one site of unidimensionally-measurable disease. The trial also has exclusion criteria, such as pre-existing hepatomegaly with disease measures greater than or equal to 2 cm below the costal margin, secondary to malignancy, and administration of cancer-specific therapy within certain periods prior to study drug initiation. The trial requires signed informed consent and lab results within 10 days of MKC-1 administration.",
    "The sample is a record from a clinical trial table that includes information about the trial's phase, diseases being studied, icd-10 codes of those diseases, drugs being used, and eligibility criteria for participants. In this particular sample, the trial is in phase 1/phase 2 and is studying colorectal carcinoma. The icd-10 codes associated with the disease are listed, as well as the drugs being used in the trial. The eligibility criteria for participants are also listed, including requirements such as having received only one prior chemotherapy regimen for metastatic disease and having normal organ and marrow function. The exclusion criteria are also listed, such as having a diagnosis of any secondary malignancies within the last 5 years or being pregnant or breastfeeding.",
    "The sample is a phase 2 clinical trial for patients aged 1 to 21 years with relapsed or refractory acute myelogenous or lymphoblastic leukemia and minimal residual disease (MRD). The trial involves the use of drugs such as clofarabine, cytarabine intravenous, methotrexate, and intrathecal (it) cytarabine. The eligibility criteria include having an ANC >500/\u03bcL off cytokine support for at least 24 hours, platelets >50,000 K/\u03bcL without platelet transfusion in the past seven days, and a shortening fraction > 28% by echocardiogram or an ejection fraction > 50% by MUGA. Patients must also have adequate renal and hepatic functions, and must not have had previous HSCT within the previous 180 days or prior treatment with clofarabine. The exclusion criteria include having a previous history of veno-occlusive disease (VOD), systemic fungal, bacterial, viral, or other infection not controlled, or any significant concurrent disease, illness, psychiatric disorder or social issue that would compromise patient safety or compliance.",
    "The sample is a phase 2 clinical trial for adult attention deficit hyperactivity disorder. The trial includes subjects who meet the Diagnostic and Statistical Manual of Mental Disorders Fourth Edition criteria for a primary diagnosis of ADHD. The subjects must have a lifetime history of treatment with at least one medication for ADHD and must be between 18 to 55 years old. The trial involves the use of drugs such as sep-225289 and placebo. The eligibility criteria include negative breath alcohol and urine drug screen, negative serum pregnancy test for female subjects, and the use of effective birth control throughout the study period. The exclusion criteria include a history of drug dependence or substance abuse, current use of antidepressant medication or St. John's Wort, and a clinically significant abnormality on screening evaluation.",
    "The sample is a phase 2 clinical trial for the treatment of castrate resistant prostate cancer, chemotherapy naive prostate cancer, and prostate cancer. The trial involves the use of two drugs, pasireotide and everolimus. The eligibility criteria for the trial include being at least 18 years old, having histological confirmation of prostatic adenocarcinoma, having a PSA level of at least 2 ng/ml, and having PSA progression or disease progression on imaging studies. Other criteria include being minimally symptomatic, discontinuing all antiandrogen, ketoconazole, and investigational drugs for at least 4 weeks prior to the study, maintaining castrate levels of testosterone, having a Karnofsky Performance Status of at least 60%, having a life expectancy of more than 3 months, and having adequate hematologic, renal, and liver function. Exclusion criteria include having a currently active second malignancy other than non-melanoma skin cancers, having clinically significant cardiovascular disease, having progressive pulmonary disease, having known CNS disease, having poorly controlled diabetes mellitus or hypercholesterolemia, currently using chronic steroids, having active gallbladder disease or hepatitis, having serum creatinine above 1.5 upper limit of normal or on dialysis, and having prior use of a somatostatin analog or mTOR inhibitor for the treatment of PC.",
    "The sample is a phase 2 clinical trial for patients with refractory solid cancer for which curative or palliative measures have failed or patients whose treatments are considered ineffective or intolerable. The trial includes patients with non-colorectal cancers who are progressing at the time of the screening assessment and for whom no other treatment exists. Patients must have at least one measurable tumor, histological or cytological documentation of cancer, and an ECOG performance status of 0 or 1. Patients must also have a life expectancy of at least 12 weeks and adequate bone marrow, liver, and renal function. Exclusion criteria include non-small cell lung cancer, hepatocellular cancer, CML and AML, serious cardiac arrhythmia, congestive heart failure, active coronary artery disease or ischemia, active acute infections, known HIV infection, metastatic brain or meningeal tumors, and several other conditions. Patients must not have received anticancer chemotherapy or immunotherapy during the study or within 4 weeks prior to the first dose of study drug, radiotherapy during the study or within 3 weeks prior to the first dose of study drug, or bone marrow transplant or stem cell rescue within 4 months prior to the first dose of study drug. Patients must also not have any previous exposure to a Ras pathway inhibitor. Pregnant or breastfeeding patients are excluded, and women of childbearing potential must have a negative pregnancy test. Adequate barrier contraception is required for both male and female patients during the entire course of the trial. Patients with substance abuse, medical or psychological or social conditions that may interfere with the patient's participation in the study or evaluation of the study results are also excluded.",
    "The sample is a phase 2 clinical trial for the treatment of hepatitis C. The trial is looking at the effectiveness of the drugs grazoprevir and ribavirin in treating chronic, compensated hepatitis C genotype 1. The trial has specific inclusion criteria, such as having the IL28B CC genotype and no signs of advanced liver disease or cirrhosis. There are also exclusion criteria, such as having a non-genotype 1 HCV infection or a history of depression associated with hospitalization or severe psychiatric disorders. The trial requires participants to use two acceptable methods of birth control and refrain from participating in another study. The sample also includes a list of diseases and their corresponding ICD-10 codes, as well as eligibility criteria for the trial.",
    "The sample is a record of a clinical trial with a phase 1/phase 2 designation. The trial is focused on the treatment of acute lymphoblastic leukemia, a type of cancer affecting the blood and bone marrow. The trial is open to subjects between the ages of 1 and 55 who have relapsed after their first remission or who are still refractory to first-line chemotherapy for ALL. The trial requires written informed consent from patients or their parents if they are children. The record also includes a list of exclusion criteria.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on the disease of menopause, which is identified by the ICD-10 codes E28.310 and E28.319. The trial involves the use of two drugs, esterified estrogens 1.25mg and methyltestosterone 2.5mg, and esterified estrogens 1.25 mg. The eligibility criteria for the trial includes being a hysterectomized, menopausal woman between the ages of 30 and 65 years old who is experiencing symptoms of estrogen and/or androgen deficiency that are not currently controlled by estrogen therapy.",
    "The sample is a record of a clinical trial in phase 2 for the treatment of colitis, ulcerative. The trial involves the use of drugs such as anti-ip-10 antibody and placebo. The eligibility criteria for the trial include a clinical diagnosis of moderate to severe UC confirmed by endoscopic and histologic evidence, Mayo score of at least 6 with an endoscopic subscore of at least 2, and inadequate response or intolerance to conventional therapies. Exclusion criteria include a diagnosis of Crohn's Disease or Indeterminate Colitis, UC limited to the rectum, evidence of fulminant colitis, toxic megacolon, or bowel perforation, current need for a colostomy or ileostomy, and previous total or subtotal colectomy.",
    "The sample is a phase 2 clinical trial for testicular cancer. The trial is looking at the effectiveness of three drugs - paclitaxel, cisplatin, and gemcitabine. The eligibility criteria for the trial include having a confirmed germ cell tumor with measurable metastatic disease, being male and over 18 years old, having a performance status of 0, 1, 2, or 3, and meeting certain blood and renal function requirements. The trial also has exclusion criteria, such as having uncontrolled severe clinical infection or a second malignancy other than basal or squamous cell skin cancer.",
    "The sample is a phase 2 clinical trial for the treatment of opioid-induced constipation in adults aged 18 to 75 years old. The trial includes participants who have been taking a stable daily dose of opioids for chronic noncancer pain for at least 30 days before screening. The trial aims to test the efficacy of two drugs, placebo and adl5945 0.25 mg, in treating constipation. The eligibility criteria include having a body weight of at least 45 kg and a body mass index (BMI) of no more than 40 kg/m^2, experiencing less than three spontaneous bowel movements per week, and having experienced at least one other bowel movement symptom for at least 25% of the total bowel movements. The trial excludes participants who are pregnant, lactating, or planning to become pregnant during the study, have a recent history of myocardial infarction or unstable angina, have an active malignancy of any type, or have gastrointestinal or pelvic disorders known to affect bowel transit.",
    "This sample is for a phase 2 clinical trial for patients with metastatic colon or rectal cancer who have progressed or relapsed after first-line treatment. The trial is testing the drug bevacizumab (also known as Avastin). The eligibility criteria include requirements for adequate contraception for women of childbearing potential and exclusion criteria such as untreated brain metastases, spinal cord compression, or primary brain tumors. Patients who have had major surgical procedures, open biopsies, or significant traumatic injuries within 28 days prior to the study start are also excluded. Additionally, patients who have received any investigational drug or participated in another investigational study within 30 days prior to enrollment are excluded.",
    "The sample is a record of a clinical trial in phase 2 for the treatment of overactive bladder. The trial involves the use of two drugs, uk-369,003 and placebo. The eligibility criteria for the trial includes male subjects aged 18 years and above with a clinical diagnosis of overactive bladder, urinary frequency of at least 8 times per day, and more than one episode of urgency per day. The exclusion criteria includes neurological diseases that affect bladder function and urinary tract infections. The diseases are listed as 'urinary bladder, overactive' and the corresponding ICD-10 code is 'N32.81'.",
    "The sample is a phase 2 clinical trial for the treatment of T-cell Prolymphocytic Leukemia using the drug Velcade. The trial includes patients who have previously been refractory or have relapsed since treatment and first documented response. The eligibility criteria include confirmed diagnosis of T-cell PLL, Eastern Cooperative Group (ECOG) 0-2, and specific bilirubin and ALT levels. Exclusion criteria include platelet count and absolute neutrophil count below certain levels, peripheral neuropathy, recent myocardial infarction or heart failure, hypersensitivity to the drug or its components, pregnancy or breastfeeding, and other medical conditions that may interfere with the patient's participation in the study. The trial requires voluntary written informed consent and the use of acceptable methods of birth control for female subjects and contraception for male subjects.",
    "The sample is a phase 2 clinical trial for patients with multiple sclerosis. The trial is testing the effectiveness of a combination of drugs including alemtuzumab, fludarabine, and cyclophosphamide. The eligibility criteria for the trial includes being between the ages of 18-60, having a diagnosis of multiple sclerosis according to the McDonald's criteria, having an EDSS score of 3.5-5.5, and having failed primary disease modifying therapy with interferon and another therapy. Patients must also not have a history of allergic reactions to certain medications, not be pregnant, and have a life expectancy of more than 6 months. The trial excludes patients with a diagnosis of primary progressive MS.",
    "The sample is a record of a clinical trial in phase 2, focused on treating neuropathic pain. The record includes a list of diseases and their corresponding ICD-10 codes, as well as a list of drugs being tested. The eligibility criteria for the trial are also included, with specific requirements for gender and menopause status, as well as a diagnosis of neuropathic pain by a neurologist. The exclusion criteria are the same as the inclusion criteria.",
    "The sample is a phase 2 clinical trial for colorectal cancer patients with metastases. The trial involves the use of three drugs: bevacizumab (also known as Avastin), capecitabine, and irinotecan. The eligibility criteria for the trial include being an adult patient over 18 years of age with colon or rectal cancer and at least one measurable lesion. Exclusion criteria include previous systemic treatment for advanced disease, recent radiotherapy, daily use of aspirin or anticoagulants, and co-existing malignancies or malignancies diagnosed within the last 5 years (except for basal cell cancer or cervical cancer in situ).",
    "The sample is a phase 2 clinical trial for patients with invasive breast cancer who have not received prior treatment. The trial is testing the effectiveness of the drug everolimus in combination with breast-conserving surgery. Patients must meet certain criteria, including having a HER2-positive primary tumor and meeting specific medical requirements. Patients must also not have any concurrent severe medical conditions or be taking certain medications. The trial is not allowing any other concurrent anti-cancer treatments such as chemotherapy, immunotherapy/biological response modifiers, endocrine therapy, or radiotherapy.",
    "The sample is a phase 2 clinical trial for sickle cell anemia and sickle \u00df0-thalassemia. The trial involves the drugs l-glutamine and placebo. The eligibility criteria include being at least five years of age, having had at least two episodes of painful crises within 12 months of the screening visit, and having a documented diagnosis of sickle cell anemia or sickle \u00df0-thalassemia. The patient must also have given written informed consent and agree to practice a recognized form of birth control if female and of child-bearing potential. Exclusion criteria include having a significant medical condition that required hospitalization (other than sickle painful crisis) within two months of the screening visit, having diabetes mellitus with untreated fasting blood sugar >115 mg/dL, and being pregnant or lactating.",
    "The sample is a phase 2 clinical trial for the treatment of chronic obstructive pulmonary disease (COPD). The trial includes patients who are male or female, aged 40 to 80 years, with a diagnosis of stable, moderate to severe COPD. Patients must be current or former cigarette smokers with a smoking history of at least 10 pack-years. The trial involves the use of several drugs, including aclidinium and formoterol, as well as a placebo. Eligibility criteria include having post-albuterol/salbutamol FEV1 values between 30% and 80% of the predicted value, and post-albuterol/salbutamol FEV1/FVC values less than 70%. Patients must also be in good stable health, with COPD symptoms and FEV1 values that are stable compared to those at screening. Exclusion criteria include recent hospitalization for an acute COPD exacerbation, respiratory tract infections, clinically significant respiratory conditions other than COPD, and a history or presence of asthma.",
    "The sample is a phase 2 clinical trial for patients with chronic kidney disease stage 3 or 4, not requiring dialysis, and suffering from anemia. The trial involves the use of two drugs, placebo and peginesatide. The eligibility criteria include having a GFR of 15-60 mL/min, hemoglobin values of \u2265 9 g/dL and \u2264 11 g/dL, and one serum ferritin level \u2265 100 \u00b5g/L and one transferrin saturation \u2265 20%. Exclusion criteria include prior treatment with any erythropoiesis stimulating agent, history of pure red cell aplasia, and hemoglobinopathy. The trial also excludes patients with chronic, uncontrolled, or symptomatic inflammatory disease, malignancy, and life expectancy < 12 months.",
    "The sample is a phase 2 clinical trial for patients with recurrent glioblastoma multiforme or gliosarcoma. The trial is testing the effectiveness of pazopanib hydrochloride as a treatment option. The eligibility criteria include having failed prior radiotherapy, having no more than 2 prior relapses, and having a Karnofsky performance status of 60-100%. Patients must also meet certain medical criteria, such as having a life expectancy of more than 8 weeks and normal blood counts. The trial excludes patients with certain medical conditions or who are taking certain medications. The trial also requires patients to use effective contraception during the study therapy.",
    "The sample is a phase 2 clinical trial for patients with relapsed mantle cell lymphoma. The trial is testing the effectiveness of the drugs bortezomib and gemcitabine hydrochloride. Patients must have received 1-3 prior systemic chemotherapy regimens and have had no disease progression while receiving chemotherapy or within 1 month of the last dose of the most recent therapy. Patients must also have clinically and/or radiologically documented disease, with at least 1 site of disease bidimensionally measurable by CT scan or MRI. Patients must meet certain eligibility criteria, including having an ECOG performance status of 0-2, a life expectancy of at least 12 weeks, and meeting certain laboratory values. Patients must not have preexisting ascites or pleural effusion \u2265 grade 2, known CNS involvement by lymphoma, or other serious illnesses or medical conditions that would preclude compliance with study requirements. Prior concurrent therapy is also specified in the eligibility criteria.",
    "The sample is a phase 2 trial for the treatment of Hodgkin's lymphoma. The trial includes patients who are 21 years of age or younger and have not received any prior treatment. The trial also has specific inclusion criteria, such as the patient having histologically confirmed previously untreated Hodgkin's disease and being in Ann Arbor stages IIB-IV. The trial involves the use of various drugs, including 12 week Stanford V chemotherapy, 4 cycles of VAMP chemotherapy, and 2 or 3 alternating cycles of VAMP/COP chemotherapy. The eligibility criteria for the trial are listed in detail, including the exclusion of pregnant or lactating women and the requirement for signed informed consent. The trial also includes treatment options for patients with favorable or unfavorable risk features.",
    "The sample is a clinical trial in phase 2 for the treatment of myocardial infarction using the drug epoetin alfa. The trial includes patients who have undergone successful primary PCI for a first acute myocardial infarction and meet certain criteria, such as having chest pain suggestive of acute myocardial infarction and ECG with ST-T segment elevation. The trial also has exclusion criteria, such as patients with hemoglobin levels above 10.6 mmol/L and those with other serious medical conditions. Patients who meet the inclusion criteria and do not meet the exclusion criteria will be randomized to receive either epoetin alfa or a placebo.",
    "The sample is a phase 2 trial for patients with advanced or metastatic breast cancer that is estrogen receptor-negative and progesterone receptor-negative. The trial includes patients with measurable disease and no known brain metastases. Patients must have had progression of disease following no more than one first-line chemotherapy regimen. The trial drug is saracatinib. The eligibility criteria include various medical and health-related factors, such as normal blood counts, liver and kidney function, and no history of allergic reactions to similar drugs. Patients must also be willing to use adequate contraception and sign a written informed consent document.",
    "The sample is a record of a clinical trial with a phase 2/phase 3 designation. The trial is focused on anaplastic thyroid cancer and includes a list of icd-10 codes for the disease. The trial involves the use of three drugs: ca4p, paclitaxel, and carboplatin. The eligibility criteria for the trial include confirmation of the disease through pathology review, refractory or progressed disease, limited systemic therapy, and adequate bone marrow and organ function. Exclusion criteria include tumors confined to the thyroid, brain metastasis, and history of certain medical conditions.",
    "The sample is a phase 2 clinical trial for the treatment of myelodysplastic syndrome. The trial includes patients who meet certain criteria, such as having a diagnosis of MDS that meets International Prognostic Scoring System criteria for low risk, intermediate-1 risk, or intermediate-2 risk, having an Eastern Cooperative Oncology Group performance status score of 0, 1, or 2, and being willing and able to attend study visits. The trial also has exclusion criteria, such as having any serious medical illness that might limit survival to less than 2 years, having received prior anti-lymphocyte serotherapy, having certain abnormal lab values, and having a history of a grade 2 National Cancer Institute common toxic criteria allergic reaction to rabbit proteins. The trial involves the use of antithymocyte globulin (atg) and prednisone as drugs, and patients must be willing to use acceptable forms of contraception prior to study entry and for the duration of the study.",
    "The sample is a phase 2 clinical trial for patients with multiple myeloma. The trial includes patients with relapsed or refractory multiple myeloma, with Durie-Salmon stage I or greater at diagnosis. Patients with non-secretory or oligo-secretory MM must have at least 30% bone marrow plasma cells, while patients with secretory MM must have measurable disease defined as serum monoclonal protein of at least 1 g/dL or urinary M-spike of at least 200 mg/24 hours. Patients must have received at least 1, but no more than 5 prior therapy regimens, and have a performance status of ECOG 0-2 or ECOG 0-3 if secondary to neuropathy or acute bone event. Patients must also meet certain laboratory criteria, including absolute neutrophil count, bilirubin, alkaline phosphatase, AST, and creatinine levels. Patients must not have had a myocardial infarction within the past 6 months, and must not have any uncontrolled serious medical conditions or infections. Patients must not have any other active malignancy, and must not be pregnant or nursing. Fertile patients must use effective contraception, and patients must not have had prior allogeneic stem cell transplantation. Patients must not have had concurrent biologic therapy or other concurrent chemotherapy, and must not have had concurrent corticosteroids except for chronic corticosteroids for disorders other than myeloma. The trial drug is alvocidib, and concurrent bisphosphonates are allowed if on a stable dose before study entry.",
    "The sample is a clinical trial for patients with locally advanced inoperable or metastatic adenocarcinoma of the pancreas or biliary tract who have not previously received more than one systemic treatment for their disease. The trial is in phase 1/phase 2 and involves the use of oxaliplatin, capecitabine, and sorafenib. The eligibility criteria include age at least 18 years old, ECOG performance status 0-2, adequate organ and marrow function, at least one measurable lesion, and the ability to understand and sign a written informed consent document. Exclusion criteria include concomitant radiation therapy or other systemic cancer therapies, known brain metastases, history of allergy to certain compounds, uncontrolled intercurrent illness, pregnancy or nursing, major surgery or significant traumatic injury within 4 weeks of first study drug, and other conditions that impair the patient's ability to swallow whole pills.",
    "The sample is a phase 2 clinical trial for small cell lung cancer patients with either limited or extensive stage disease. The trial is testing the effectiveness of the drug dasatinib on patients who have had a relapse after initial treatment with platinum-based chemotherapy. Patients must have measurable disease and meet certain eligibility criteria, including having an ECOG performance status of 0-1, platelet count of at least 100,000/mm^3, and no known brain metastases. Patients must also not have significant cardiac disease and must not have had more than one prior chemotherapy regimen. The trial excludes patients who have had prior treatment with dasatinib or similar compounds, and those who are pregnant or nursing. Patients must use effective contraception during and for at least 6 weeks after completion of study therapy if they are fertile.",
    "The sample is a phase 2 clinical trial for breast cancer patients. The trial includes patients who have undergone definitive breast surgery with axillary lymph node dissection or evaluation within 60 days of study registration. The trial includes patients with operable breast cancer, either mastectomy or breast conserving surgery with axillary lymph node dissection. The patients must have histologically free margins of resected specimen from definitive surgery. The trial includes lymph node-positive or lymph node-negative patients with high-risk features as determined by the investigator. The patients must have normal cardiac function and meet certain hematology and hepatic function criteria. The trial excludes patients who have received prior systemic anticancer therapy for breast cancer, prior radiation therapy for breast cancer or any radiotherapy to the chest wall for any other malignancy, bilateral invasive breast cancer, pregnant or lactating subjects, and male subjects. The trial also excludes patients with other serious illnesses or medical conditions.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on lower urinary tract symptoms and bladder outlet obstruction, with the inclusion of patients who meet certain criteria such as having a BOO indication by a Bladder Outlet Obstruction Index (BOOI) of at least 20 and a total International Prostate Symptom Score (IPPS) score of at least 8. The trial involves the use of drugs such as solifenacin succinate, tamsulosin hydrochloride, and placebos. The sample also includes exclusion criteria such as a history of urinary retention in the preceding 12 months and clinically significant cardiovascular or cerebrovascular diseases within 6 months prior to Visit 1.",
    "The sample is a record of a clinical trial in phase 2 for the treatment of amyotrophic lateral sclerosis using the drug memantine. The trial has specific eligibility criteria, including being clinically diagnosed with ALS, having elevated levels of Tau in CSF, and being between the ages of 18 and 85. There are also exclusion criteria, such as having a history of liver disease or severe renal failure, being pregnant or breastfeeding, or having an unwillingness to use birth control if of childbearing age. The sample also includes the ICD-10 code for ALS and lists the inclusion and exclusion criteria in detail.",
    "The sample is a phase 2 clinical trial for patients with metastatic colorectal cancer. The trial includes patients who have been treated with no more than three standard systemic regimens for metastatic disease and have a life expectancy of more than 3 months. The trial involves the use of drugs such as ngr-htnf, oxaliplatin, and capecitabine. The eligibility criteria include adequate baseline bone marrow, hepatic and renal function, ECOG Performance status 0-1, and patients must give written informed consent to participate in the study. The exclusion criteria include patients with myocardial infarction within the last six months, uncontrolled hypertension, and pregnancy or lactation.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on breast neoplasms, which are listed in the \"diseases\" field. The \"icdcodes\" field contains a list of ICD-10 codes associated with the disease. The trial is testing the drug sunitinib, which is listed in the \"drugs\" field. The \"criteria\" field contains the eligibility criteria for the trial, including inclusion criteria such as a histologically or cytologically proven diagnosis of breast cancer and exclusion criteria such as prior treatment with VEGF inhibitors.",
    "The sample is a phase 2 clinical trial for the treatment of chemotherapy-induced nausea and vomiting in patients with solid malignant tumors who have not previously received chemotherapy. The trial involves the use of the drugs gw679769, dexamethasone, and ondansetron hydrochloride. The eligibility criteria include providing written informed consent, being scheduled to receive chemotherapy, and not having received any investigational product within 30 days of enrollment. Exclusion criteria include pregnancy, recent radiation therapy to the abdomen or pelvis, and current treatment for conditions that may cause nausea or vomiting.",
    "The sample is a phase 2 clinical trial for the treatment of breast neoplasms and mtor protein using the drugs tamoxifen and everolimus. The trial is open to menopausal female patients over the age of 18 who have previously received first or second line of hormonotherapy for metastatic disease and have been treated with anti-aromatase in adjuvant and/or in metastatic line. Patients must have at least one mesurable or evaluable metastatic lesion and at least one target lesion not previously irradiated. Patients must also have an ECOG Performance status of less than 2 and adequate biological values. The trial has a list of exclusion criteria, including patients with only local metastatic disease that can be treated by surgery, uncontrolled brain metastases, pulmonary carcinomatosal lymphangitis, hepatic metastases, and previous treatment by Tamoxifen unless in adjuvant and terminated more than a year before metastatic relapse. Patients with a tumor surexpressing HER2 that should be treated by trastuzumab, patients that need an immediate local antalgic radiotherapy, thrombo-embolism disease, serious concomitant pathology or uncontrolled that is susceptible to compromise the participation in the study, history of another malignancy within past 5 years that could confound diagnosis or staging of breast cancer, and patients with an history of significant cardiovascular impairment are also excluded. Patients with any medical or psychiatric condition that, in the opinion of the Principal Investigator, would preclude her from participating in this study, known allergy to one or several of the study compounds, patients who may not be regularly available due to geographical, social or family reasons, history of renal, hepatic or metabolic pathology that could preclude with metabolism or elimination of the study product, deficiencies of the upper intestinal tract, malabsorption syndrome, patient who is pregnant, breast-feeding or using inadequate contraception, treatment with experimental drugs (mTor inhibitor or tyrosin kinase inhibitor), and patient treated with molecules that interfer with isoenzyme CYP3A are also excluded.",
    "The sample is a phase 2 clinical trial for patients with critical lower limb ischemia and vascular disease. The trial involves the use of two drugs, Hemospan and Voluven, and has specific eligibility criteria for patients to be included in the study. These criteria include having a history of pain at rest and/or ulceration, ankle systolic BP/Brachial systolic BP Index (ABI) <0.6, and ankle systolic BP <70 mmHg and/or toe systolic BP <50 mmHg. Patients must also have received written and verbal information about the investigational product and the protocol, and have signed an Informed Consent Form (ICF) approved by the independent Ethics Committee (EC). The sample also lists exclusion criteria, such as severe congestive heart failure, recent acute coronary syndrome, and chronic hepatic or renal disease. Patients involved in any investigational drug or device trial within 30 days prior to this study are also excluded.",
    "The sample is a phase 2 clinical trial for the treatment of nonseminoma germ cell tumor of any extracranial primary site. The trial includes patients who have poor prognosis features such as high levels of AFP or hCG, nonpulmonary visceral metastases, or a mediastinal primary site. The patients must be male, have a WHO performance status of 0-3, and a glomerular filtration rate of over 50 mL/min. They must not have any comorbid conditions that would prevent treatment and must use effective contraception if fertile. The trial will use a combination of carboplatin, cisplatin, etoposide phosphate, and vincristine sulfate as the study therapy. The eligibility criteria include no prior chemotherapy except low-dose chemotherapy to stabilize the disease before the study therapy.",
    "This sample is a phase 2 clinical trial for patients with squamous cell carcinoma of the head and neck (SCCHN). The trial is testing the effectiveness of the drugs bevacizumab, erlotinib, and sulindac. The eligibility criteria include having documented SCCHN, being 18 years or older, having locoregional and/or metastatic disease that is not appropriate for surgical resection or radiotherapy, having failed to respond to or relapsed from at least one prior chemotherapy or chemoradiotherapy, having a life expectancy of at least 4 months, having an ECOG performance status of 0-2, and using effective means of contraception if of child-bearing potential. Exclusion criteria include having another malignancy within 5 years, concurrent anticancer therapy other than that of this study, treatment with any anticancer drug within 28 days of day 1, and various other medical conditions.",
    "The sample is a phase 2 clinical trial for the treatment of chronic hepatitis C virus (HCV) infection. The trial includes participants who are treatment-naive and have a documented FibroTest score in combination with an Aspartate Aminotransferase to Platelet Ratio Index (APRI), or a liver biopsy within the last 12 months to document absence of cirrhosis. The trial excludes pregnant or breastfeeding females, participants with clinically significant cardiac, respiratory, renal, gastrointestinal, hematologic, neurologic disease, or any uncontrolled medical illness or psychiatric disease or disorder, and those with current or past clinical evidence of cirrhosis or bridging fibrosis. The trial involves the use of the drugs abt-267, pegylated interferon (pegIFN), and ribavirin (RBV). The eligibility criteria also specify that females must be either postmenopausal for at least 2 years or surgically sterile, and males must be surgically sterile or practicing specific forms of birth control.",
    "The sample is a phase 2 clinical trial for non-small-cell lung carcinoma and adenocarcinoma. The trial involves the use of drugs such as bevacizumab, carboplatin, paclitaxel, and ag-013736 (axitinib). The eligibility criteria for the trial include having advanced non-squamous cell lung cancer and no prior treatment for lung cancer except for adjuvant therapy if the last dose was more than 12 months prior to enrollment. Exclusion criteria include prior therapy for advanced lung cancer, the need for blood-thinners, and coughing up blood. The icd-10 codes for the diseases are also provided.",
    "The sample is a phase 2 clinical trial for patients with heart failure. The trial involves the use of a drug called CK-1827452 and a placebo. The eligibility criteria for the trial include being 18 years or older, having a documented diagnosis of heart failure with an ejection fraction of less than 40%, and being on a stable dose of a beta blocker and an ACE inhibitor or an ARB for at least 4 weeks. Patients must also have given signed informed consent and be considered to be in suitable health in the opinion of the investigator. The trial has a list of exclusion criteria, including recent hospitalization for heart failure or other cardiac indications, significant obstructive valvular disease or significant congenital heart disease, and being on chronic anti-arrhythmic therapy. The trial also has a list of other criteria that must be met, such as having interpretable echocardiographic images on a screening echocardiogram and having pre-study clinical laboratory findings that are within normal range.",
    "The sample is a phase 2 clinical trial for the treatment of chronic hepatitis C genotype 1. The trial includes both male and female participants who are 18 years or older and have not received prior treatment for their condition. The trial involves the use of several drugs, including ach-0141625 (sovaprevir), placebo, pegylated interferon alpha-2a, and ribavirin. The eligibility criteria for the trial include various medical and demographic factors, such as BMI, pregnancy status, and history of drug or alcohol dependence. The trial also has exclusion criteria, such as co-infection with HBV and/or HIV, liver disease, and history of moderate or severe psychiatric disease.",
    "The sample is a clinical trial for patients with newly diagnosed stage I and II nasal Natural Killer (NK) cell lymphoma. The trial is in phase 1/phase 2 and involves the use of cyclophosphamide, doxorubicin, vincristine, and prednisone as drugs. The eligibility criteria include adequate blood cell counts, liver and renal function, left ventricular ejection fraction, and negative pregnancy test for female patients. Patients with active Hepatitis B and/or Hepatitis C infection, active infections requiring specific anti-infective therapy, known HIV positive, pre-existing cardiovascular disease requiring ongoing treatment, prior exposure to anthracyclines, pregnant or breastfeeding, psychiatric illness and/or social situations that would limit compliance with the study medication and requirements, and prior radiation to the site of current primary disease are excluded from the trial.",
    "The sample is a phase 2 clinical trial for the treatment of high-risk Ewing's family of tumors, including Ewing's sarcoma of bone, extraosseous Ewing's sarcoma, and peripheral neuroepithelioma. The trial involves the use of drugs such as cyclophosphamide, dexrazoxane hydrochloride, disaccharide tripeptide glycerol dipalmitoyl, doxorubicin hydrochloride, and vincristine sulfate. The eligibility criteria include specific disease characteristics, patient characteristics such as age and performance status, and prior concurrent therapy. Patients must not be pregnant or nursing, and fertile patients must use effective contraception.",
    "The sample is a phase 2 clinical trial for patients with non-small cell lung cancer and leptomeningeal carcinomatosis. The trial is testing the effectiveness of the drug erlotinib for patients with EGFR mutation. The eligibility criteria include being over 18 years old, having confirmed leptomeningeal carcinomatosis, and having an expected life time of at least 4 weeks. Chemotherapy-na\u00efve patients are eligible, and previous EGFR TKI is allowed if it was not specifically used for CNS metastases. Exclusion criteria include being pregnant or lactating, having a history of another malignant disease within the past 3 years, and having certain laboratory test results outside of normal ranges. Patients with serious diseases such as uncontrolled cardiac arrhythmia or neurological disorders are also excluded.",
    "The sample is a phase 2 clinical trial for breast cancer patients. The trial includes patients with locally advanced breast cancers or primary breast cancers with concomitant gross metastatic disease. The patients must be female, have negative serum pregnancy test, and have kidney and liver function tests within 1.5 times of the institution's upper limit of normal. The patients must also have a performance status (World Health Organization [WHO] scale) < 2 and life expectancy > 6 months, and be over 18 years old. Patients with brain and/or leptomeningeal disease or previous or current malignancies at other sites within the last 5 years, with the exception of adequately treated cone-biopsied in situ carcinoma of the cervix uteri and basal or squamous cell carcinoma of the skin, are excluded. The trial uses the drug taxotere.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on the disease of lung neoplasm, which is identified by a list of icd-10 codes. The drug being tested is vinorelbine. The eligibility criteria for the trial are listed under inclusion and exclusion criteria, which include requirements such as a documented inoperable stage IIIA N2 or IIIB NSCLC, absence of malignant pleural effusion, and a performance status of 1. Patients with metastatic disease, small cell lung carcinoma, prior chemotherapy or radiotherapy, resectable tumor, any unstable systemic disease, or any other malignancies within 5 years are excluded from the trial.",
    "The sample is a record of a clinical trial in phase 2, focused on seasonal allergic rhinitis. The trial includes a list of icd-10 codes for the disease, a list of drugs being tested (including a placebo), and eligibility criteria for participants. The inclusion criteria include being between 18 and 70 years old, having a clinical history of symptomatic seasonal allergic rhinitis associated with mountain cedar pollen for the last two years, having adequate exposure to mountain cedar pollen, and having a positive skin prick test to mountain cedar allergen within 12 months of screening. The exclusion criteria include having non-allergic rhinitis, a bacterial or viral respiratory tract infection, chronic respiratory disorders, asthma requiring treatment other than inhaled short-acting Beta2-agonists, ocular infections or surgery, nasal obstruction, nasal biopsy or surgery, sinus surgery or perforation, smoking within the last year, ongoing or recent treatment for seasonal allergic rhinitis, and initiation of allergen immunotherapy within 6 months of screening.",
    "The sample is a phase 2 clinical trial for patients with estrogen receptor-positive and HER2-negative breast cancer. The trial includes patients with stage II and III breast cancer, and the eligibility criteria include various medical and physical requirements, such as a negative pregnancy test, normal organ and marrow function, and a palpable tumor measuring over 2 cm. The trial involves the use of four drugs, including goserelin acetate, letrozole, anastrozole, and chemotherapy. The trial also requires patients to meet certain exclusion criteria, such as not having had prior treatment for invasive breast cancer or not being pregnant or breastfeeding.",
    "The sample is a record of a clinical trial in phase 2 for the treatment of non-small cell lung carcinoma. The trial involves the use of drugs such as pemetrexed and pemetrexed + pf-3512676. The eligibility criteria for the trial include having locally advanced or metastatic NSCLC, measurable disease, and an ECOG PS score of 0 or 1. However, individuals with known CNS metastasis or pre-existing autoimmune or antibody mediated disease are excluded from the trial. The icd-10 codes associated with the disease are also provided.",
    "The sample is a clinical trial for head and neck cancer patients in phase 1/phase 2. The trial is testing the effectiveness of the drugs cisplatin, fluorouracil, and iressa. The eligibility criteria include having histologically confirmed primary squamous cell carcinoma of the head and neck region, excluding certain areas, and being in stage III or IV with no evidence of nodal disease below the clavicles or distant hematogenous metastases. Patients must also meet certain patient characteristics such as having an ECOG performance status of 0-1 and not having any severe, uncontrolled systemic disease. Prior concurrent therapy is also taken into consideration. The sample provides a detailed list of eligibility criteria that patients must meet to participate in the trial.",
    "The sample is a phase 2 clinical trial for the treatment of breast cancer using the drug letrozole. The trial is for postmenopausal women with locally advanced or metastatic breast cancer that is not curable with standard treatment. The eligibility criteria include a confirmed diagnosis of adenocarcinoma of the breast, a documented decrease in CA 15-3 levels with letrozole or anastrozole therapy, and evidence of hormone sensitivity. The trial also requires patients to have a life expectancy of at least 3 months and an ECOG Performance Status of 0, 1, or 2. Exclusion criteria include premenopausal status, recent radiation therapy, and other concurrent cancer treatments.",
    "The sample is for a phase 2 clinical trial for the treatment of hormone-refractory metastatic prostate cancer. The trial involves the use of drugs such as docetaxel, estramustine phosphate sodium, and isotretinoin. The eligibility criteria include having confirmed prostate cancer, measurable disease or a prostate-specific antigen level of at least 10 ng/mL, and meeting certain patient characteristics such as having an estimated life expectancy of at least 6 months and no history of severe hypersensitivity reaction to the drugs being used. Prior concurrent therapy is also taken into consideration.",
    "The sample is a record of a clinical trial in phase 2 for the treatment of relapsing remitting multiple sclerosis. The trial involves the use of drugs such as natalizumab, interferon beta 1-a, methylprednisolone, and glatiramer acetate. The eligibility criteria for the trial include a diagnosis of relapsing MS and treatment with natalizumab according to locally approved prescribing information, among other protocol-defined inclusion/exclusion criteria.",
    "The sample is a clinical trial for a drug called bavituximab and pegylated interferon (peg-ifn) for the treatment of chronic hepatitis C virus (HCV) genotype 1 infection. The trial is in phase 1/phase 2 and the eligibility criteria include being between the ages of 18 and 65 years, having a documented positive HCV serology, and no clinically significant abnormalities in hematology, coagulation, or chemistry variables. The exclusion criteria include previous interferon-based antiviral therapy for chronic HCV infection, previous treatment with known immunogenic drugs, and concomitant human immunodeficiency (HIV) or hepatitis B virus (HBV) infection. Female patients must have a negative urine pregnancy test and be willing to practice effective contraception.",
    "The sample is a clinical trial for a drug called xpf-001, which is being tested on patients with primary or inherited erythromelalgia. The trial is in phase 1/phase 2 and the table includes information on the diseases being studied, the icd-10 codes associated with those diseases, the drugs being used, and the eligibility criteria for participants. The eligibility criteria include being between 18-75 years old, experiencing moderate pain caused by erythromelalgia, and being generally healthy apart from the pain. Participants must also stop taking their usual pain medications for 9 days and cannot be pregnant or breastfeeding. The trial involves an out-patient screening visit, a 9-day/8-night in-patient treatment visit at Nijmegen Medical Center, and a follow-up phone call. Participants must take the investigational medication daily and record their pain levels during their stay at the Medical Center. There are also exclusion criteria, such as having a coexistent source of pain from other conditions, receiving professional psychological support for dealing with IEM, or having a history of major psychiatric disturbance.",
    "The sample is a phase 2 clinical trial for patients with follicular non-Hodgkin lymphoma. The trial is testing the effectiveness of a combination of drugs including cyclophosphamide, doxorubicin hydrochloride, prednisolone, and vincristine sulfate. Patients must meet certain eligibility criteria, including having confirmed grade 1, 2, or 3 follicular non-Hodgkin lymphoma, being in first or second relapse after prior treatment with a rituximab-containing chemotherapy regimen or chemotherapy alone, and having at least one symptom requiring treatment. Patients must also meet certain patient characteristics, such as having an ECOG performance status of 0-2 and no evidence of active infection requiring IV antibiotics. Prior concurrent therapy is also taken into consideration.",
    "The sample is a phase 2 clinical trial for HIV infections. The trial is testing a combination of drugs including abacavir sulfate, emtricitabine, lamivudine, lopinavir/ritonavir, saquinavir, tenofovir disoproxil fumarate, and zidovudine. The eligibility criteria for the trial include being HIV infected with no available therapeutic options that would likely result in long-term suppression of the virus to less than 400 copies/ml, having previous exposure to non-nucleoside reverse transcriptase inhibitors (NNRTIs), NRTIs, and PIs, and experiencing virologic failure. The trial also requires resistance to 2 or more drugs in the most recent treatment regimen within 26 weeks prior to study screening. Participants must be willing to swallow study medications, use acceptable methods of contraception, and have a parent or guardian willing to provide informed consent if applicable. Exclusion criteria include previous cumulative exposure to TDF for more than 24 weeks, history of allergy or hypersensitivity to any of the study drugs, active CDC Stage C opportunistic infection or serious bacterial infection requiring therapy at the time of screening, chemotherapy for active cancer, abnormal kidney function, and any clinically significant diseases other than HIV infection or findings during medical history screening that may interfere with the study. Pregnancy or breastfeeding is also an exclusion criterion.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on prostate cancer and includes a list of ICD-10 codes for related diseases. The trial involves the use of the drug Zometa and has specific eligibility criteria for participants, including a histologic diagnosis of adenocarcinoma of the prostate, a detectable PSA level, and an ECOG performance status of less than 2. There are also exclusion criteria, such as prior treatment with a GnRH analogue or anti-androgen, evidence of immunosuppression, or current use of certain medications. The sample includes a detailed list of inclusion and exclusion criteria for the trial.",
    "The sample is a phase 2 clinical trial for the treatment of moderate to severe chronic plaque psoriasis. The trial includes adult males and females aged 18 to 60 years who require systemic treatment. The trial excludes patients with other forms of psoriasis, autoimmune disorders other than psoriasis, ongoing bacterial, viral or fungal infections, and a history or presence of malignancy. There are additional inclusion and exclusion criteria related to medical conditions and concomitant treatments that could affect patients' risk from participating in the study. The trial involves the use of two drugs, act-128800 and placebo. The icd-10 codes associated with the disease are also provided.",
    "The sample is a phase 2 clinical trial for Crohn's disease. The eligibility criteria include being between the ages of 18-75, able to adhere to the study schedule, and having a minimum weight of 50 kg. Female participants of childbearing potential must have a negative pregnancy test and agree to use two forms of contraception during the study. Participants must have confirmed ongoing disease activity and a CDAI score between 220 and 450. They must have also failed or had an inadequate response to a previous treatment. Exclusion criteria include any significant medical condition or laboratory abnormality that would prevent participation in the study.",
    "The sample is a phase 2 clinical trial for the treatment of esophageal cancer. The trial includes patients with newly diagnosed adenocarcinoma of the esophagus or gastroesophageal junction that is surgically resectable and meets specific criteria. The patients must have stage T2-3, N0-1, M0-1a tumor, and no CNS metastasis. The trial involves the use of cisplatin, gefitinib, and paclitaxel as drugs. The eligibility criteria include various medical conditions, such as granulocyte count, platelet count, and creatinine clearance, and exclude patients with severe hypersensitivity to gefitinib or any of its excipients, evidence of severe or uncontrolled systemic disease, and other significant clinical disorders. The trial also requires patients to use effective contraception during and for 3 months after completion of study therapy if they are fertile.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on Alzheimer's disease and involves a list of ICD-10 codes, drugs, and eligibility criteria. The inclusion criteria include having a clinical diagnosis of mild-to-moderate Alzheimer's disease, a documented 6-month history of AD symptoms, and a regular caregiver who can attend visits and report on the subject's status. Female subjects of child-bearing potential must agree to pregnancy testing and approved form of birth control. The exclusion criteria include a diagnosis of possible, probable or definite vascular dementia, history/evidence of any other CNS disorder that could be interpreted as a cause of dementia, history of known or suspected seizures, loss of consciousness or significant head trauma, and subjects with ECG, blood pressure and laboratory values outside of protocol criteria. Subjects with known photosensitivity, a history of previous exposure to SB-742457, taking agents for which there is a theoretical risk of interaction with SB-742457, or taking medication for Alzheimer's disease or centrally acting agents which might impact study outcomes may not participate.",
    "The sample is a phase 2 clinical trial for the treatment of myelodysplastic syndromes (MDS) using the drug belinostat. The trial is open to patients with de novo, previously treated, or secondary MDS, who have less than 5% bone marrow blasts and meet certain eligibility criteria. The criteria include having symptomatic anemia, thrombocytopenia, or neutropenia, as well as meeting certain performance status, life expectancy, and medical condition requirements. Patients must also not have a history of allergic reactions to similar compounds, not be pregnant or nursing, and use effective contraception if fertile. The trial excludes patients with acute myeloid leukemia, HIV positivity, significant cardiovascular disease, and other serious medical conditions. Prior therapies for MDS are limited to no more than 2, and prior HDAC inhibitors are not allowed. Concurrent use of certain medications that may cause torsades depointes is also excluded.",
    "The sample is a phase 2 clinical trial for Alzheimer's disease. The eligibility criteria include being male, 65 years or older, diagnosed with probable Alzheimer's disease, and taking a drug for the treatment of Alzheimer's disease. The patient must also have a Mini Mental State Examination score of 12 to 24, a brain imaging study consistent with a diagnosis of Alzheimer's disease, and a Rosen Modified Hachinski score of 4 or lower. The patient must be fluent in English or Spanish, completed at least 6 years of education, and have a caregiver who sees them at least three times a week for a total of at least 10 hours. The exclusion criteria include being female, younger than 65 years of age, having significant neurological or psychiatric disease other than Alzheimer's disease, and having current significant systemic illness or symptoms of organ failure.",
    "The sample is a phase 2 clinical trial for patients with relapsed or refractory lymphoma, including various types of aggressive, indolent, and uncommon lymphomas. The trial is testing the drug everolimus. Eligibility criteria include having previously treated disease, measurable disease, and meeting certain health requirements such as a certain level of blood counts and liver function. Patients must also be willing to provide blood samples and bone marrow aspirate and biopsy during the study. Prior concurrent therapy is allowed under certain conditions, but no other concurrent chemotherapy, immunotherapy, or radiotherapy is allowed.",
    "The sample is a phase 2 clinical trial for Crohn's disease. The trial includes patients who are 16 years or older and have been diagnosed with Crohn's disease for more than a month. The patients must have CDAI scores between 220 and 450 at the randomization visit and Crohn's disease involving any portion of the colon with or without distal or terminal ileal disease. The trial excludes female patients who are pregnant or breastfeeding, patients with allergies or contraindications to ciprofloxacin or metronidazole, patients experiencing complications of Crohn's disease requiring urgent surgical intervention, patients with subacute small bowel obstruction, and patients with significant, symptomatic Crohn's disease of the esophagus, stomach, duodenum, or jejunum. The trial also excludes patients who have received certain medications or therapies within a certain timeframe, have positive stool culture tests for enteric pathogens or Clostridium difficile toxin, have other clinically significant medical or psychiatric illnesses, have had a resection of more than 100 cm of their small intestine or more than half of their colon, or are unable to provide informed consent.",
    "The sample is a phase 2 clinical trial for patients with primary peritoneal carcinoma, fallopian tube epithelial ovarian carcinoma, Stage III or IV ovarian epithelial cancer. The trial includes patients with various histologic epithelial cell types, such as serous adenocarcinoma, endometrioid adenocarcinoma, mucinous adenocarcinoma, undifferentiated carcinoma, clear cell adenocarcinoma, mixed epithelial carcinoma, transitional cell carcinoma, malignant Brenner's Tumor, or adenocarcinoma not otherwise specified (NOS). The trial involves the use of paclitaxel, carboplatin, and erlotinib as drugs. The eligibility criteria include various medical conditions, such as ECOG performance status, absolute neutrophil count, platelets count, total bilirubin, AST(SGOT)/ALT(SGPT), creatinine, neuropathy, and medical contraindications. The trial also has exclusion criteria, such as patients who have had courses of chemotherapy within the five years prior to entering the study, patients with known brain metastases, and pregnant women.",
    "The sample is a phase 2 clinical trial for breast cancer patients. The trial is testing the drug \"rad 001\". The eligibility criteria for the trial includes having an Eastern Cooperative Group (ECOG) performance status of 2 or less, being at least 18 years old, having at least one measurable site of disease according to RECIST criteria that has not been previously irradiated, and having adequate bone marrow, liver, and renal function. Patients must also have controlled diabetes and fasting serum cholesterol and triglycerides within certain limits. Exclusion criteria include currently receiving or having received anticancer therapies within 4 weeks of the start of the study drug, major surgery or significant traumatic injury within 4 weeks of the start of the study drug, and not having recovered from the side effects of any major surgery. Other exclusion criteria include uncontrolled brain or leptomeningeal metastases, other malignancies within the past 3 years (except for adequately treated carcinoma of the cervix and basal or squamous cell carcinomas of the skin), and severe and/or uncontrolled medical conditions or other conditions that could affect their participation in the study. Female patients who are pregnant or breastfeeding, or adults of reproductive potential who are not using effective birth control methods are also excluded. Prior treatment with an mTOR inhibitor (sirolimus, temsirolimus, everolimus) or known hypersensitivity to RAD001 (everolimus) or other rapamycin drugs (sirolimus, temsirolimus) or to its excipients are also exclusion criteria.",
    "The sample is a record of a clinical trial for Alzheimer's disease, specifically for phase 2. The trial involves the drug rosiglitazone and includes a list of inclusion and exclusion criteria for participants. Inclusion criteria include completing a previous 12-month treatment without issues, being post-menopausal or using effective contraception, providing informed consent, and having a caregiver who also provides consent. Exclusion criteria include experiencing a serious adverse event during the previous treatment, being deemed unsuitable for the study, experiencing a significant cardiovascular event, or starting treatment with certain medications. The record also includes lists of disease names and ICD-10 codes.",
    "The sample is a phase 2 clinical trial for the treatment of diabetic macular edema. The trial includes patients with a confirmed diagnosis of diabetes mellitus and retinal thickening involving the center of the fovea. The study eye must have a foveal thickness of at least 250 \u03bcm and a best corrected visual acuity score of 20/40 to 20/320. The trial involves the use of ranibizumab and patients must meet certain inclusion criteria, such as being over 18 years old and having a negative pregnancy test if female. There are also exclusion criteria, such as having undergone certain eye surgeries or having uncontrolled diabetes. The trial aims to evaluate the safety and efficacy of ranibizumab in treating diabetic macular edema.",
    "The sample is a phase 2 clinical trial for patients with non-small cell lung cancer. The trial is testing the effectiveness of the drugs celecoxib and docetaxel. The eligibility criteria include having a diagnosis of stage IIIB with pleural effusion or stage IV NSCLC, being 70 years or older with a SWOG performance status of 0-2 or being between 18 and 69 years old with a SWOG performance status of 2, having measurable or evaluable disease, and meeting certain medical criteria such as having no symptomatic or untreated brain or leptomeningeal metastases, having certain blood counts and liver and kidney function within normal limits, and not having certain medical conditions such as uncontrolled congestive heart failure or active psychiatric disorder. Prior treatment with biologic or chemotherapy for NSCLC is not allowed, but intermittent use of non-steroidal anti-inflammatory drugs (NSAIDs) is allowed. The trial also has other exclusion criteria such as having a history of chronic hepatitis or prior hypersensitivity reaction to docetaxel or other drugs formulated with polysorbate 80. Patients must not be pregnant or nursing and must use effective contraception if fertile. The trial has other requirements for prior and concurrent therapy and medical history.",
    "The sample is a phase 2 clinical trial for patients with metastatic colorectal adenocarcinoma. The trial involves the use of cetuximab and lenalidomide drugs. The eligibility criteria include confirmed K-RAS mutant tumor, disease progression on oxaliplatin- AND irinotecan-containing regimens, with at least one of these regimens containing bevacizumab, and an Eastern Cooperative Oncology Group (ECOG) performance status of \u2264 1. The exclusion criteria include previous treatment with cetuximab, panitumumab, pomalidomide (CC-4047), lenalidomide or thalidomide, untreated, symptomatic brain metastases, venous thromboembolism \u2264 6 months before day1 of the first cycle, current congestive heart failure (classes II to IV of the New York Heart Association), myocardial infarction \u2264 12 months before day1 of the first cycle, and uncontrolled hypertension.",
    "The sample is a phase 2 clinical trial for the treatment of photosensitive epilepsy. The trial includes patients with a firm diagnosis of idiopathic, photosensitive epilepsy with a generalized photoparoxysmal EEG response. The trial involves the use of two drugs, jnj-26489112 and placebo. The eligibility criteria include having a BMI between 18.5 and 35 kg/m2, being a male or postmenopausal/surgically sterile female, and having all values for hematology, coagulation, chemistry, and urinalysis within clinically acceptable ranges. The exclusion criteria include having a history of liver or renal insufficiency, significant cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic (except epilepsy and febrile seizures), hematologic, psychiatric, or metabolic disturbances, and being pregnant or lactating.",
    "The sample is a phase 2 clinical trial for bladder cancer. The trial is looking for patients with transitional cell carcinoma of the bladder that has biopsy-proven muscle invasion suitable for resection leaving no residual visible or palpable tumor mass. The patients should have unifocal disease, no greater than 5 cm, and stages II and III (T2-T3a, N0-NX, M0). The patients should not have had prior treatment for bladder cancer other than endoscopic resection, intravesical chemotherapy, or intravesical immunotherapy. The trial is looking for patients who are fit for cisplatin-containing combination chemotherapy, radical radiotherapy, or cystectomy. The patients should not have active infections, should not be pregnant or nursing, and should not have any concurrent illness that significantly affects clinical assessments. The sample includes a list of drugs that will be used in the trial, including cisplatin, doxorubicin hydrochloride, methotrexate, and vinblastine sulfate. The eligibility criteria for the trial are also listed, including patient characteristics such as age, performance status, life expectancy, hematopoietic, hepatic, renal, cardiovascular, and other factors. The sample also includes information on prior concurrent therapy, including biologic therapy, chemotherapy, endocrine therapy, radiotherapy, and surgery.",
    "The sample is a phase 2 clinical trial for patients with myelodysplastic syndromes. The trial is testing the effectiveness of the drug metoclopramide. The eligibility criteria for the trial include being in IPSS risk group low or intermediate-1, or intermediate-2 if over 60 years old and not eligible for high intensity therapies. Patients must also have anemia, a low reticulocyte count, a high neutrophil count, and a high platelet count. They must be between the ages of 18 and 72 and have an ECOG performance status of 2 or less. Patients must not have high IPSS risk, secondary MDS, or a history of dystonic or anaphylactic reactions to metoclopramide. They must also not have certain medical conditions or be taking certain medications. Additionally, patients must not have used metoclopramide in the 4 months prior to the study and must not have hyperprolactinemia.",
    "The sample is a phase 2 clinical trial for patients with hepatocellular carcinoma. The trial includes patients who are 18 years or older, have a proven primary HCC, and have an ECOG Performance Status of 0 or 1. Patients must have a life expectancy of at least 12 weeks and an inoperable tumor. They must also be considered appropriate for systemic therapy and have at least one measurable lesion by CT-scan or MRI. Patients who have not received any systemic anti-cancer treatment for HCC are eligible, but those who have received local therapy must have a target lesion which has not been subjected to local therapy and/or the target lesion(s) within the field of the local therapy has shown an increase of 25% in the size. The trial also has exclusion criteria, including patients with congestive heart failure, serious cardiac arrhythmias, active coronary artery disease or ischemia, active clinically serious infections, known history of HIV infection, known metastatic brain or meningeal tumors, history of seizure disorder, history of organ allograft, previous malignancy, and clinically significant gastrointestinal bleeding within the past month prior to study entry. The trial also excludes patients who have received any systemic anticancer treatment or any agent administered with antineoplastic intent, including chemotherapy, immunotherapy, vaccines or hormonal therapy given before study entry or during study treatment. Pregnant or breast-feeding patients are also excluded.",
    "The sample is a phase 2 clinical trial for pancreatic cancer. The trial includes adult patients who are 18 years or older and have locally advanced-unresectable or metastatic pancreatic cancer. Patients must have measurable disease according to RECIST and have failed at least one prior chemotherapy regimen or are deemed unsuitable for chemotherapy. Patients must also have an ECOG performance status of 0-2. Exclusion criteria include local or locally advanced-resectable pancreatic cancer, any other malignancies within the last 5 years (except for adequately treated cancer in situ of the cervix or basal or squamous cell skin cancer), and major surgery within 2 weeks prior to randomization. The trial will test the effectiveness of erlotinib and placebo.",
    "The sample is a phase 2 clinical trial for patients with stage IV malignant melanoma, a type of skin cancer. The trial is testing the effectiveness of a drug called abt-510. Patients must have measurable disease and no history of or current central nervous system (CNS) metastases or carcinomatous meningitis. They must also meet certain patient characteristics, such as having an ECOG performance status of 0-2 and a life expectancy of at least 6 months. Patients must not be pregnant or nursing, and fertile patients must use effective contraception. They must also have certain laboratory values within normal limits and not have certain medical conditions or recent bleeding events. Patients must not have received certain prior therapies within a certain timeframe and must not be receiving concurrent anticoagulation or antiplatelet therapy or other antineoplastic agents except for local radiotherapy for supportive reasons involving a small radiation field.",
    "The sample is a phase 2 clinical trial for patients with myelodysplastic syndromes (MDS) or chronic myelomonocytic leukemia (CMML), refractory anemia (RA), or refractory anemia with ringed sideroblasts (RARS). The trial is testing the effectiveness of azacitadine and hematopoietic growth factors as a treatment. The eligibility criteria include a diagnosis of MDS, bone marrow aspirate and biopsy with karyotyping performed within the past 8 weeks, and meeting certain criteria for symptomatic anemia, thrombocytopenia, or neutropenia. Patients must also meet certain patient characteristics, such as having an ECOG performance status of 0-2 and a life expectancy of more than 2 months. Prior concurrent therapy is not allowed, and patients must not have a history of leukemia or known primary or metastatic hepatic tumor.",
    "The sample is a phase 2 clinical trial for patients with histologically proven adenocarcinoma of the rectum. The trial is testing the effectiveness of intensified preoperative chemotherapy. The inclusion criteria require patients to have T3/4 or any node positive disease, no evidence of metastatic disease, and be considered either resectable at the time of entry or thought to become resectable after preoperative chemoradiation. Patients must also be 18 years or older, have a WHO Performance Status of 0-2, and have not received prior radiotherapy, chemotherapy, or any targeting therapy for rectal cancer. The exclusion criteria include malignancy of the rectum other than adenocarcinoma, any unrested synchronous colon cancer, other co-existing malignancy or malignancy within the past 5 years, significant heart disease, pregnancy or lactation, and females with a positive or no pregnancy test unless childbearing potential can be otherwise excluded.",
    "The sample is a phase 2 clinical trial for hypertension. The trial includes male and female participants between the ages of 18 and 70 with a mean seated systolic blood pressure of 140-180 mmHg and mean seated diastolic blood pressure of 90-109 mmHg at two consecutive qualifying visits. Women of child-bearing potential must use two reliable forms of contraception or be postmenopausal for at least 1 year. The trial excludes participants with serious disorders that may limit the ability to evaluate the efficacy or safety of the drug, a history of myocardial infarction or heart failure, cerebrovascular accident or transient ischemic attack, clinically significant cardiac conduction defects, hemodynamically significant valvular disease, and history of type 1 diabetes mellitus or type 2 diabetes mellitus using antihyperglycemic medication. The trial will test the efficacy and safety of the drugs irbesartan, placebo, and ps433540.",
    "The sample is a phase 2 clinical trial for the treatment of myelodysplastic syndrome. The trial involves the use of the drugs decitabine and patients must meet certain eligibility criteria to be enrolled. These criteria include being 18 years or older, having a performance status of 0-2, and having adequate renal and hepatic function. Female patients must have a negative pregnancy test and both men and women must use contraception throughout the study. Patients who have received prior therapy with decitabine or azacitidine, or who have received growth factor support or lenalidomide in the 30 days prior to the first dose of decitabine, will be excluded from the study. Patients with active, uncontrolled, systemic infection considered opportunistic, life-threatening or clinically significant, or any severe, concurrent disease, which would make the patient inappropriate for study entry, will also be excluded.",
    "The sample is a phase 2 clinical trial for the treatment of urinary tract infections. The trial includes adult subjects with a list of specific inclusion criteria, such as having a documented fever and at least two UTI symptoms. The trial also has a list of exclusion criteria, such as having a urinary catheter or suspected prostatitis. The trial involves the use of two drugs, gsk2251052 and imipenem-cilastatin. The eligibility criteria also includes requirements for contraception for female subjects. The trial is designed to last between 5 and 14 days and involves hospitalization for parenteral treatment.",
    "The sample is a phase 2 clinical trial for patients with metastatic renal cell carcinoma or neoplasm metastases. The trial is testing the effectiveness of the drugs gemcitabine and sunitinib. The eligibility criteria include having measurable disease, a certain performance status, and meeting certain laboratory values. Patients with brain metastasis must have been treated with whole brain radiation at least 4 weeks prior to enrollment. Exclusion criteria include prior treatment with sunitinib or gemcitabine, uncontrolled high blood pressure, and certain cardiac conditions. Patients with certain psychiatric illnesses or concurrent malignancies requiring active systemic therapy are also excluded.",
    "The sample is a phase 2 clinical trial for breast cancer. The trial includes patients with metastatic breast adenocarcinoma who have not received prior chemotherapy. The trial also requires patients to have HER-2 overexpression and measurable disease not in a prior irradiation field. The trial allows for endocrine therapy as adjuvant or first line treatment for metastatic disease. Patients must meet certain eligibility criteria, including adequate bone marrow, liver, renal, and cardiac function, and must provide informed consent. Exclusion criteria include pregnancy or nursing, certain concurrent agents, uncontrolled brain metastatic disease, and other concurrent uncontrolled illness.",
    "The sample is a record of a clinical trial in phase 2 for the treatment of migraine. The trial involves the use of two drugs, ketorolac tromethamine and placebo. The eligibility criteria for the trial include a diagnosis of migraine with or without aura, onset of migraine prior to age 50, and 2-8 moderate to severe migraine headaches per month. The exclusion criteria include subjects receiving any investigational drug within 30 days before study entry, more than 15 headache days per month, known allergy or hypersensitivity to ketorolac and/or excipients, allergy to aspirin or other NSAIDs, currently receiving other NSAIDs or aspirin, and medical history that would preclude NSAID use. The diseases associated with the trial are listed as 'migraine' and the icd-10 codes associated with the disease are also provided.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on the disease of hypertension, with a list of associated ICD-10 codes provided. The trial involves the use of two drugs, eplerenone and losartan. The eligibility criteria for the trial are listed, including requirements for hypertension history and withdrawal from previous antihypertensive medications. Exclusion criteria are also listed, including the presence of secondary hypertension or the inability to withdraw from certain medications.",
    "The sample is a clinical trial for individuals with type 2 diabetes mellitus. The trial is in phase 1/phase 2 and includes a list of diseases and their corresponding icd-10 codes, as well as a list of drugs. The eligibility criteria for the trial include being between the ages of 19 and 70, having a stable regimen of metformin or DPP-4 inhibitor, having a serum creatinine below the upper limit of normal, having a BMI between 25.0 and 40.0 kg/m^2, and meeting certain gender-specific criteria. Exclusion criteria include having a clinically significant medical condition, having received certain treatments within a certain timeframe, and having certain allergies or intolerances.",
    "The sample is a phase 2 clinical trial for ovarian cancer patients with progressive or recurrent disease. The trial includes patients with measurable or non-measurable disease, with a maximum of 2 prior chemotherapies. Patients must have an ECOG performance status grade of 0 or 1, be between the ages of 18 and 75, and have adequate hematological, liver, and renal function. The trial also requires patients to have a life expectancy of at least 3 months and a signed informed consent. Exclusion criteria include pre-existing peripheral neuropathy, serious cardiac or neurological disorders, and active infection. The trial involves the use of two drugs, bortezomib and pegylated liposomal doxorubicin, and eligibility criteria are outlined in detail.",
    "The sample is a clinical trial for patients with transient ischemic attack or minor acute ischemic stroke. The trial is in phase 2/phase 3 and involves the use of aspirin, clopidogrel, and simvastatin. The eligibility criteria include being aged 40 years or older, having weakness or language disturbance at the time of the attack, and having a duration of neurological deficit of more than 5 minutes. Patients must not be candidates for acute thrombolysis or other acute intervention indicated as the current standard of care. Exclusion criteria include having pure sensory symptoms, being on certain medications, having a neurological deficit due to intracranial hemorrhage or tumor, and having a presumed cardiac source of embolus. Women who are pregnant or breastfeeding are also excluded. The trial requires written, informed consent from patients and has a follow-up period of at least 90 days.",
    "The sample is a phase 2 clinical trial for patients with hematologic malignancies, including myelodysplastic syndromes, who are eligible for certain conditioning therapies with allogeneic stem cell support. The trial requires subjects to have a 6/6 HLA-matched family member or unrelated donor who can provide donor marrow or peripheral progenitor stem cells. The trial will test the effectiveness of palifermin, a drug that has not been previously used by the subjects, compared to a placebo and methotrexate. The eligibility criteria include a Karnofsky Performance Status of at least 70%, being 18 years or older, and providing written informed consent. Exclusion criteria include having cancer other than specified types, prior bone marrow or peripheral blood stem cell transplantation, and inadequate organ function. The trial will also exclude subjects who are currently enrolled in or have not yet completed other investigational device or drug trials, or who are receiving other investigational agents.",
    "The sample is a phase 2 clinical trial for patients with colorectal cancer and metastatic cancer. The trial involves the use of three drugs: fluorouracil, leucovorin calcium, and oxaliplatin. The eligibility criteria include having a history of completely resected primary adenocarcinoma of the colon or rectum, liver metastases that meet certain criteria, measurable disease, and no evidence of extrahepatic metastases. Patients must also meet certain patient characteristics such as being 18 years or older, having a performance status of ECOG 0-1, and having no preexisting chronic hepatic disease. The trial also has specific prior concurrent therapy requirements, such as no prior systemic chemotherapy for metastatic disease and no prior radiotherapy to the liver.",
    "The sample is a phase 2 trial for chronic obstructive pulmonary disease. The trial includes patients between the ages of 40 and 80 with a clinical history of COPD and airflow limitation that is not fully reversible. The trial also requires females to have a negative pregnancy test and acceptable contraceptive methods. Current/former smokers with at least a 10 pack-year history of cigarette smoking are also included. The trial has specific inclusion and exclusion criteria, such as no primary diagnosis of asthma, no abnormal chest X-ray not due to the presence of COPD, and no prior lung volume reduction surgery. The trial also excludes patients with clinically significant medical conditions that preclude participation in the study. The trial requires patients to be able to change COPD treatment as required by the protocol.",
    "The sample is a phase 2 clinical trial for patients with type 2 diabetes mellitus who have been treated with insulin for at least 12 months and prandial insulin for at least 2 months. The trial is testing the effectiveness of insulin glargine as a basal insulin for the duration of the study. The patients must have a BMI between 23.0 and 45.0 kg/m^2 and a HbA1C level between 7.0 and 8.5%. They must also be willing to avoid the use of an insulin infusion pump or unblinded continuous glucose monitoring during the study. The trial has exclusion criteria, including allergies to any of the study drugs, exclusive use of pre-mixed insulins, and use of certain drugs that could interfere with the interpretation of study results or cause clinically relevant interference with insulin action or glucose utilization. Patients with recurrent severe hypoglycemia or hypoglycemic unawareness are also excluded.",
    "The sample is a record of a clinical trial with a phase 2/phase 3 designation. The trial is focused on patients with metastatic breast cancer and involves the use of drugs such as trastuzumab and vinorelbine. The eligibility criteria for the trial include confirmation of carcinoma of the breast, metastatic breast cancer, HER-2/neu overexpression, age over 18, adequate hepatic, renal, and hematologic function, and adequate cardiac function. The trial also has exclusion criteria, such as no recent treatment with chemotherapy or trastuzumab, prior therapy with vinorelbine, and known hypersensitivity to certain proteins. The sample includes a detailed list of inclusion and exclusion criteria for the trial.",
    "The sample is a phase 2 clinical trial for non-small cell lung cancer. The trial includes patients with stage III NSCLC who have not received chemotherapy or radiotherapy for lung cancer before. The trial involves the use of cisplatin, docetaxel, and pegfilgrastim. The eligibility criteria include measurable or evaluable disease, performance status 0-2, and various laboratory values within normal limits. Exclusion criteria include known sensitivity to certain products, concurrent use of investigational drugs, and severe hypersensitivity reactions to certain drugs.",
    "The sample is a phase 2 clinical trial for cytomegalovirus infections. The trial is testing a placebo drug. The eligibility criteria include being 18 years or older, awaiting a liver or kidney transplant, and having a negative pregnancy test for female patients of childbearing potential. Additionally, female patients must agree to use an effective form of birth control while receiving the vaccine and for 30 days after completion of the course of vaccine. The trial also requires patients to have a compatible HLA type with tetramer assays, currently A2, A24, B7, B8, or B35. Exclusion criteria include being unable or unwilling to provide informed consent, being pregnant or breastfeeding, having a history of life-threatening reaction to the trial vaccine or a vaccine containing the same substances, and being HIV positive.",
    "The sample is a phase 2 clinical trial for the treatment of metastatic or recurrent squamous cell cancer of the head and neck using the drug perifosine. The trial includes patients who are not eligible for surgery or radiotherapy and have unidimensionally measurable disease. Patients must meet certain eligibility criteria related to their age, performance status, life expectancy, hematopoietic, hepatic, renal, and cardiovascular health, as well as their prior concurrent therapy. The sample includes a list of diseases and their corresponding ICD-10 codes, as well as the eligibility criteria for the trial.",
    "The sample is a phase 2 clinical trial for the treatment of idiopathic pulmonary fibrosis. The trial includes patients who have been diagnosed with IPF according to the American Thoracic Society/European Respiratory Society guideline and have a forced vital capacity (FVC) of 50-90% and a diffusing capacity for carbon monoxide (DLCO) of 30-79%. Patients who have been on a steady dose of pirfenidone for at least 3 months are also included. The trial excludes patients with certain liver or lung conditions, active infections, or who are being treated with certain medications. Patients who are expected to go on to lung transplantation, have rapidly deteriorating disease, or have a life expectancy less than 3 months from screening are also excluded.",
    "The sample is a phase 2 clinical trial for the treatment of hepatitis C virus. The trial includes patients aged 18 to 70 years with documented chronic genotype 1, 2, or 3 HCV infection who have not received previous treatment with HCV antiviral medications. The trial involves the use of drugs such as sofosbuvir, placebo to match sofosbuvir, peg, and rbv. The eligibility criteria include a body mass index (BMI) of greater than 18 kg/m2 but not exceeding 36 kg/m2, a liver biopsy obtained within 3 years prior to the Day 1 visit, and a fibrosis classification of non-cirrhotic as judged by a local pathologist. The exclusion criteria include a positive test at Screening for HBsAg, anti-HBc IgM Ab, or anti-HIV Ab, history of any other clinically significant chronic liver disease, and treatment with herbal/natural remedies with antiviral activity within 30 days prior to baseline.",
    "The sample is a phase 2 clinical trial for patients with chronic lymphocytic leukemia. The trial involves the use of valproic acid and fludarabine as a treatment. The eligibility criteria for the trial include having received at least one prior therapy for CLL and being treated with a nucleoside analogue, having an ECOG performance status of 2 or less, and not having certain medical conditions such as autoimmune cytopenias or hepatic disease. The exclusion criteria include being pregnant or breastfeeding, having platelets or neutrophil counts below certain levels, and having a history of pancreatitis or other medical conditions. The trial does not include patients with active infections, HIV, or active viral hepatitis, or those diagnosed with more aggressive lymphoproliferative disorders such as Richter's transformation.",
    "The sample is a record from a clinical trial table that includes information about the phase of the trial, which is a combination of phase 2 and phase 3. The trial is focused on colorectal cancer, with a list of associated ICD-10 codes. The table also includes a list of drugs being used in the trial, which are cpt-11 and ts-1, as well as cpt-11, 5-fu, and l-lv. The eligibility criteria for the trial are also included, with a list of inclusion and exclusion criteria. The inclusion criteria include having histologically confirmed colorectal cancer, being locally advanced and/or metastatic, having prior chemotherapy as first line treatment, and being able to take oral medication, among other requirements. The exclusion criteria include having prior radiotherapy for colorectal cancer, having other malignancies in the past 5 years, and having serious illness or medical conditions.",
    "The sample is a phase 2 clinical trial for patients with recurrent de novo or transformed diffuse large B cell lymphoma or one of its variants. The trial involves the drug sorafenib tosylate and has a list of inclusion and exclusion criteria. The table includes information on the phase of the trial, the diseases being studied, the icd-10 codes of those diseases, the drugs being used, and the eligibility criteria for patients to participate in the trial.",
    "The sample is a phase 2 clinical trial for foot ulcers in diabetic patients. The trial includes patients with type 1 or type 2 diabetes mellitus who have problems with the nerves in their feet and have a large ulcer or multiple ulcers on the bottom surface of their foot that has been present for 3 weeks or more. The patients must be able to apply the study drug to their ulcer or have a caregiver do it, and they must be able to visit the doctor regularly during the 4\u00bd month study. The trial excludes patients whose ulcer is caused by bad blood flow to their foot, is infected, or who cannot wear an off-loading device during the study to take pressure off the ulcer. Additionally, patients with certain other diseases or who are using certain types of drugs may not participate in the study. The study drug being used is called mre0094, and a vehicle gel is also being used.",
    "The sample is a phase 2 clinical trial that focuses on patients with neoplasm metastasis and palliative care. The trial involves administering tanezumab 10 mg iv and iv placebo for tanezumab to patients with prostate cancer, breast cancer, renal cell carcinoma, or multiple myeloma that has spread to bone and is causing moderate to severe bone pain. The eligibility criteria include requiring daily opioid medication and having bone pain caused by cancer. Exclusion criteria include not having bone pain caused by cancer, starting chemotherapy or completing radiotherapy less than 4 weeks ago, having a known history or evidence of osteoarthritis, and having a known history of rheumatoid arthritis.",
    "The sample is a record from a clinical trial table that includes information about the phase of the trial (phase 1/phase 2), the disease being studied (hormone refractory prostate cancer), the ICD-10 codes associated with the disease, the drugs being tested (picoplatin and docetaxel), and the eligibility criteria for participants. The eligibility criteria include requirements such as confirmed adenocarcinoma of the prostate, evidence of metastatic disease, and stable pain levels, as well as exclusion criteria such as prior treatment with certain therapies, brain or leptomeningeal metastases, and serious medical or psychiatric illness that could interfere with the completion of the study treatment.",
    "The sample is a phase 2 clinical trial for patients with non-small cell lung cancer. The trial is testing the effectiveness of the drugs cisplatin and etoposide in treating the disease. The eligibility criteria include having confirmed primary stage IIIB NSCLC, being between the ages of 18 and 75, having a WHO performance status of 0-1, and meeting various hematopoietic, hepatic, renal, cardiovascular, and pulmonary requirements. Patients must not have had prior chemotherapy or radiotherapy for NSCLC, and must not have any other primary malignancy except for certain exceptions. The trial also has various exclusion criteria, such as pre-existing sensory neurotoxicity grade 2 or greater, active uncontrolled infection requiring IV antibiotics, and psychological, familial, sociological, or geographical conditions that would preclude study compliance. Prior concurrent therapy is also restricted.",
    "The sample is a phase 2 clinical trial for the treatment of schizophrenia. The trial includes patients who have been clinically stable for at least 8 weeks prior to the baseline visit and have received treatment with olanzapine, oral risperidone, or paliperidone for at least 6 weeks prior to the screening visit. The patients must be in good health, except for the diagnosis of schizophrenia, and must be willing and able to comply with study restrictions. The trial excludes patients with any Axis I disorder, tardive dyskinesia, clinically significant uncontrolled medical or surgical conditions, previous sensitivity to study drug ingredients, and pregnant or lactating women. The trial involves the use of armodafinil and placebo as drugs. The eligibility criteria for the trial are listed in detail under Key Inclusion Criteria and Key Exclusion Criteria.",
    "The sample is a phase 2 clinical trial for patients with advanced non-small cell lung cancer. The trial includes patients who have not been previously treated with anticancer drugs for advanced disease and have an ECOG performance status of 0-1. The trial involves the use of two drugs, erlotinib and docetaxel, either alone or in combination. The eligibility criteria include factors such as age, life expectancy, ability to take oral medication, and certain blood counts and liver function tests. Patients with certain medical conditions or who have had prior exposure to certain drugs are excluded from the trial. The trial requires patients to provide written informed consent and provide tumor tissue samples for analysis.",
    "The sample is a phase 2 clinical trial for ovarian cancer patients who have platinum-resistant disease. The trial involves two drugs, vintafolide and pegylated liposomal doxorubicin (PLD). The eligibility criteria include having a confirmed diagnosis of epithelial ovarian, fallopian tube, or primary peritoneal carcinoma, having at least one measurable lesion, and having an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2. Additionally, patients must have recovered from prior cytotoxic therapy-associated acute toxicities and have adequate organ function. Exclusion criteria include prior exposure to PLD or anthracycline therapy, concurrent malignancy or history of other cancer within the last 5 years, and symptomatic central nervous system metastasis.",
    "The sample is a phase 2 clinical trial for the treatment of ulcerative colitis. The trial involves the drugs aeb071 and placebo. The eligibility criteria include being between 18-75 years old, having moderate to severe disease, and having a poor response to or no toleration of conventional therapy. Female subjects of childbearing potential must be using two methods of contraception. Exclusion criteria include allergy to the drug, ongoing treatment with specific other medication, and diagnosis of primary sclerosing cholangitis, among others. Other protocol-defined inclusion/exclusion criteria also apply.",
    "The sample is a phase 2 clinical trial for the treatment of various types of brain tumors, including glioblastoma multiforme and gliosarcoma, using the drug vorinostat. The trial has specific eligibility criteria, including confirmation of the disease, measurable or evaluable disease by MRI or CT scan, and a performance status of ECOG 0-2. Patients must also meet certain blood count and organ function requirements, and cannot have had a myocardial infarction within the past 6 months or be immunocompromised. Patients must not be pregnant or nursing, and must use effective contraception during and for 6 months after completion of study treatment. Prior adjuvant chemotherapy is allowed, but patients must have gone more than 4 weeks without chemotherapy (6 weeks for nitrosoureas) and more than 2 weeks without small molecule cell cycle inhibitors. Concurrent corticosteroids are allowed as long as the dose has been stable for at least 1 week. Patients must have evidence of tumor progression by MRI or CT scan after radiotherapy and must have gone more than 8 weeks without radiotherapy. If patients have undergone stereotactic radiosurgery or interstitial brachytherapy, they must have gone more than 6 weeks without it, unless there is a separate lesion outside of the prior treatment field or evidence of recurrent disease by biopsy, MRI spectroscopy, or positron-emission tomography scan. Patients must have gone more than 2 weeks without valproic acid.",
    "The sample is a record from a clinical trial table that includes information about the trial's phase, diseases being studied, icd-10 codes associated with those diseases, drugs being tested, and eligibility criteria for participants. In this particular sample, the trial is in phase 2/phase 3 and is studying hypertension. The icd-10 codes associated with hypertension are listed, as well as the drugs being tested (olmesartan medoxomil and placebo). The eligibility criteria for participants are also listed, including requirements for blood pressure levels, negative test results for hepatitis B and C, and HIV, and exclusion criteria such as a history of congestive heart failure or sensitivity to olmesartan medoxomil.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on prostate cancer and the associated diseases are listed as well as the corresponding ICD-10 codes. The trial involves the use of three drugs: aminoglutethimide, ketoconazole, and therapeutic hydrocortisone. The eligibility criteria for the trial include having histologically proven adenocarcinoma of the prostate at stage IV, with PSA progression after testicular androgen ablation with or without antiandrogen therapy. The patient must have no other medical conditions that would increase risk and must use effective contraception if fertile. The trial excludes patients who have had prior aminoglutethimide or ketoconazole for prostate cancer, and those taking certain medications known to interact with ketoconazole.",
    "The sample is a record of a clinical trial with a combination of gleevec and temozolomide as a potential treatment for advanced melanoma. The trial is in phase 1/phase 2 and the eligibility criteria include having metastatic or unresectable melanoma, measurable disease, ECOG performance status <= 2, and a life expectancy greater than 3 months. Exclusion criteria include no prior treatment with temozolomide or imatinib mesylate, organ allografts, prior radiotherapy or intratumor injection therapy to areas of measurable disease, pregnancy or lactation, history of second cancer, known hypersensitivity to temozolomide or imatinib, and use of any experimental therapy within 3 weeks prior to baseline evaluations done prior to enrollment. The diseases associated with the trial are melanoma and advanced melanoma, and the icd-10 codes associated with these diseases are listed.",
    "This sample is a phase 2 clinical trial for patients with ovarian carcinoma or peritoneal neoplasms. The trial is testing the effectiveness of the drug combination of docetaxel and gemcitabine. The eligibility criteria include having platinum-resistant disease, measurable or evaluable disease, being over 18 years old, having a GOG performance status less than or equal to 2, and meeting certain laboratory values. Patients must also have fully recovered from any acute toxicities from prior treatments and sign an informed consent. Exclusion criteria include prior treatment with gemcitabine or docetaxel, underlying medical, psychiatric, or social conditions that would preclude treatment, peripheral neuropathy greater than or equal to Grade 2, and no prior treatment with cisplatin or carboplatin.",
    "The sample is a phase 2 clinical trial for breast cancer patients with stage IIIB, IIIC, or IV who have not responded to standard doses of Herceptin. The trial is testing the effectiveness of the drug neratinib for patients with over-expression of HER2. The trial has inclusion criteria such as having at least one measurable lesion and exclusion criteria such as prior treatment with Herceptin and inadequate cardiac function. The trial also requires tumor tissue for analysis at screening and prohibits participation of pregnant or breastfeeding women.",
    "This is a sample from a clinical trial table that includes information about a phase 2 trial for pancreatic cancer. The trial requires patients to have histologically or cytologically confirmed pancreatic adenocarcinoma that is locally advanced or metastatic by radiological evidence. Patients must also have biopsy material available for correlative studies and cannot have endocrine tumor or lymphoma of the pancreas or a history of CNS metastases. Other patient characteristics include a SWOG performance status of 0-1, life expectancy of at least 12 weeks, and various blood and organ function requirements. Patients cannot be pregnant or nursing, must use effective contraception if fertile, and cannot have active infections or conditions that would limit the ability to receive oral medications. Prior concurrent therapy is also restricted. The trial drugs are erlotinib hydrochloride and gemcitabine hydrochloride.",
    "The sample is a phase 2 clinical trial for patients with hormone-resistant or recurrent prostate cancer. The trial is testing the drug saracatinib. The eligibility criteria include having confirmed prostate cancer with certain characteristics, being surgically or medically castrated, having a certain performance status, and meeting certain laboratory values. Patients must also agree to use adequate contraception and have recovered from previous therapies. Exclusion criteria include having brain metastases, certain medical conditions, and use of certain drugs. The trial is investigating the safety and efficacy of saracatinib in treating prostate cancer.",
    "The sample is a phase 2 clinical trial for the treatment of migraines. The trial includes patients who have been experiencing migraines for at least 6 months and have 2 to 10 attacks per month with at least 3 migraine days per month. The trial involves the use of three drugs: ast-726 low dose, ast-726 high dose, and ast-726 placebo. The eligibility criteria include having migraines according to International Headache Society guidelines, being between the ages of 18 and 65, and not having used certain migraine medications within 60 days prior to study enrollment. The trial also has exclusion criteria, such as having excessive use of acute migraine medications and having failed more than 3 clinical studies of effective migraine prevention medications.",
    "The sample is a record of a clinical trial that is in phase 2/phase 3. The trial is focused on the disease of ocular hypertension, which is identified by a list of ICD-10 codes. The drug being tested is bimatoprost. The eligibility criteria for the trial include a clinical diagnosis of glaucoma or ocular hypertension in both eyes and a requirement for IOP-lowering drug in both eyes. The exclusion criteria include uncontrolled medical conditions and ocular seasonal allergies within the past 2 years.",
    "The sample is a phase 2 clinical trial for the treatment of hepatitis C virus. The trial includes patients with HCV genotype 1a or 1b, who are at least 18 years old and have an HCV RNA level of at least 10,000 IU/mL. Participants with compensated cirrhosis are also allowed to participate. The trial involves the use of three drugs: daclatasvir, simeprevir, and ribavirin. The eligibility criteria include various medical conditions that would exclude a patient from participating in the trial, such as liver or any other transplant, evidence of a medical condition contributing to chronic liver disease other than HCV infection, and uncontrolled diabetes or hypertension. The trial also has exclusion criteria, such as prior exposure to an HCV direct-acting agent and any criteria that would exclude the patient from receiving ribavirin.",
    "The sample is a clinical trial for Parkinson's disease, in which patients with a modified Hoehn and Yahr scale of II to IV at \"on\" time are eligible. The trial is in phase 2/phase 3 and the patients must have received an individual dosage of L-DOPA at a stable dose for at least 4 weeks before the baseline visit. The trial aims to address therapeutically problematic issues or status based on L-DOPA therapy, such as wearing-off phenomena, no on/delayed on, dystonia at off time, on-off phenomena, freezing phenomena at off time, or sub-optimal dose of L-DOPA due to side effects or therapeutic strategy. The sample includes inclusion and exclusion criteria, such as excluding patients with atypical parkinsonian syndromes, dementia, psychiatric disorders, clinically significant ECG abnormalities, hypotension, or other clinically significant diseases. Patients who are pregnant or breastfeeding, sexually active females of childbearing potential not using a medically approved method of birth control, or those with certain serum levels or complications are also excluded.",
    "The sample is a record of a clinical trial that is in phase 2/phase 3. The trial is focused on the disease of seizures and includes a list of icd-10 codes associated with the disease. The trial involves two drugs, levetiracetam 1 g iv + lorazepam 2 mg iv and placebo + lorazepam 3 mg iv. The eligibility criteria for the trial includes having seizures as an inclusion criteria, while exclusion criteria includes pregnancy, renal failure, and hepatic impairment.",
    "The sample is a phase 2 trial for the treatment of type 2 diabetes mellitus. The trial includes patients who have a historical diagnosis of type 2 diabetes mellitus without the chronic use of antidiabetic therapy within 8 weeks prior to screening, or who have a historical diagnosis of mellitus and are stable on at least 1500 mg per day or the respective maximal tolerated dose of metformin as monotherapy for at least 2 months prior to screening. The trial involves the use of the drugs tak-875, glimepiride, and placebo. The eligibility criteria include specific glycosylated hemoglobin levels, fasting plasma glucose levels, and fasting C-peptide concentrations, as well as stable doses of chronic medications and a specific body mass index range. The trial also requires participants to monitor their glucose levels and use contraception if sexually active. The exclusion criteria include various medical conditions and medications that may interfere with the evaluation of the study medication.",
    "The sample is a phase 2 clinical trial for the treatment of gastric cancer. The trial is looking for patients with localized cancer that is potentially curable by surgery and who meet certain eligibility criteria, such as having a confirmed diagnosis of adenocarcinoma of the stomach or gastroesophageal junction, being over 18 years old, and having a certain level of white blood cell count, platelet count, and bilirubin. The trial is testing a combination of drugs including cisplatin, fluorouracil, leucovorin calcium, and paclitaxel. Patients who have had prior chemotherapy, significant heart disease, or are pregnant or lactating are excluded from the trial. The trial also has specific re-registration criteria for patients who undergo surgery.",
    "The sample is a clinical trial for patients with alveolitis and systemic sclerosis in phase 1/phase 2. The trial involves the use of imatinib as a drug treatment. The eligibility criteria include fulfilling the criteria for SSc by ACR criteria, having dyspnea on exertion, and showing evidence of alveolitis. Patients must also be over 18 years old, able to complete a 6MWT with a walking distance of at least 150m, and provide written informed consent. Exclusion criteria include having severe and/or uncontrolled medical disease, known chronic liver disease, and a known diagnosis of HIV infection.",
    "The sample is a clinical trial for the treatment of restless legs syndrome. It is a phase 2/phase 3 trial that includes patients who are at least 18 years old and have been diagnosed with idiopathic RLS. The trial involves the use of the drugs rasagiline and placebo (sugar pill). The eligibility criteria include having moderate or severe symptoms of RLS, not currently receiving treatment for RLS, and being on a stable dose of certain antidepressants for at least 30 days prior to the baseline visit. Female subjects must not be of childbearing potential or must agree to use contraception for the duration of the study. The exclusion criteria include having signs consistent with a secondary cause of RLS, history of initial unresponsiveness to dopaminergic RLS treatment, and use of certain drugs or supplements contraindicated with rasagiline.",
    "The sample is a record from a clinical trial table that includes information about the phase of the trial, the disease being studied (in this case, rheumatoid arthritis), the corresponding ICD-10 codes, the drugs being tested (including sarilumab, placebo, methotrexate, and folic acid), and the eligibility criteria for participants. The eligibility criteria include specific requirements for the duration and severity of the disease, as well as exclusion criteria such as age restrictions and previous treatments. The sample also includes a disclaimer that the information provided is not exhaustive and may not include all relevant considerations for potential participants in the trial.",
    "The sample is a phase 2 clinical trial for patients with unresectable, metastatic or recurrent colorectal cancer. The trial is testing the effectiveness of the drugs capecitabine and oxaliplatin. The eligibility criteria include having confirmed adenocarcinoma of the colon or rectum, not being amenable to potentially curative treatment, and having a performance status of ECOG 0-2. Patients must also meet certain hematopoietic, hepatic, renal, cardiovascular, gastrointestinal, immunologic, and other criteria. Prior concurrent therapy is also restricted.",
    "The sample is a phase 2 clinical trial for breast cancer patients with locally advanced or metastatic disease. The trial involves the use of the drugs celecoxib and letrozole. The eligibility criteria include having histologically or cytologically confirmed adenocarcinoma of the breast, measurable disease, and being estrogen receptor- or progesterone receptor-positive. Patients must also meet certain age, sex, menopausal status, performance status, and life expectancy requirements, as well as have certain hematopoietic, hepatic, and renal levels within normal ranges. Patients cannot have a history of brain metastases unless controlled with radiotherapy or surgical resection for at least 6 months before study entry, and cannot have any other medical condition that would preclude study participation. Prior concurrent therapies are also specified.",
    "The sample is a phase 2 trial for patients with breast cancer, including recurrent and stage IV breast cancer. The trial is testing the effectiveness of pazopanib hydrochloride as a treatment option. The eligibility criteria for the trial include having no prior bevacizumab treatment, having measurable disease, and having an ECOG performance status of 0-1 or Karnofsky PS 60-100%. Patients with HER-2 positive disease who have not yet received trastuzumab are ineligible, and patients with hormone receptor-positive breast cancer should have received appropriate sequential hormonal therapy for metastatic disease until disease progression. The trial also has various medical criteria that patients must meet, such as having normal levels of bilirubin and platelets, and not having any serious or non-healing wounds or fractures. Patients must also not be pregnant or nursing, and fertile patients must use effective contraception. The trial has various exclusion criteria, such as having poorly controlled hypertension or having had a myocardial infarction or cerebrovascular accident within a certain time frame. Patients must have had at least 4 weeks since prior chemotherapy, radiotherapy, or surgery, and no more than 2 prior palliative systemic chemotherapy regimens for de novo metastatic disease. The trial also has restrictions on the use of certain medications during or after completion of study treatment.",
    "The sample is a phase 2 clinical trial for rheumatoid arthritis. The trial includes patients who have been diagnosed with RA for at least 6 months and have active disease, as defined by certain criteria. The trial also requires patients to have had an inadequate response to at least one disease-modifying anti-rheumatic drug. The trial will test the effectiveness of several drugs, including mlta3698a, adalimumab, leflunomide, methotrexate, and placebo. Patients must meet certain inclusion criteria, such as having a positive rheumatoid factor or anti-cyclic citrullinated peptide antibody, and must not meet certain exclusion criteria, such as having a history of anaphylactic reactions or being pregnant or breastfeeding.",
    "The sample is a phase 2 clinical trial for the treatment of geographic atrophy, a type of macular degeneration. The trial involves the use of two drugs, al-78898a and sham injection. The eligibility criteria for the trial include a confirmed diagnosis of bilateral geographic atrophy, a certain level of visual acuity in the study eye, and the absence of certain ophthalmologic conditions or medical history. Exclusion criteria include a history of certain eye conditions or surgeries, participation in other clinical trials or use of experimental treatments, and certain medical or psychiatric conditions. Women of childbearing potential must be using a highly effective method of birth control.",
    "The sample is a phase 2 clinical trial for depressive disorder. The trial includes the drugs gsk372475, venlafaxine, and a placebo. The eligibility criteria for the trial include having a major depressive episode associated with Major Depressive Disorder, having symptoms of decreased energy, pleasure, and interest, and having a current episode that is at least 12 weeks duration and less than 2 years. Exclusion criteria include having a current diagnosis of Panic Disorder, or symptoms of generalized anxiety or panic attacks that could interfere with their ability to complete the trial, having symptoms of MDE better accounted for by another diagnosis, and having a diagnosis of Bipolar, schizophrenia, other psychotic disorder(s), borderline or antisocial personality disorder, or dementia. Other exclusion criteria include having started psychotherapy within 3 months prior to the Screening, having received electroconvulsive therapy or transcranial magnetic stimulation within 6 months prior to screening, having received psychoactive drugs within 4 weeks of randomization, having a positive urine drug screen or positive blood alcohol, having suicidal risk or has had any previous suicide attempt, a family history of suicide attempt, having a positive pregnancy test, having a history of seizure disorder, myocardial infarction (< 1yr), or unstable medical condition, and having failed to respond to an adequate course of pharmacotherapy of at least 2 different antidepressants.",
    "The sample is a phase 2 clinical trial for the treatment of leukemia using the drugs clofarabine and cytarabine. The eligibility criteria include having a confirmed diagnosis of acute myeloid leukemia (AML) or acute lymphoblastic leukemia (ALL), being in first or second relapse or refractory to initial induction therapy, and meeting certain patient characteristics such as having an ECOG performance status of 2 or lower and no active, uncontrolled systemic infection. Prior concurrent therapy is also taken into consideration. The diseases are listed as 'leukemia' and the icd-10 codes associated with the diseases are also provided.",
    "The sample is a phase 2 clinical trial for patients with type 2 diabetes mellitus. The trial includes patients who have had T2DM for at least 1 year, are at least 18 years old, and have been using metformin and/or sulfonylurea(s) with once daily glargine or NPH for at least 3 months prior to the study. The trial also requires patients to have a stable dose of oral antihyperglycemic medications for 6 weeks prior to the study, with a maximum insulin dose of 1.0 unit/kilogram/day (U/kg/day). Patients must have an HbA1c level less than or equal to 10.5% before randomization and a BMI between 19 and 45 kg/m\u00b2. Patients must be willing and capable of preparing and injecting insulin with a syringe, monitoring their own blood glucose, completing the study diary, and complying with study visits and telephone calls between visits. Women of childbearing potential must test negative for pregnancy before receiving treatment and agree to use reliable birth control until completing the follow-up visit. The trial excludes patients who have used short- or rapid-acting or premixed insulin within the 6 months before the study, have used any glucose-lowering medications not allowed by the inclusion criteria in the 3 months before entry into the study, have used prescription or over-the-counter medications to promote weight loss within 3 months before entry into the study, are currently participating in a weight loss program, or plans to do so during the study, have been treated with any antibody-based therapy within 6 months prior to the study, have used chronic systemic glucocorticoid therapy currently or within 4 weeks prior to the study, have had more than 1 episode of severe hypoglycemia within 6 months prior to the study, have liver disease, history of renal transplantation, current renal dialysis, or creatinine >2.0 milligram/deciliter (mg/dL) (177 micromole/Liter [\u03bcmol]/L), cardiac disease with a marked impact on physical functioning, clinically significant electrocardiogram (ECG) abnormalities at screening, malignancy other than basal cell or squamous cell skin cancer, fasting triglycerides >500 mg/dL, known diabetic autonomic neuropathy, known hypersensitivity or allergy to study insulin or its excipients, blood transfusion or severe blood loss within 3 months prior to entry into the study or known hemoglobinopathy, hemolytic anemia, or sickle cell anemia, or any other traits of hemoglobin abnormalities known to interfere with the HbA1c methodology, and irregular sleep/wake cycle. Women who are breastfeeding are also excluded from the trial.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on the disease of asthma and includes a list of ICD-10 codes associated with the disease. The trial involves testing several drugs, including formoterol fumarate dpi, mometasone furoate/formoterol fumarate mdi (ex-actuator) without spacer, and mometasone furoate/formoterol fumarate mdi (ex-actuator) with spacer, as well as a placebo mdi with spacer, a placebo mdi without spacer, and mometasone furoate dpi. The eligibility criteria for the trial include having a diagnosis of asthma for at least 6 months, having taken an Inhaled Corticosteroid (ICS) for at least 3 months prior to the screening visit, and having an FEV1 of at least 70% predicted after all restricted medications have been withheld for the appropriate intervals. The exclusion criteria include having been treated in the emergency room for a severe asthma exacerbation requiring systemic glucocorticosteroid treatment, requiring ventilator support for respiratory failure secondary to asthma, and experiencing a clinical deterioration in asthma that results in emergency treatment, hospitalization due to asthma, or treatment with additional, excluded asthma medication.",
    "The sample is a phase 2 trial for the treatment of various types of cancer, including cervical, endometrial, ovarian, and fallopian tube cancer, as well as sarcoma and neurotoxicity. The proposed treatment involves a combination of cisplatin and paclitaxel, and patients must be ineligible for a higher priority GOG protocol. Eligibility criteria include specific disease characteristics, as well as age, performance status, hematopoietic, hepatic, renal, and cardiovascular factors. Patients must also have no history of neuropathy or significant infection, and must not have any physical disabilities that would prevent vibration perception threshold testing. Prior concurrent therapy is not specified, except for restrictions on prior chemotherapy and radiotherapy.",
    "The sample is a phase 2 clinical trial for the treatment of postherpetic neuralgia, a type of nerve pain that occurs after a shingles infection. The trial is testing the effectiveness of the drug levetiracetam in reducing pain in patients with this condition. The eligibility criteria for the trial include being at least 18 years old, having had neuralgia for at least 3 months, and having a certain level of pain intensity. Patients with certain medical conditions or who are receiving certain types of therapy are excluded from the trial. The trial is designed to evaluate the safety and efficacy of levetiracetam in treating postherpetic neuralgia.",
    "The sample is a phase 2 clinical trial for the treatment of glaucoma and ocular hypertension. The trial involves the use of three different drugs: latanoprost 0.005%, ar-12286 ophthalmic solution 0.5%, and timolol maleate ophthalmic solution 0.5%. The eligibility criteria for the trial include being 18 years or older, having a diagnosis of open angle glaucoma or ocular hypertension, and currently using prostaglandin analogue for at least one month in both eyes. The trial also requires participants to have a certain level of intraocular pressure and visual acuity, and to be willing to follow study instructions. Exclusion criteria include a history of certain eye conditions, hypersensitivity to certain medications, and certain systemic diseases. Women who are pregnant, nursing, planning a pregnancy, or not using a medically acceptable form of birth control are also excluded from the trial.",
    "The sample is a phase 2 clinical trial for prostate cancer. The trial includes patients with various stages of prostate cancer, excluding those with central nervous system metastases. The trial involves the use of five different drugs, including bicalutamide and leuprolide acetate. The eligibility criteria include having a confirmed diagnosis of prostate cancer, a PSA level of at least 4.0 ng/mL, and adequate organ function. Patients must also have an ECOG performance status of 0-2 and be able to understand and sign informed consent. Exclusion criteria include prior hormonal therapy, prior radiation therapy to the prostate, and concurrent malignancy. Patients must be willing to complete all required follow-up visits.",
    "The sample is a phase 2 clinical trial for advanced hepatobiliary carcinoma that is not amenable to conventional surgery. The trial includes patients with gall bladder carcinoma, cholangiocarcinoma, carcinoma of the ampulla, and hepatocellular carcinoma (eligible for cohort II only). The trial requires measurable disease and excludes patients with known brain metastases. Patients must be 18 years or older with an ECOG performance status of 0-2 and a life expectancy of at least 12 weeks. Hematopoietic, hepatic, renal, and cardiovascular criteria must also be met. Patients cannot be pregnant or nursing, must have a negative pregnancy test, and fertile patients must use effective contraception. Prior concurrent therapy is not specified, but patients cannot have had prior chemotherapy for cholangiocarcinoma or hepatobiliary carcinoma. There is no concurrent combination antiviral therapy for HIV-positive patients. The drug being tested is becatecarin.",
    "The sample is a phase 2 clinical trial for cervical cancer patients with tumors greater than 4 cm in diameter. The trial is for previously untreated patients with invasive squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma of the uterine cervix. The trial includes a list of inclusion and exclusion criteria, such as negative para-aortic nodes, adequate bone marrow and renal function, and a Zubrod Performance Status of 0 or 1. The trial involves the use of two drugs, bevacizumab and carboplatin. The sample also includes a list of diseases and their corresponding ICD-10 codes.",
    "The sample is a phase 2 clinical trial for patients with uncontrolled epilepsy who experience at least two seizures a month for three consecutive months. The trial is open to patients between the ages of 18 and 50 who have been diagnosed with partial onset epilepsy and have not responded to two or more main-line anti-epileptic drugs. Patients must be able to keep a seizure diary and have a normal brain MRI, with the exception of hippocampal sclerosis. The trial excludes patients with a history of severe prematurity or neonatal distress, febrile seizures, traumatic brain injury, stroke, brain tumor, meningitis, encephalitis, neurocutaneous syndromes, or intracranial metal objects. Patients with psychogenic epilepsy, convulsive status epilepticus, primary generalized epilepsy in a first degree relative, or a known serious medical illness are also excluded.",
    "The sample is a phase 2 clinical trial for patients with HIV infections. The trial involves a combination of drugs including raltegravir potassium, darunavir/ritonavir, etravirine, and an optimized background regimen. The eligibility criteria include being 18 years or older, having documented HIV-1 infection, a history of virological failure on NNRTIs, and being on a combination antiretroviral therapy for at least 8 weeks prior to the screening visit. Patients must also be naive to darunavir, etravirine, and integrase inhibitors. The trial requires a plasma viral load at the screening visit over 1000 copies/ml and genotypic resistance testing. There are also exclusion criteria, such as non-effective barrier contraception in women of childbearing potential, pregnant or breastfeeding women, and patients with certain medical conditions or taking certain medications.",
    "The sample is a phase 2 clinical trial for patients with ischemic heart disease, including heart failure, myocardial ischemia, and angina pectoris. The trial involves testing the effectiveness of several drugs, including ck-1827452, in treating the disease. The eligibility criteria for the trial include being at least 18 years old, having a history of exercise-induced angina, and having a left ventricular ejection fraction of 35% or less. The trial also has exclusion criteria, such as having acute myocarditis or significant co-morbid conditions that may limit exercise capacity. The trial requires patients to complete at least 4 minutes of a Modified Naughton ETT and has a list of drugs and their dosages that will be administered.",
    "The sample is a phase 2 clinical trial for metastatic colorectal cancer. The trial includes patients with a histologically proven diagnosis of colorectal adenocarcinoma and metastatic disease present in the liver only. The trial excludes patients with extrahepatic metastases and those who have received previous treatment for metastatic colorectal cancer. The trial also requires patients to be medically fit to undergo neoadjuvant treatment and surgery with curative intent. The eligibility criteria include the absence of pre-existing liver dysfunction of Childs Pugh Grade B or greater. The trial involves the use of capecitabine, oxaliplatin, and bevacizumab as drugs. The trial requires liver-only metastases to be determined as unresectable at presentation on a pre-treatment liver MRI with an appropriate liver-specific contrast by a specialist multidisciplinary team. The guidelines for determining unresectability include the presence of more than four metastases, size greater than 5cm, location and distribution of metastatic disease within the liver unsuitable for resection with clear margins, extent of liver involvement precluding resection with adequate post-resection residual liver parenchyma volume for viable liver function in the immediate post-operative period, and inability to retain adequate vascular in flow and outflow to maintain viable liver function. The trial also requires the feasibility of surgery with curative intent. If the primary colorectal tumor is in situ, the primary tumor must also be resectable with curative intent. Patients presenting with liver metastases only relapse after initially curative resection of their primary colorectal cancer followed by treatment with adjuvant chemotherapy may not be entered into the study if the relapse has occurred within 12 months of completion of adjuvant treatment.",
    "The sample is a phase 2 trial for the treatment of autism spectrum disorders, including autistic disorder, Asperger syndrome, and autism spectrum disorder. The trial involves the drug aripiprazole and has a list of inclusion and exclusion criteria for participants. Inclusion criteria include being between 30 months and 17 years 11 months old, having a diagnosis of autism spectrum disorder, and having a guardian who can provide written consent. Exclusion criteria include having Rett's syndrome or Child Disintegrative Disorder, taking certain psychotropic medications, and being pregnant or nursing.",
    "The sample is a phase 2 clinical trial for patients with uterine cancer. The trial is investigating the effects of the drug celecoxib on patients with clinical stage I or stage II disease. The eligibility criteria include being at least 18 years old, having histologically confirmed uterine cancer of certain types, having a Zubrod/ECOG/GOG performance status \u22642 that permits surgery, and signing a written informed consent. Exclusion criteria include known hypersensitivity to Celecoxib, daily usage of any form of NSAID or aspirin prior to endometrial biopsy, and impairment of hepatic, renal or hematologic function. Women of child-bearing potential must agree to use a chemical or barrier contraceptive during the dosing portion of the study.",
    "The sample is a record from a clinical trial table that includes information about the phase of the trial (phase 1/phase 2), the diseases being studied (multiple myeloma and multiple myeloma in relapse), the corresponding ICD-10 codes for the diseases, the drugs being tested (perifosine, bortezomib, and dexamethasone), and the eligibility criteria for participants. The eligibility criteria include a diagnosis of multiple myeloma based on specific criteria, previous treatment with bortezomib, and relapsed or refractory disease. Other criteria include age, performance status, ability to adhere to the study schedule, and understanding and signing of an informed consent document. Exclusion criteria include renal insufficiency, history of allergic reactions to similar compounds, and certain medications taken within two weeks prior to the start of the trial. Women of child-bearing potential must have a negative pregnancy test and agree to use adequate contraception throughout the study.",
    "The sample is a phase 2 clinical trial for the treatment of posttraumatic stress disorder. The trial involves the use of the drugs nepicastat and placebo. The eligibility criteria include having a diagnosis of PTSD, being a military veteran or currently serving, and being free of psychotropic medication for 2 weeks prior to randomization. Exclusion criteria include a history of certain mental disorders, unstable medical conditions, and pregnancy or breastfeeding. The trial requires signed informed consent and the use of medically-approved methods of birth control for women of childbearing potential.",
    "The sample is a phase 2 clinical trial for the treatment of nasal polyposis and asthma. The trial involves the use of two drugs, omalizumab and placebo. The eligibility criteria for the trial include being at least 18 years old, having a diagnosis of bilateral nasal polyps that have recurred after surgical resection or are grades 3 or 4 in both nares, and having a diagnosis of asthma for more than 2 years. Participants must also be in good health, willing to adhere to visit schedules and medication restrictions, and agree to perform daily diary entries. Exclusion criteria include pregnancy, breast feeding, premenarcheal, history of systemic reactions to the study medication, and acute sinusitis or concurrent nasal infection.",
    "The sample is a phase 2 clinical trial for asthma. The trial is looking for participants who have had a three-month history of reversible asthma, are non-smokers or ex-smokers with a negative cotinine screen, and are able to perform PFT. The trial is excluding participants with significant diseases other than asthma or allergic rhinitis, uncontrolled asthma, respiratory tract infection or exacerbation within 4 weeks, and those who have participated in another interventional study. Pregnant or nursing women and women of childbearing potential who are not using appropriate methods of birth control as defined by the protocol are also excluded. The trial is testing the effectiveness of drugs such as bi671800 and fluticasone placebo. The eligibility criteria include signed informed consent consistent with ICH-GCP, diagnosis of asthma prior to 40 years, and ACQ at least 1.5 at randomization.",
    "The sample is a phase 2 clinical trial for non-small-cell lung carcinoma. The trial is testing the drug erlotinib on patients who have previously been treated with 1-2 platinum- or taxane-containing regimens and have measurable disease. The trial is specifically looking for African American patients who are 18 years or older and may have had prior surgery and external beam radiation. Patients with known brain metastases, prior treatment with EGFR targeting therapies, and pregnant or lactating women are excluded from the trial. The eligibility criteria for the trial are listed in the \"Inclusion Criteria\" and \"Exclusion Criteria\" sections.",
    "The sample is a phase 2 clinical trial for patients with melanoma (skin cancer) that has spread or cannot be removed surgically. The trial involves the use of two drugs, sorafenib tosylate and temozolomide. The eligibility criteria include having confirmed melanoma, measurable disease, and meeting certain patient characteristics such as having a good performance status and normal blood counts. Patients must also not have any other concurrent malignancies or serious illnesses. Prior therapy is allowed, but patients must have recovered from it and meet certain time requirements. Concurrent use of certain medications is not allowed. The sample includes detailed disease and patient characteristics, as well as prior and concurrent therapy requirements.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on the disease of diabetes mellitus, type 2, and includes a list of corresponding ICD-10 codes. The trial involves the use of three drugs: pf-00734200 30 mg qd, pf-00734200 20 mg qd, and placebo. The eligibility criteria for the trial includes men and women between the ages of 18-80 with poorly controlled Type 2 diabetes, while the exclusion criteria includes individuals with Type 1 or secondary forms of diabetes, as well as those currently using insulin.",
    "The sample is a phase 2 trial that involves patients with myalgia, hypercholesterolemia, and hyperlipidemia. The trial is testing the effectiveness of the drugs ppd10558 and atorvastatin, as well as a placebo. The eligibility criteria for the trial include a diagnosis of primary hypercholesterolemia, a history of statin-associated myalgia, and specific LDL-C and triglyceride levels. Patients must also agree to stop taking certain medications and supplements. Exclusion criteria include chronic pain, liver disease, and certain medical conditions. Patients who meet the eligibility criteria and do not have any exclusion criteria may be eligible to participate in the trial.",
    "This sample is a phase 2 clinical trial for patients with multiple myeloma. The trial is testing the effectiveness of the drug palonosetron in preventing nausea and vomiting in patients receiving a specific chemotherapy regimen followed by autologous stem cell transplant. The eligibility criteria include being over 18 years old, having confirmed multiple myeloma, and having a Karnofsky index of at least 50%. Women of childbearing potential must use reliable contraception and have negative pregnancy tests. Exclusion criteria include recent use of investigational drugs, certain antiemetic medications, ongoing vomiting, and contraindications to 5-HT3 receptor antagonists.",
    "The sample is a phase 2 clinical trial for patients with metastatic melanoma or skin cancer. The trial involves the use of cyclophosphamide and fludarabine phosphate drugs. The eligibility criteria include having measurable disease, being a non-responder or having recurred after receiving high dose interleukin-2 (IL-2), being positive for gp100 by immunohistochemistry (IHC), having tumor infiltrating lymphocyte (TIL) cells not available for treatment on other Surgery Branch protocols, being at least 18 years old, having a clinical performance status of Eastern Oncology Oncology Group (ECOG) 0 or 1, having a life expectancy of greater than three months, and meeting various hematology and chemistry requirements. Women of child-bearing potential must have a negative pregnancy test and practice birth control for four months after receiving the preparative regimen. Patients must also meet certain serology and exclusion criteria.",
    "The sample is a phase 2 clinical trial for Parkinson's disease. The eligibility criteria include having a diagnosis of idiopathic PD, having received prior therapy with L-dopa for more than 1 year, being on a stable, optimal dopaminergic treatment regimen for at least 4 weeks before randomization, experiencing motor fluctuations with or without dyskinesias, and having a minimum of 2 hours/day of \"off\" time. The exclusion criteria include having a form of drug-induced or atypical parkinsonism, cognitive impairment, bipolar disorder, schizophrenia, or other psychotic disorder, having had surgery for PD, having an untreated major depressive disorder, and having participated in any studies using preladenant or any other clinical trial within 90 days of screening.",
    "The sample is a phase 2 clinical trial for the treatment of asthma. The trial includes subjects who are 12 years of age or older and have a documented clinical history of persistent asthma. The trial also requires subjects to be using an inhaled corticosteroid and have been maintained on a stable dose for 4 weeks prior to the start of the trial. The trial will test the efficacy of the drug GW642444M compared to a placebo. The eligibility criteria include various medical and lifestyle factors, such as not being pregnant or lactating, not having a history of life-threatening asthma, and not having any clinically significant, uncontrolled condition or disease that would put the subject's safety at risk through study participation. The trial also requires subjects to be capable of withholding salbutamol/albuterol use for at least 6 hours prior to clinic visits. The trial will exclude subjects who have used tobacco products within the past year, have a smoking history of 10 pack years or more, or have used certain asthma medications within 14 days of the start of the trial.",
    "The sample is a phase 2 clinical trial for patients with chronic lymphocytic leukemia or stage 0-IV small lymphocytic lymphoma. The trial involves the use of cyclophosphamide and pentostatin as chemotherapy. Patients must meet certain eligibility criteria, including having previously untreated disease and evidence of progressive marrow failure or symptomatic lymphadenopathy, splenomegaly, or hepatomegaly. Patients must also have a certain level of kidney and liver function, and be willing to provide blood samples and adhere to the study visit schedule. Exclusion criteria include certain comorbid conditions, pregnancy or nursing, and current use of corticosteroids.",
    "The sample is a record of a clinical trial in phase 2 for the treatment of epilepsy using the drug clonazepam. The trial includes patients with refractory epilepsy and excludes those with certain medical conditions or who are currently taking clonazepam. The diseases are listed as 'epilepsy' and the icd-10 codes associated with it are also provided. The eligibility criteria for the trial are also listed, including both inclusion and exclusion criteria.",
    "The sample is a clinical trial with a combination of phase 1 and phase 2. The trial is focused on treating diseases such as leukemia, lymphoma, neuroblastoma, immunodeficiencies, and anemia. The trial involves the use of drugs such as alemtuzumab, melphalan, busulfan, phenytoin, fludarabine, cyclophosphamide, horse antithymocyte globulin, rabbit antithymocyte globulin, and thiotepa. The eligibility criteria for the trial include having a TNC of at least 4x107/kg of two combined units, adequate renal, liver, cardiac, and pulmonary function, and not having a matched family donor or a 10/10 unrelated adult donor. The exclusion criteria include being pregnant or breastfeeding and having an uncontrolled infection at the time of study entry.",
    "This sample is for a phase 2 clinical trial for the treatment of locally advanced or metastatic papillary or follicular thyroid carcinoma using the drug vandetanib. The trial is looking for patients who have previously confirmed histological diagnosis of the disease and have measurable lesions. Patients must have had progressive disease following RAI131 or be unsuitable for RAI131 after surgery. The inclusion and exclusion criteria are listed in detail.",
    "The sample is a phase 2 clinical trial for the treatment of prostate cancer. The trial includes patients with a histologic or cytologic diagnosis of prostate carcinoma who have progressive metastatic prostate cancer despite adequate medical or surgical castration therapy. The patients must have previously received docetaxel for prostate cancer and have an ECOG performance status of 0-2. The trial involves the use of carboplatin and paclitaxel as drugs. The eligibility criteria include various medical conditions and the exclusion criteria include prior investigational therapy within 4 weeks of treatment and grade > 1 peripheral neuropathy.",
    "The sample is a phase 2 trial for patients with non-small cell lung cancer that has progressed after first-line therapy. The trial includes patients with stage IIIB/IV disease and requires histologic or cytologic documentation of NSCLC. Patients must have measurable or non-measurable disease and an ECOG performance status of 0-1. The trial excludes patients with ongoing cardiac dysrhythmias, atrial fibrillation, or a history of corrected QT interval > 500 msec. Patients with hypertension that cannot be controlled by medications, or who require therapeutic anticoagulation for thromboembolic disease, are also excluded. The trial involves the use of two drugs, pemetrexed disodium and sunitinib malate, and has a list of eligibility criteria that must be met.",
    "The sample is a phase 2 clinical trial for the treatment of urinary bladder cancer. The trial includes patients with unresectable urothelial carcinoma of the bladder or upper urinary tract, who have wild-type HRAS and are in general condition ECOG 0-1. The trial also requires patients to have a life expectancy of at least 12 weeks and locally advanced or metastatic disease. Patients must have at least one measurable lesion detectable in CT or MRI corresponding to the RECIST criteria. The trial excludes patients with HRAS mutation, dialysis-dependence following nephrectomy, cerebral tumours and/or cerebral metastases, clinically significant cardiovascular disease, uncontrolled hypertension, interstitial lung disease, thrombotic or embolic events, recent or known history of haemorrhagic diathesis, significant neurological or psychiatric disorders, serious inflammatory eye conditions, hearing impairment, pulmonary, haemopoietic, hepatic or renal disorders, poorly controlled diabetes mellitus, serious bacterial or fungal infections, chronic hepatitis B or C, HIV infection, autoimmune disease, allergic reaction to one of the medications to be used, status post organ transplantation, status post autologous bone marrow transplantation or stem cell transplantation in the 4 months prior to study commencement, manifest secondary malignancy or other form of cancer in the previous 5 years, subject pregnant or breast feeding, or planning to become pregnant within 6 months after the end of treatment, and active participation in other clinical studies in the previous 4 weeks. The trial requires patients to use highly effective methods of contraception during treatment and for 3 months after the end of treatment. The trial also excludes patients who have had prior systemic therapy with cytostatics or immunotherapeutic agents, concurrent use of other anticancer treatments after study commencement, intravesical chemotherapy in the previous 4 weeks, radiotherapy in the previous 4 weeks, previous radiotherapy in which all lesions to be used for the evaluation of tumour response were irradiated, and patients in a closed institution according to an authority or court decision.",
    "The sample is a record from a clinical trial table that includes information about the phase of the trial (phase 2), the disease being studied (breast neoplasms), the ICD-10 codes associated with the disease, the drugs being tested (lapatinib and pazopanib), and the eligibility criteria for participants. The eligibility criteria include specific requirements related to the patient's medical history, organ function, and other factors. The record also includes exclusion criteria, which outline conditions that would prevent a patient from participating in the trial.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on treating lymphoma, specifically aggressive non-Hodgkin's lymphoma of certain subtypes. The trial involves the use of several drugs, including cyclophosphamide, doxorubicin hydrochloride, prednisone, and vincristine sulfate. The eligibility criteria for the trial include specific disease characteristics, such as the stage of the lymphoma and the expression of CD20, as well as patient characteristics, such as age and performance status. The sample also includes information on prior concurrent therapy and other medical contraindications.",
    "The sample is a phase 2 clinical trial for prostate cancer. The trial is testing the drug enzastaurin. The eligibility criteria include being at least 18 years old, having evidence of androgen-independent PSA-progressive disease without metastatic disease, and having functioning organs. Participants must not have been treated with chemotherapy for their prostate cancer, except for one prior docetaxel-based chemotherapy regimen for cohort 2. The trial excludes participants who are unable to swallow pills, have another illness besides prostate cancer, have taken another experimental drug within the last 30 days, have a serious heart condition, or are receiving another anti-cancer therapy.",
    "The sample is a phase 2 clinical trial for breast cancer. The trial includes participants who are women aged 18 to 70 years old with histologically proven breast cancer. The participants must have had definitive surgical treatment and must be either \"lymph node positive\" or \"high risk lymph node negative\". The trial involves the use of drugs such as docetaxel, doxorubicin, carboplatin, cyclophosphamide, trastuzumab, and bevacizumab. The eligibility criteria include normal cardiac function, confirmed by left ventricular ejection fraction (LVEF) or shortening fraction (echocardiography [ECHO] or multiple-gated acquisition [MUGA] scan respectively), and the following hematology criteria confirmed within 2 weeks prior to study registration: absolute neutrophil count (ANC) >1,500/microL, platelets >100,000/microL, and hemoglobin \u2265 9 g/dL. The exclusion criteria include prior systemic anticancer therapy for invasive breast cancer, prior anthracycline therapy, taxoids, or platinum salts for any malignancy, and pre-existing motor or sensory neurotoxicity of a severity >Grade 2 by National Cancer Institute Common Toxicity Criteria for Adverse Events (NCI CTCAE) version 3.0.",
    "The sample is a phase 2 clinical trial for patients with multiple myeloma who have relapsed or progressed after at least one prior therapy. The trial is testing the drug bortezomib (velcade). The eligibility criteria include having measurable disease, a performance status of less than 2, adequate platelet count and ANC, adequate renal and hepatic function, and being at least 18 years old. Patients must also provide informed consent and agree to use contraception if applicable. Exclusion criteria include certain medical conditions, recent chemotherapy or radiotherapy, pregnancy or breastfeeding, and recent use of investigational drugs or bisphosphonates.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on breast cancer and breast neoplasms, with a list of corresponding ICD-10 codes. The trial involves the use of the drugs pemetrexed and gemcitabine, with multiple instances of each drug listed. The eligibility criteria for the trial include having received prior chemotherapy with Taxol or Taxotere, having had less than three different chemotherapy treatments for metastatic disease, and having received prior treatment with hormonal and/or radiation therapy. In addition, the patient must have a measurable disease and be able to take care of their personal hygiene. Exclusion criteria include being pregnant or breastfeeding, having cancer that has spread to the brain, having received treatment with Gemcitabine or Pemetrexed, being unable to take folic acid or Vitamin B12, and having received treatment for another cancer within the last 5 years.",
    "The sample is a phase 2 clinical trial for attention-deficit/hyperactivity disorder (ADHD). The trial includes subjects who have voluntarily signed an informed consent form, meet diagnostic criteria for ADHD, are in first grade or higher in a school setting 3 days/week, are generally in good health based on medical history, physical examination, clinical lab tests, and ECG, weigh at least 37 pounds (17 kg), and have been judged by the study doctor to be reliable to keep required appointments for clinic visits and all tests, including blood draws, and examinations. Female subjects of childbearing potential must have a negative urine pregnancy test at screening and baseline and agree to comply with applicable contraceptive requirements. The trial excludes subjects who are not functioning at an age-appropriate level intellectually, have a current or past diagnosis of bipolar disorder, psychosis, autism, Asperger's syndrome, or pervasive developmental disorder, have a current diagnosis of obsessive-compulsive disorder, eating disorder, anxiety disorder or depressive disorder requiring treatment of any kind, have a history of significant allergic reaction to any drug, require ongoing treatment with any psychiatric medication, have a serious medical condition, seizure disorder (except febrile seizures as an infant), or history of substance abuse or dependence. The trial includes the drugs abt-089, atomoxetine, and placebo.",
    "The sample is a phase 2 clinical trial for the treatment of type 1 diabetes mellitus using the drug pramlintide acetate. The trial is looking for participants who have been diagnosed with type 1 diabetes mellitus for at least 1 year and are on a stable regimen requiring multiple daily injections of basal and mealtime insulin or continuous subcutaneous insulin infusion for at least 2 weeks prior to screening. Participants must also have an HbA1c between 6.0% and 10.0%, inclusive, at screening and a body weight of at least 50 kg. Exclusion criteria include current treatment with certain medications, previous treatment with Symlin/pramlintide, or receipt of any investigational drug within 1 month of screening. The eligibility criteria are listed in detail under inclusion and exclusion criteria.",
    "The sample is a phase 2 clinical trial for patients with esophageal cancer that is unlikely to respond to existing therapy and for which no curative therapy exists. The trial is testing the effectiveness of two drugs, antineoplaston a10 and antineoplaston as2-1. Patients must meet certain eligibility criteria, including having measurable disease by MRI or CT scan, being at least 18 years old, having a Karnofsky performance status of 60-100%, and having a life expectancy of at least 2 months. Patients must also meet certain hematopoietic, hepatic, renal, cardiovascular, and pulmonary criteria, and cannot have certain medical or psychiatric illnesses or active infections. Prior concurrent therapy is also taken into consideration.",
    "The sample is a phase 2 clinical trial for the treatment of non-first episode schizophrenia. The trial includes patients who are clinically stable for at least 3 months prior to the study start and are receiving stable treatment with one of the following SGA: aripiprazole, olanzapine, quetiapine, risperidone, or ziprasidone. The trial aims to test the efficacy of the drug MK-8435 (Org 25935) at different doses (4-8 mg and 12-16 mg) compared to a placebo. The eligibility criteria include meeting Diagnostic and Statistical Manual (Version IV) criteria for non-first episode schizophrenia, having a score \u22654 on 3 or more of the PANSS negative subscale items, and having an overall PANSS negative subscale score > 20. The exclusion criteria include having an overall PANSS positive subscale score \u226520, having a score \u22655 on 2 or more of the PANSS positive subscale items, having a score \u22659 on the modified InterSePT Scale for Suicidal Thinking, and having a concurrent diagnosis of substance dependence other than nicotine or caffeine dependence in the past 6 months prior to study start, among others.",
    "The sample is a phase 2 clinical trial for the treatment of rheumatoid arthritis. The trial involves testing two drugs, mk0812 and a placebo, over a period of 12 weeks. The eligibility criteria for the trial include having a diagnosis of RA for at least 6 months, having a minimum level of disease activity, and being in good general health. Patients who are mentally or legally incapacitated, have a history of certain diseases, or are pregnant or breastfeeding are excluded from the trial. The diseases and their corresponding ICD-10 codes are also listed in the sample.",
    "The sample is a phase 2 clinical trial for patients with persistent or intermittent abdominal pain due to underlying intra-abdominal pathology. The trial involves the use of the drugs namisol and diazepam/placebo and requires patients to be at least 18 years old, undergoing elective, open abdominal surgery with planned use of an epidural catheter, and scoring I to III in the American Society of Anesthesiologists physical status classification system. Patients must also be willing and able to comply with the trial procedures and meet certain eligibility criteria, while also not meeting any of the exclusion criteria. The trial excludes patients who have used cannabinoids, have major psychiatric illness, or have sensitivity to THC or diazepam, among other criteria. Female patients who intend to conceive a child, are pregnant or breastfeeding, or do not use acceptable birth control measures are also excluded.",
    "The sample is a clinical trial for small cell lung cancer in phase 2/phase 3. The trial compares the effectiveness of carboplatin plus irinotecan versus carboplatin plus etoposide. The eligibility criteria for the trial include having cytological or histological proven SCLC Stage I or II at first diagnosis, no prior chemotherapy, measurable tumor disease, and a Karnofsky performance score of 70. The exclusion criteria include having a second malignancy (except basal cell carcinoma or CA in situ Cervix uteri), NYHA III, chronic diarrhea, or obstructive bowel syndrome.",
    "The sample is a clinical trial for the treatment of benign prostatic hyperplasia. The trial is in phase 1/phase 2 and involves the use of two drugs, prx302 and placebo. The eligibility criteria for the trial include having lower urinary tract symptoms attributable to BPH for at least 6 months, having an IPSS score of 12 or higher, having a prostate volume of 30-100 mL as determined by TRUS, having a maximum urine flow of 4-15 mL/sec, and being refractory, intolerant, or refusing the use of alpha-blockers and/or 5 alpha-reductase inhibitors. The trial also requires participants to be unwilling or unable to undergo conventional surgical or available minimally invasive treatments and to have blood PSA values less than 10 ng/mL. The exclusion criteria include inability to void at least 125 mL of urine, PVR volume greater than 200 mL, presence of or history of certain conditions that could interfere with study results or endanger the subject, and use of certain prescribed medications that could interfere with study results.",
    "The sample is a phase 2 clinical trial for asthma. The trial includes subjects between the ages of 4 to 11 years old who have been diagnosed with asthma for at least 6 months prior to the study. The trial involves the use of two drugs, levalbuterol hfa mdi followed by racemic albuterol hfa mdi and racemic albuterol followed by levalbuterol hfa mdi. The eligibility criteria include being in good health with the exception of their reversible airways disease, having a chest X-ray taken within 12 months prior to randomization, and having a parent or legal guardian who can complete diary cards and medical event calendars reliably on a daily basis. The exclusion criteria include being pregnant or lactating, having participated in an investigational drug study within 30 days prior to study start, and having a history of hospitalization for asthma within 4 weeks prior to study start.",
    "The sample is a phase 2 clinical trial for patients with high-risk hematological malignancies, including leukemia, myelodysplastic syndrome, and lymphoma. The trial involves the use of mycophenolate mofetil, thymoglobulin, and sirolimus as drugs. The eligibility criteria include being between 18-75 years old, having a HLA-identical sibling or matched unrelated donor, and meeting certain medical criteria such as having a bilirubin level of less than or equal to 1.5 mg/dl. The exclusion criteria include prior treatment with certain medications and conditions such as HIV seropositivity and uncontrolled infection.",
    "The sample is a phase 2 clinical trial for non-squamous cell non-small cell lung cancer patients with stage IIIA (N2) disease. The trial involves the use of four drugs - gemcitabine, cisplatin, bevacizumab, and etoposide. The eligibility criteria include having measurable disease, no prior treatment for lung cancer, age greater than or equal to 18 years, and adequate pulmonary and cardiovascular function. The trial also requires patients to have a life expectancy of greater than 3 months and an Eastern Cooperative Oncology Group (ECOG) performance status of 0-1. The exclusion criteria include having squamous cell cancer or mixed tumors with small cell elements, a history of hemoptysis, metastatic disease, and serious illness or medical condition. Patients must not be on therapeutic anticoagulation or chronic daily treatment with aspirin 325mg/day within 10 days prior to day 1 on study. The trial also requires patients to have a negative pregnancy test and both men and women must be willing to consent to using effective contraception while on treatment and for at least 3 months thereafter.",
    "The sample is a phase 2 clinical trial for patients with metastatic breast cancer or advanced ovarian cancer. The trial involves the use of drugs such as bevacizumab, fludarabine, melphalan, and thymoglobulin. The eligibility criteria include being between the ages of 18 and 65, having a Zubrod performance status of 1 or less, and having an HLA-matched related or unrelated donor willing to donate peripheral blood stem cells or bone marrow and/or lymphocytes. Patients must also have achieved a tumor response by pre-transplant therapy and meet certain organ function requirements. Exclusion criteria include prior history of allogeneic stem cell transplantation, severely limited life expectancy, and presence of certain infections or diseases.",
    "The sample is a phase 2 clinical trial for patients with coronary artery disease who are scheduled for non-urgent elective PCI. The trial involves the use of drugs such as reg1 and unfractionated heparin. The eligibility criteria include being able to give informed consent, having negative pregnancy test or documented surgical sterilization or menopause, and not having certain cardiac parameters. Exclusion criteria include having a weight over 120 kg, recent acute coronary syndrome with elevated cardiac markers or ST segment depression at rest, evidence of clinical instability, and contraindication to anticoagulation or increased risk of bleeding. Other exclusion criteria include use of prohibited medications or investigational drugs prior to the study, clinically significant abnormal laboratory findings, planned use of femoral sheath greater than a certain size, known allergy or intolerance to drugs mandated by the study, use of devices other than angioplasty balloons and coronary stents, a history of licit drug abuse or illicit drug use or current evidence of such abuse, lactation, currently enrolled in this or another clinical trial (with some exceptions), and participation in an investigational drug or device trial in the past 30 days.",
    "The sample is a phase 2 clinical trial for liver cancer patients who have confirmed hepatocellular carcinoma (HCC) that is localized, unresectable, or metastatic. The trial involves the use of two drugs, everolimus and sorafenib tosylate. The eligibility criteria include having a WHO performance status of 0-1, certain blood counts and liver function tests within normal limits, and no history of certain medical conditions or treatments. Patients must also be able to take oral medications and complete a baseline quality of life questionnaire. Prior systemic anticancer treatment is not allowed, but certain liver-directed therapies and surgeries are allowed if completed within the past 4 weeks. No concurrent experimental drugs or anticancer therapy or treatment in another clinical trial within the past 30 days is allowed.",
    "The sample is a phase 2 trial for small cell lung cancer. The trial includes patients who are at least 18 years old and have a probable life expectancy of at least 3 months. The patients must have adequate bone marrow reserve and adequate kidney and liver function. They must also have measurable disease according to World Health Organization criteria, as determined by diagnostic tests. The trial involves the use of two drugs, topotecan and carboplatin. The eligibility criteria include adequate contraception methods, absence of active infection, no prior chemotherapy for SCLC or any chemotherapy within 5 years of the diagnosis of SCLC, and performance status ECOG 0-1. The exclusion criteria include concurrent or planned chemotherapy, immunotherapy, radiotherapy, or investigational therapy for the treatment of SCLC, concurrent severe medical problems other than the diagnosis of SCLC, and ongoing tumor or previous tumor other than lung cancer within the last 5 years.",
    "The sample is a clinical trial for a contraceptive patch that is in phase 1/phase 2. The trial is for women aged 18-44 who have good general health, an intact uterus with at least one ovary, and regular menstrual cycles. The trial aims to test the effectiveness of the patch in preventing pregnancy. The trial includes a list of diseases and their corresponding icd-10 codes, as well as a list of drugs used in the trial. The eligibility criteria for the trial include having a Pap test within the last 12 months, having a cervical mucus score of >7, and being heterosexually abstinent or using male or female condoms for the entire duration of the study. The exclusion criteria include known hypersensitivity or contraindication to progestins, known or suspected pregnancy, and prior hysterectomy or bilateral oophorectomy. Women with a BMI \u226540 kg/m2 are also excluded from the trial.",
    "The sample is a phase 2 clinical trial for patients with metastatic pancreatic adenocarcinoma. The trial includes patients who have received adjuvant chemotherapy or radiotherapy at least 6 months prior to randomization, and have undergone palliative radiotherapy at least 1 month prior to randomization. Patients must have a confirmed diagnosis of metastatic tissue (not primary tumor) by a central pathology laboratory. The trial also requires patients to have a CT scan within 30 days prior to randomization, a performance status (ECOG) of 0 or 1, and an estimated life expectancy of at least 12 weeks. Patients must be at least 18 years old and have adequate hematological and biological function. The trial has a list of exclusion criteria, including prior palliative chemotherapy for pancreatic cancer, symptomatic brain metastases, and participation in other investigational drug clinical studies within 30 days prior to randomization. Females who are pregnant or breastfeeding are also excluded from the trial. The trial requires written consent on an Institutional Review Board/Institutional Ethics Committee-approved Informed Consent Form prior to any study-specific evaluation.",
    "The sample is a phase 2 clinical trial for pancreatic cancer. The eligibility criteria include having histologically confirmed adenocarcinoma of the pancreas that is either newly diagnosed or previously treated metastatic disease, or unresectable disease. Patients must be over 18 years old, have an ECOG performance status of 0-1, and a life expectancy of more than 3 months. They must also meet certain hematopoietic, hepatic, renal, and cardiovascular requirements, and cannot have any serious systemic disease or recent traumatic injury. Patients cannot be pregnant or nursing, and must use effective contraception if fertile. There are no specified prior concurrent therapies allowed, and certain time periods must have passed since prior major surgery or open biopsy, fine needle aspirations or core biopsies, and adjuvant therapy. No prior systemic therapy for metastatic disease is allowed. The drugs being tested are capecitabine and gemcitabine hydrochloride.",
    "The sample is a phase 2 clinical trial for the treatment of nonalcoholic steatohepatitis. The trial involves the use of two drugs, cystadane and an identical placebo. The eligibility criteria for the trial include being an adult between the ages of 18 and 70 with abnormal aminotransferase levels, histologic evidence of steatohepatitis on liver biopsy, absence of sustained alcohol ingestion, and compensated liver disease. Other criteria include normal thyroid-stimulating hormone levels, appropriate exclusion of other liver diseases, and adequate contraception for sexually active patients. Exclusion criteria include previous treatment with certain drugs, evidence of decompensated liver disease, and any pre-existing medical conditions that could interfere with the patient's participation in the trial.",
    "The sample is a phase 2 clinical trial for individuals with type 1 diabetes mellitus. The trial is testing the effectiveness of several insulin drugs, including insulin lispro, recombinant human hyaluronidase ph20, insulin aspart, and insulin glulisine. The trial has specific eligibility criteria, including being aged 18 or older, having a BMI between 18.0 and 40.0 kg/m^2, and having a HbA1C level between 6.7% and 8.2%. Participants must also be willing to use insulin glargine as basal insulin for the duration of the study and avoid using an insulin infusion pump or unblinded continuous glucose monitoring. The trial has exclusion criteria, including allergies to any of the study drugs, use of certain medications that could interfere with the study results, and recurrent severe hypoglycemia or hypoglycemic unawareness.",
    "The sample is a phase 2 clinical trial for patients with stage IV invasive breast cancer. The trial is testing the effectiveness of a combination of drugs including igf-1r inhibitor osi-906, erlotinib hydrochloride, goserelin, and letrozole. The eligibility criteria for the trial include having no locally recurrent resectable disease, no symptomatic brain metastases, and being estrogen receptor and/or progesterone receptor positive. Patients must also have an ECOG performance status of 0-1, a life expectancy of at least 6 months, and meet certain laboratory values. Patients must not have any other invasive cancer within the past 5 years, no malabsorption syndrome significantly affecting gastrointestinal function, and no concurrent uncontrolled illness. Prior therapy must be recovered from and patients must not have had more than 4 prior chemotherapy treatments in the metastatic setting. Patients must not be receiving ongoing anti-hyperglycemic therapies and must not have concurrent CYP3A4 or CYP1A2 modifiers. No other concurrent anticancer therapy is allowed except for concurrent radiotherapy to painful bone metastases or areas of impeding bone fracture initiated before study therapy.",
    "The sample is a phase 2 clinical trial for patients with systemic scleroderma and pulmonary hypertension. The trial involves the use of bosentan and placebo drugs. The eligibility criteria include patients over 18 years old with NYHA functional Class I/II symptoms, who are willing to participate in the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma (PHAROS) long term study. The patients must also meet certain criteria for right heart catheterization and exercise echocardiogram study. The exclusion criteria include established resting pulmonary hypertension, congestive heart failure, diastolic dysfunction, pregnancy, inability to adequately walk/exercise, and severe liver disease.",
    "The sample is a record of a clinical trial in phase 2 for the treatment of major depressive disorder using the drug glyx-13. The trial includes patients who have been diagnosed with major depressive disorder and have had a current episode lasting more than 8 weeks with a Hamilton Depression score of greater than or equal to 21. Patients who have experienced less than a 25% reduction in depression during the current episode assessed by ATRQ are also included. However, patients with other psychiatric disorders, experiencing hallucinations, delusions, or other psychotic symptomatology, or who have undergone ECT during the current episode are excluded from the trial. The icd-10 codes associated with major depressive disorder are also included in the record.",
    "The sample is a clinical trial for patients with metastatic breast cancer in phase 1/phase 2. The trial involves the use of dasatinib, trastuzumab, and paclitaxel drugs. The eligibility criteria include female patients with confirmed breast cancer with documented metastasis and HER2 overexpression, measurable or non-measurable disease, and a Performance Status (ECOG) of 0 or 1. Patients must have recovered from any previous therapies and have adequate organ function. Exclusion criteria include patients who are pregnant or breastfeeding, have uncontrolled central nervous system metastases, have had malignancy requiring radiotherapy or systemic treatment within the past 5 years, have concurrent medical conditions that may increase the risk of toxicity, and have a history of significant bleeding disorder unrelated to cancer. Patients must also be able to give written informed consent prior to study participation.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on treating patients with various diseases including pulmonary hypertension, lung disease, sickle cell disease, cardiac transplant, and lung transplant. The diseases are identified by their corresponding ICD-10 codes. The trial involves the use of inhaled nitric oxide as a treatment. The eligibility criteria for the trial include patients with pulmonary arterial hypertension or chronic lung disease with severe impairment of gas exchange unresponsive to conventional medical management. Patients receiving prostacyclin infusion treatment must have started it at least one month prior to starting INO therapy. The trial also requires the establishment of a clinical investigator and a drug shipment site in the local area. Exclusion criteria include patients who are unable to manage safe administration of home nitric oxide therapy and maintain appropriate drug accountability and storage, as well as pregnant or nursing women.",
    "The sample is a phase 2 trial for the treatment of allergic rhinitis. The trial includes patients between the ages of 18 and 65 with a history of seasonal allergic rhinitis and a positive skin prick test. The trial excludes patients with a history or presence of perennial allergic rhinitis, recent respiratory tract infections, significant pulmonary disease other than allergic rhinitis or mild asthma controlled by beta-2-agonists alone, and recent immunizations or vaccinations. The trial will test the effectiveness of two drugs, sparc1203 and placebo.",
    "The sample is a clinical trial with a combination of phase 1 and phase 2. The trial is focused on treating myelodysplastic syndromes, acute myeloid leukemia, and leukemia. The trial uses a combination of drugs including oxaliplatin, fludarabine, and cytarabine. The eligibility criteria for the trial includes having a confirmed relapsed or refractory AML or high-risk myelodysplastic syndrome, a performance status of 0-2, and meeting certain medical requirements such as serum creatinine levels and bilirubin levels. The exclusion criteria includes having untreated or uncontrolled life-threatening infections, intolerance to the drugs being used, and other medical conditions that may interfere with the patient's ability to participate in the study.",
    "The sample is a phase 2 clinical trial for patients with metastatic or locally advanced breast cancer that is estrogen receptor and/or progesterone receptor positive. The trial is testing the effectiveness of the drugs everolimus and fulvestrant. The eligibility criteria include being postmenopausal, having failed aromatase inhibitor therapy within the previous 6 months, and having measurable or evaluable disease. Patients must not have received chemotherapy, radiation therapy, or had surgery within 4 weeks prior to enrollment. The trial also has exclusion criteria, such as premenopausal status, other coexisting malignancies, and uncontrolled intercurrent illness. Patients must have adequate organ function and a WHO performance status of 0, 1, or 2. The trial requires patients to provide a tumor paraffin block if available and to sign a written informed consent for participation.",
    "The sample is a phase 2 clinical trial for patients with chronic graft-versus-host disease. The trial is testing the effectiveness of the drug bortezomib. The eligibility criteria for the trial include being over 18 years old, having a diagnosis of steroid-refractory cGVHD, and not having received previous treatment with bortezomib for cGVHD. Patients must also have a Total Bilirubin level of \u2264 1.5x ULN, an ECOG PS<3, and a life expectancy of more than 3 months. Female patients must be post-menopausal or surgically sterilized or willing to use an acceptable method of birth control, while male patients must agree to use an acceptable method of contraception. Exclusion criteria include having a platelet count of <50x 10^9/L, an absolute neutrophil count of <1.0 x 10^9/L, or a calculated or measured creatinine clearance of <30 mL/minute. Patients with Total Bilirubin > 1.5x ULN or \u2265 Grade 2 peripheral neuropathy are also excluded. Additionally, patients with serious medical or psychiatric illness likely to interfere with participation in the study, primary malignancy not in remission, or diagnosed or treated for another malignancy within 3 years of enrollment are excluded. Patients who have received radiation therapy within 3 weeks before randomization are also excluded.",
    "This sample is for a phase 2 clinical trial for Huntington's disease and chorea. The trial includes patients with a UHDRS maximal chorea score of over 10 and a DNA test showing polyQ >36. Patients with concomitant Huntington's medication are allowed, but the total daily dose and dosing regimen must be stable for at least one month prior to randomization. Female patients without childbearing potential must use double-barrier local contraception. Patients with marked cognitive impairment, presence of psychosis and/or confusional states, and a history or presence of renal impairment and/or liver disease are excluded. Other protocol-defined inclusion/exclusion criteria may apply.",
    "The sample is a phase 2 clinical trial for patients with prostate cancer and fatigue. The trial is testing the effectiveness of methylphenidate hydrochloride compared to a placebo. The eligibility criteria include being over 18 years old, having confirmed prostate cancer, and experiencing measurable fatigue. Exclusion criteria include having a current or previous malignancy, anemia, recent myocardial infarction, and other serious medical conditions. Patients must also be able to read and write in English and give written informed consent.",
    "The sample is a record from a clinical trial table that includes information about the phase of the trial (phase 2/phase 3), the disease being studied (carcinoma, non-small-cell lung), the ICD-10 codes associated with the disease, the drug being tested (1st line chemotherapy), and the eligibility criteria for participants. The eligibility criteria include requirements such as a confirmed diagnosis of non-small cell carcinoma of the lung, MUC1 antigen expression on the tumor, and adequate hematological, hepatic, and renal function. The exclusion criteria include factors such as concomitant brain metastases, previous history of other malignancies, and serious concomitant medical disorders.",
    "The sample is a phase 2 clinical trial for patients with atrial fibrillation. The trial involves the use of drugs such as azd1305 and placebo. The eligibility criteria for the trial include having documented atrial fibrillation but in stable sinus rhythm for at least 2 hours and a maximum of 28 days, as well as having sinus rhythm at randomization. Exclusion criteria include having a haemodynamically unstable condition, personal or family history of certain ventricular tachycardias or syndromes, sinus bradycardia, prolonged QTc interval, abnormal potassium levels, prolonged QRS duration, and use of certain medications.",
    "The sample is a phase 2 clinical trial for patients with mild-to-moderate asthma. The trial involves testing the effectiveness of various drugs, including formoterol fumarate and a placebo. Patients must have been on a stable dose of inhaled corticosteroids for at least 30 days prior to the trial and must meet certain spirometry requirements. The trial has specific inclusion and exclusion criteria, such as not having any clinically significant respiratory conditions other than mild to moderate asthma and not having had a severe asthma exacerbation requiring hospitalization in the previous 12 months. Patients must also be able to withhold use of inhaled short-acting beta-agonist for at least 6 hours prior to the visit.",
    "The sample is a phase 2 clinical trial for breast cancer. The eligibility criteria include being at an increased risk for breast cancer, having no prior or suspected invasive breast cancer or ductal carcinoma in situ, and having normal gynecologic and breast examinations. The trial is for female patients aged 35 and over who are premenopausal and ovulating or postmenopausal. The drug being tested is tamoxifen citrate, and patients must not have taken it or other selective estrogen-receptor modulators before. Other medical conditions and medications are also taken into consideration for eligibility.",
    "The sample is a phase 2 clinical trial for the treatment of Friedreich's ataxia. The trial includes patients who have been diagnosed with the disease and have a specific genetic test result. The patients must also meet certain criteria, such as having a specific score on a test and being over 18 years old. The trial involves the use of two drugs, lu aa24493 and placebo. The sample also includes a list of exclusion criteria, such as having certain illnesses or taking certain medications. Patients who meet the inclusion criteria and do not meet any of the exclusion criteria may be eligible to participate in the trial.",
    "The sample is a phase 2 clinical trial for the treatment of Waldenstr\u00f6m's macroglobulinemia, a type of cancer. The trial involves the drug perifosine and has eligibility criteria that include having received prior therapy for the disease, measurable disease levels, and certain laboratory values within normal ranges. Exclusion criteria include uncontrolled infection, other active malignancies, and pregnancy or unwillingness to use contraception. The trial also has specific requirements for the patient's age, performance status, and life expectancy.",
    "The sample is a phase 2 clinical trial for patients with non-small cell lung cancer. The trial is testing the effectiveness of the drug dasatinib. The eligibility criteria include having a documented diagnosis of NSCLC, having received prior treatment for the disease, and having adequate organ function. Exclusion criteria include having a previous or concomitant malignancy, having symptomatic pleural effusions, and having cardiac symptoms. Patients must also be able to take oral medication and agree to use adequate contraception during treatment. The trial requires a fresh tissue biopsy for genomics analysis prior to initiating dasatinib.",
    "The sample is a record of a clinical trial for a drug called \"velusetrag\" in phase 2, aimed at treating gastroparesis. The trial involves patients with symptoms of gastroparesis for at least 3 months prior to screening, with a BMI between 18 and 35 kg/m2, and a Gastroparesis Cardinal Symptom Index (GCSI-2W) composite score between 2 and 4. The trial also requires patients to have delayed gastric emptying, as determined by a [13C]-octanoate breath test, and to have ruled out upper gastrointestinal obstruction by endoscopy or other imaging. The trial has exclusion criteria, including a history of gastric surgery, recurrent vomiting, and uncontrolled thyroid dysfunction. The trial involves administering different doses of velusetrag and a placebo to the patients and monitoring their response.",
    "The sample is a phase 2 trial for patients with anemia and kidney disease. The trial is testing the drug akb-6548. The eligibility criteria includes being between 18 to 79 years old, having chronic kidney disease stage 3 or 4, having a hemoglobin level below 10.5 g/dl, and having a TSAT level above 20% with normocytic red blood cell morphology. Exclusion criteria includes having a BMI over 40, having received a red blood cell transfusion within the past 12 weeks, having received androgen therapy within the past 21 days, having received any approved or experimental erythropoiesis stimulating agent within the past 10 weeks, having met the criteria for ESA resistance within the past 4 months, having received individual doses of intravenous iron of 250 mg or larger within the past 21 days, having AST or ALT levels above 1.8x ULN, having alkaline phosphatase levels above 2x ULN, having total bilirubin levels above 1.5x ULN, having uncontrolled hypertension, having New York Heart Association Class III or IV congestive heart failure, or having had a myocardial infarction, acute coronary syndrome, or stroke within the past 6 months prior to dosing.",
    "The sample is a record of a clinical trial with a phase 2/phase 3 designation. The trial is focused on the disease of obesity, with a list of associated ICD-10 codes. The trial involves the use of two drugs, cp-945,598 and sibutramine. The eligibility criteria for the trial include a BMI of 30-40 kg/m2 for subjects without additional co-morbidities, and a BMI of 27-40 kg/m2 for subjects with co-morbidities such as essential hypertension and/or dyslipidemia. The exclusion criteria include subjects with high blood pressure, type 2 diabetes, a history of eating disorders, and those taking appetite or weight modifying drugs.",
    "This sample is for a phase 2 clinical trial for the treatment of hyponatremia using the drug tolvaptan. The eligibility criteria for the trial include having non-artifactual hyponatremia in euvolemic or hypervolemic states, being 18 years or older, and able to give written informed consent. Exclusion criteria include having hyponatremia in hypovolemic states, acute and transient hyponatremia associated with head trauma or post-operative state, and history of sustained ventricular tachycardia or ventricular fibrillation within the last 30 days. Other exclusion criteria include uncontrolled diabetes mellitus, severe pulmonary artery hypertension, and hyponatremia due to lab artifacts or medications that cannot be safely withdrawn.",
    "The sample is a clinical trial with a combination of phase 1 and phase 2. The trial is focused on HIV infections and the participants must have taken at least two combination anti-HIV treatments containing three or more drugs for a total of at least 24 months. The trial requires the participants to have failed two previous combination treatments of three or more drugs and have a viral load of more than 5000 copies/ml on stable antiretroviral regimen within 60 days prior to study entry. The participants must be willing to stay on the current failing anti-HIV treatment until starting study treatment and use acceptable methods of contraception. The trial also requires access to optimized background (OB) regimen drugs and the ability to bring OB regimen drugs to the screening visit. The exclusion criteria include prior use of DAPD or ENF, drug or alcohol use that would interfere with the study, history of any illness that would interfere with study participation, and certain mutations in HIV-1 reverse transcriptase. Other exclusion criteria include unexplained fever within 7 days prior to study entry, cancer that requires chemotherapy, and measurable loss of vision due to lens opacity. The trial also excludes participants with diabetes mellitus, except for gestational diabetes.",
    "The sample is a phase 2 clinical trial for breast cancer patients who have primary resistance to anthracyclines or taxane or both. The trial includes patients with locally advanced breast cancer who are not eligible for surgery and have measurable disease in their breast/nodal regions or at a distant organ site(s). Patients must have recovered from acute toxic effects of any prior therapy and have a Zubrod performance status less than or equal to 2. The trial also includes eligibility criteria related to bone marrow function, renal function, liver function, and hormonal therapies. Patients with brain metastases whose disease remained stable for more than 3 months after completing therapy to the brain are eligible. The trial has exclusion criteria related to psychiatric or social disorders, clinical contraindications of continued anthracycline or taxane therapy, and operable primary breast cancer. The trial allows concomitant bisphosphonate therapy for bone metastasis and continuation of Herceptin if it has previously been started.",
    "The sample is a phase 2 clinical trial for the treatment of irritable bowel syndrome using the drug rifaximin. The trial includes subjects who are 18 years or older and have been confirmed to have irritable bowel syndrome according to the Rome II Criteria. The trial also requires a lower endoscopic examination that demonstrates normal colonic anatomy. The inclusion criteria also specifies that the subject should not have exclusively constipation-predominant IBS or alternating IBS with constipation-associated symptoms. Additionally, the subject should not have had adequate control of their DIBS and their symptom of bloating the week preceding the screening visit or at the time of randomization. The exclusion criteria includes a positive stool culture for O & P (ovum and parasite) and/or Clostridium difficile, and failure to record 2 negative weekly global assessments during the past 10 days prior to randomization.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on prostate cancer and includes a list of ICD-10 codes associated with the disease. The trial involves the use of the drug degarelix, with multiple instances of the drug listed. The eligibility criteria for the trial includes males aged 18 or over with histologically proven adenocarcinoma of the prostate, who require endocrine treatment (excluding neoadjuvant hormonal therapy). Additionally, participants must have completed a previous study (FE200486 CS07) and not met any withdrawal criteria at Visit 9 (day 28) of that study.",
    "The sample is a phase 2 clinical trial for participants with type 2 diabetes and hypertension. The trial involves testing the effectiveness of different doses of ertugliflozin and hctz, as well as a placebo, on participants who are medically stable and taking up to two oral diabetes drugs and two medicines for blood pressure control. The trial has inclusion criteria such as having type 2 diabetes and hypertension, and exclusion criteria such as having type 1 diabetes, heart attack, stroke, uncontrolled blood pressure, and significant kidney disease. The diseases and icd-10 codes associated with the trial are diabetes mellitus type 2 and hypertension.",
    "The sample is a record of a clinical trial in phase 2, which is focused on treating schizophrenia and insomnia related to schizophrenia using the drug sodium oxybate. The trial has eligibility criteria for patients aged 18-45 with a DSM-IV diagnosis of schizophrenia and insomnia related to schizophrenia, confirmed by a structured interview. The trial also has exclusion criteria, including lack of capacity to give informed consent, unstable medical illness, diagnosis of restless leg syndrome, a seizure disorder, uncontrolled hypertension, unstable cardiac illness, or obstructive sleep apnea, pregnancy or lack of adequate birth control, history of substance dependence disorder, current treatment with valproic acid, succinic semialdehyde dehydrogenase deficiency (SSADH), and persistent need for treatment with benzodiazepines, barbiturates, opiates or other sedative hypnotics. The diseases being treated are schizophrenia and insomnia related to schizophrenia, and the icd-10 codes associated with these diseases are listed.",
    "The sample is a phase 2 clinical trial for patients with stable coronary artery disease. The trial involves the use of ticagrelor tablets, clopidogrel (over encapsulated) capsule, and aspirin tablets. The eligibility criteria include having documented stable coronary artery disease, being a female of childbearing potential with a negative pregnancy test and willing to use contraception, and not having a history of acute coronary syndromes within 12 months or needing revascularization. The exclusion criteria include having liver or kidney disease, increased bleeding risk, and a history of intolerance or allergy to aspirin or clopidogrel.",
    "The sample is a record from a clinical trial table that includes information about the trial's phase, diseases being studied, associated ICD-10 codes, drugs being tested, and eligibility criteria for participants. In this particular sample, the trial is in phase 2 and is studying the effects of megestrol acetate on pediatric patients with anorexia and weight changes caused by malignancies. The inclusion criteria for participants include a \u22655% weight loss from diagnosis of primary malignancy, negative pregnancy test for women of childbearing potential, and currently receiving or scheduled to receive cancer therapy. Exclusion criteria include receiving tube feedings or parenteral nutrition, evidence of ascites, and current or planned treatment with certain medications.",
    "This is a sample of a clinical trial for phase 2, focused on non-small cell lung cancer. The trial is testing the effectiveness of the drug pazopanib (gw786034) on patients who have failed no more than two prior chemotherapy regimens for Stage IIIB or IV non-small cell lung cancer, including a platinum-containing regimen. The trial has specific inclusion and exclusion criteria, including age, performance status, organ function, and medical history. The trial is looking for patients who are eligible to enroll and who have measurable disease according to RECIST. The sample also includes a list of diseases, icd-10 codes, and eligibility criteria.",
    "The sample is a phase 2 clinical trial for patients with multiple myeloma. The trial includes patients who have received a prior autologous stem cell transplantation with melphalan conditioning for multiple myeloma with subsequent disease progression and repeat autologous stem cell transplantation is deemed appropriate by the treating physicians. The trial involves induction chemotherapy including 2 to 4 cycles of anti-myeloma therapy including bortezomib, with or without immune modulating agents and/or corticosteroids. Patients must have \u2265 2x106/kg CD34+ autologous stem cells available for transplantation and must meet certain eligibility criteria, including normal bone marrow and organ function, ECOG performance status \u2264 2 or Karnofsky performance status \u2265 60%, and a life expectancy of greater than 6 months. Patients must not be refractory to induction therapy, have had disease progression requiring active treatment within 12 months of previous autologous stem cell transplant, have peripheral neuropathy \u2265 grade 3, be receiving renal replacement therapy, hemodialysis, or peritoneal dialysis, have another concurrent malignancy requiring treatment, be receiving any other investigational agents within 14 days prior to the first dose of study drug, have known brain metastases, have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to bortezomib, carmustine, etoposide, cytarabine, and melphalan, or other agents used in the study, have an uncontrolled intercurrent illness, or be pregnant and/or breastfeeding. Both men and women and members of all races and ethnic groups are eligible for this trial.",
    "The sample is a clinical trial for Parkinson's disease, with a combination of phase 1 and phase 2. The trial involves administering saline and carbidopa drugs to men and women with idiopathic Parkinson's disease who experience motor fluctuations associated with LD/CD dosing. The trial has specific inclusion and exclusion criteria, such as a modified Hoehn and Yahr stage of less than 5, stable levodopa/dopa decarboxylase inhibitor therapy, and no recent experimental medication use. Women must be postmenopausal, surgically sterilized, or using adequate birth control. The trial requires subjects to be age 30 or older and willing to give informed consent.",
    "The sample is a record of a clinical trial in phase 2 for Parkinson's disease. The trial includes patients who have been diagnosed with idiopathic Parkinson's disease for at least 5 years and have motor fluctuations and dyskinesia. The patients must have a stable regimen of levodopa/carbidopa for 30 days and show at least a 25% response/improvement in UPDRS part III scores after dosing with regular PD medications. The trial also requires patients to have a MMSE score of 25 or higher. Patients with atypical or secondary parkinsonism, prior use of neuroleptic agents, history of intracranial procedures for PD, active psychosis, history of drug or alcohol abuse in past 12 months, cardiac conduction system abnormality, or predisposing medical condition that causes nausea or vomiting or routine use of an anti-emetic are excluded from the trial. The trial will test the effectiveness of piclozotan and 0.9% sodium chloride (normal saline) as potential treatments for Parkinson's disease.",
    "The sample is a phase 2 clinical trial that involves patients with primary CNS lymphoma, drug/agent toxicity by tissue/organ, lymphoma, and thrombocytopenia. The trial uses a combination of drugs including rituxan, cyclophosphamide, etoposide, etoposide phosphate, carboplatin, sodium thiosulfate, neupogen, neulasta, and cytarabine. The eligibility criteria for the trial include having a confirmed diagnosis of primary CNS lymphoma, being CD20 positive, having progressive or relapsed disease after prior methotrexate-based chemotherapy, and meeting certain age, performance status, and laboratory criteria. Patients must also be available for follow-up for 1 year post-therapy and use effective contraception if fertile. Exclusion criteria include having radiographic signs of intra-cranial herniation and/or spinal block, being HIV positive, having systemic lymphoma, being pregnant or lactating, having an allergy to study agents, and being hepatitis B or hepatitis C positive.",
    "The sample is a phase 2 clinical trial for lupus erythematosus, both discoid and systemic. The trial includes patients with at least 2 active discoid lesions with a minimum Erythema Rating Score of \u2265 2. Patients who are taking certain medications must be receiving a stable daily dose for at least 4 weeks prior to randomization and must remain on the same dose throughout the study. The trial has exclusion criteria such as immunodeficiency, lymphoproliferative disease, poorly controlled hypertension, and exposure to excessive or chronic UV radiation.",
    "The sample is a phase 2 clinical trial for non-small cell lung cancer. The trial is for patients with inoperable stage IIIA or IIIB disease, with no direct invasion of vertebral body, no scalene, supraclavicular, or contralateral hilar node involvement, and with at least one unidimensionally measurable lesion. The trial involves the use of carboplatin, gemcitabine hydrochloride, and paclitaxel as drugs. The eligibility criteria include age 18 and over, ECOG 0-1 performance status, and certain hematopoietic, hepatic, renal, and pulmonary requirements. Patients must not be pregnant or nursing, and fertile patients must use effective contraception. The trial excludes patients with prior chemotherapy for NSCLC, concurrent hormonal therapy except for certain conditions, and prior radiotherapy for NSCLC.",
    "The sample is a phase 2 clinical trial for asthma. The eligibility criteria include having a documented physician diagnosis of persistent asthma for at least 6 months, being between 4-11 years old, having the ability to self-perform spirometry and peak expiratory flow rate measurements, and demonstrating reversible bronchoconstriction. The trial involves the use of albuterol spiromax, proair hfa, and placebo. There are also exclusion criteria, such as a history of severe milk protein allergy or a respiratory infection that has not resolved within 4 weeks prior to the screening visit.",
    "This sample is a record of a clinical trial with a phase 2 designation. The trial is focused on treating leukemia, specifically Philadelphia chromosome positive CML, in patients who are between the ages of 21 and 65. The trial includes a list of drugs, including busulfan, cyclophosphamide, g-csf, and gm-csf. The eligibility criteria for the trial include a Zubrod PS score of less than 3, creatinine levels below 1.8 mg/dl, serum bilirubin levels at or below 1.5 mg/dl, and SGPT levels below three times the normal value. Patients with an HLA identical sibling are eligible if they refuse allogeneic transplantation, or if they are ineligible for allogeneic transplantation due to age. The exclusion criteria include uncontrolled life-threatening infections or comorbid conditions that could impair tolerance to the regimen, HIV positivity, pregnancy or lactation, CML in blastic phase that has not responded to therapy given prior to enrollment in this study, hepatitis B or C virus infection, and CML in first molecular remission.",
    "The sample is a phase 2 clinical trial for non-small cell lung cancer. The trial includes patients who are 18 years or older and have advanced stage IIIb or IV lung cancer with measurable disease and an ECOG performance status of 0-1. The trial excludes patients who have received prior chemotherapy or treatment with another systemic anti-cancer agent, radiotherapy within 4 weeks prior to the first dose of study treatment, CNS metastases, or other malignancies in the past 5 years, except for adequately treated cancer in situ of the cervix, basal or squamous cell skin cancer. The trial will test the efficacy of erlotinib, bevacizumab, and standard platinum-based chemotherapy.",
    "The sample is a phase 2 clinical trial for respiratory syncytial virus infections. The trial is testing the effectiveness of two drugs, aln-rsv01 and normal saline, on single or bilateral lung transplant recipients who have confirmed RSV infection and are at least 90 days post-transplant and rejection-free for at least 30 days. The trial has inclusion and exclusion criteria, with the exclusion criteria including known respiratory co-infections, certain grades of bronchiolitis obliterans syndrome, recent use of certain medications, and active treatment for acute graft rejection.",
    "The sample is a record of a clinical trial for diabetic macular edema. The trial is in phase 2/phase 3 and the drug being tested is fluocinolone acetonide. The eligibility criteria for the trial include having DME in the study eye, edema involving fixation and being at least 1 disc area in size, visual acuity of \u226520 and \u226468 letters by ETDRS in the study eye, and having received at least one macular laser treatment > 12 weeks prior to entry into the study. The exclusion criteria include being pregnant or lactating, having an allergy to fluocinolone acetonide or any component of the delivery system, having any disease or condition that would preclude study treatment or follow up, and having a history of uncontrolled IOP within the last 12 months.",
    "The sample is a clinical trial for non-small cell lung cancer and brain metastases, in phase 1/phase 2. The trial is testing the drug icotinib and requires patients to have a histological or cytological confirmation of NSCLC, a diagnosis of brain metastases on a Gadolinium-enhanced MRI with more than 3 sites of intracranial metastases or the longest diameter of the intracranial lesion is more than 3cm, and a positive EGFR mutation. Patients who have previously used EGFR-TKI or antibody to EGFR, such as gefitinib, erlotinib, herceptin, or erbitux, or have CSF or MRI findings consistent with metastases of spinal cord, meninges, or meningeal are excluded from the trial. The table also includes a list of icd-10 codes for the diseases and eligibility criteria for the trial.",
    "The sample is a phase 2 clinical trial for B-cell non-Hodgkin's lymphoma. The trial includes the use of drugs such as cyclophosphamide, etoposide, rituximab, cytarabine, doxorubicin, and tositumomab. The eligibility criteria include being at least 18 years old, having no prior malignancy except for certain types of cancer, and meeting certain staging and laboratory tests. Patients with certain medical or psychiatric illnesses, those who are pregnant or lactating, and those with follicular lymphoma grade 1, 2, or 3A are not eligible for the trial.",
    "The sample is a phase 2 clinical trial for women with metastatic breast cancer who have histologically confirmed triple negative breast cancer. The trial is testing the effectiveness of the drugs rad001 and carboplatin. The eligibility criteria include having adequate bone marrow, liver, and renal function, as well as a negative pregnancy test and a signed informed consent. Patients must not have received anticancer therapies within 2 weeks of the start of the study drug and must not have any severe or uncontrolled medical conditions that could affect their participation in the study. The exclusion criteria include patients who have received prior treatment with an mTOR inhibitor, have a known hypersensitivity to RAD001 or other rapamycins, or have a history of noncompliance to medical regimens.",
    "The sample is a phase 2 clinical trial for patients with advanced clear cell renal cell carcinoma. The trial involves the drug vandetanib and has eligibility criteria that include confirmed diagnosis of clear cell renal cell carcinoma, advanced disease, measurable disease, and normal organ and marrow function. Patients must have previously received sunitinib or sorafenib or be unable to receive these agents. Exclusion criteria include prior malignancy of other histology, VHL disease, and known brain metastases. The trial is open to both men and women of all races and ethnic groups.",
    "The sample is a phase 2 clinical trial for patients with metastatic breast cancer who are ER-, PR-, and Her2neu- (Triple Negative). The trial involves the use of the drugs gemcitabine and oxaliplatin. The eligibility criteria include having measurable disease according to the RECIST criteria, having received a taxane in the adjuvant setting or as first-line treatment for metastatic breast cancer, being over 18 years old, having an ECOG Performance Score of 0, 1, or 2, and having adequate bone marrow, renal, and hepatic function. Patients must also have recovered from any prior surgery, radiotherapy, or other antineoplastic therapy and be able to provide informed consent. Exclusion criteria include having an active infection or fever, active CNS metastases, a history of prior malignancy within the past 5 years (except for certain types), known hypersensitivity to the drugs, and other medical conditions that may interfere with participation in the study.",
    "The sample is a phase 2 clinical trial for the treatment of type 1 diabetes using the drugs enalapril and losartan. The trial is looking for participants who have had type 1 diabetes for 2-20 years, with onset prior to age 45 and certain BMI and GAD/ICA requirements. Participants must also have normal or increased GFR, normal blood pressure, and normoalbuminuria. Exclusion criteria include hypertension, reduced GFR, microalbuminuria, and other kidney diseases or chronic conditions. Participants must also be compliant with taking the medication and not planning pregnancy within 2 years.",
    "The sample is a phase 2 clinical trial for patients with unresectable stage IV melanoma (skin cancer) that may have originated from an unknown primary site. The trial is testing the effectiveness of two drugs, temozolomide and thalidomide, in treating the disease. The eligibility criteria for patients include being 18 years or older, having a Zubrod performance status of 0-1, and meeting certain hematopoietic, hepatic, renal, and other health requirements. Patients must not have brain metastases within the past 42 days, and must not have had certain prior treatments. The sample also includes detailed information on the disease characteristics and patient characteristics, as well as prior concurrent therapy.",
    "The sample is a phase 2 clinical trial for breast cancer patients. The trial includes patients who are female and over 18 years old with invasive adenocarcinoma of the breast. Patients must have clinical Stage IIIA, IIIB, or IIIC disease with a primary breast tumor that is greater than or equal to 2.0 cm measured by clinical exam. The trial involves a combination of drugs including bevacizumab, doxorubicin, cyclophosphamide, capecitabine, and docetaxel. The eligibility criteria include various medical conditions such as adequate hepatic and renal function, left ventricular ejection fraction, and blood counts. Patients with certain medical conditions such as HER2-positive tumors, prior therapy with certain drugs, and certain cardiac conditions are excluded from the trial.",
    "The sample is a phase 2 clinical trial for the treatment of myelodysplastic syndrome. The trial includes patients with MDS and less than or equal to 10% blasts or International Prognostic Scoring System (IPSS) low or intermediate 1. Prior cytokines, biologic therapies, targeted therapies, or single agent chemotherapy are allowed, but no prior intensive chemotherapy or high-dose ara-C (>/= 1g/m2). Procrit, G-CSF are allowed before therapy. Patients with blasts < 5% must have an indication for therapy, such as transfusion needs, symptomatic anemia or Hb < 11g/dl, platelets < 100 x 10 9/L, or granulocytes < 10 9/L. The inclusion criteria also require patients to have a performance score of 0-2 (Eastern Cooperative Oncology Group (ECOG)), adequate liver function (bilirubin of < 2mg/dl) and renal function (creatinine < 2mg/dl), and adequate cardiac functions (New York Heart Association (NYHA) cardiac III-IV excluded). Patients must also sign an informed consent form. Nursing and pregnant females are excluded, and women of childbearing potential should practice effective methods of contraception. Patients with active and uncontrolled infections are also excluded. The drugs being tested in the trial are erythropoietin, cyclosporin a, g-csf, and prednisone.",
    "The sample is a record of a clinical trial for relapsing remitting multiple sclerosis in phase 2. The trial involves two drugs, laquinimod 0.3 and laquinimod 0.6, and has a list of inclusion and exclusion criteria for participants. The diseases are listed as 'relapsing remitting multiple sclerosis' and the icd-10 codes associated with it are also provided.",
    "The sample is a phase 2 trial for adult Hodgkin lymphoma patients who have relapsed or are refractory after at least one prior therapy. The trial includes patients with various subtypes of Hodgkin lymphoma, except for nodular lymphocyte predominant HL. The trial involves the use of three drugs: vinorelbine tartrate, pegylated liposomal doxorubicin hydrochloride, and gemcitabine hydrochloride. The eligibility criteria include having measurable disease, a certain level of heart function, and meeting certain blood count and liver function requirements. Patients must not have received prior treatment with certain drugs and must not have certain heart conditions. Women of childbearing potential must have a negative pregnancy test and agree to use birth control.",
    "The sample is a clinical trial for patients with schizophrenia, schizophreniform disorder, or schizoaffective disorder. The trial is in phase 2/phase 3 and involves the use of two drugs, ethyl-eicosapentaenoic acid (EPA) and vitamins E + C. The trial also includes a list of diseases and their corresponding ICD-10 codes. The eligibility criteria for the trial include being admitted to a psychiatric hospital/department within the previous twenty-one days before screening, being less than fifteen years since first psychotic symptoms, being between the ages of 18-40, and speaking fluently a Scandinavian language. The exclusion criteria include having a diagnosis of substance dependence, known allergy to study medication, and currently taking warfarin or having anamnestic indicators of impaired haemostasis.",
    "The sample is a phase 2 clinical trial for patients aged 10 years and above with \u03b2-thalassemia major or DBA or sideroblastic anemia on chronic transfusion therapy. The trial aims to study the efficacy of various drugs such as deferasirox and deferoxamine in treating transfusional iron overload and transfusional hemosiderosis. The patients must have given written consent to participate in the study and meet certain inclusion criteria such as having a lifetime history of at least 50 units of red cell transfusions and a left ventricular ejection fraction (LVEF) \u2265 56 %. However, patients with clinical symptoms of cardiac dysfunction or unable to undergo study assessments including MRI are excluded from the trial. Other protocol-defined inclusion/exclusion criteria may also apply.",
    "The sample is a phase 2 clinical trial for macular degeneration. The trial involves administering immune globulin intravenous [human], 10% caprylate/chromatography purified and albumin (human) 25%, united states pharmacopeia (usp) to patients with visual acuity in the range of 20/40 to 20/200 on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart. The trial has a set of inclusion and exclusion criteria that patients must meet to participate. The inclusion criteria include documented visual loss on a visual acuity chart in the 3-month period prior to the beginning of the run-in period, while the exclusion criteria include a history of anaphylaxis or severe systemic response to immunoglobulin or with a blood product, among others.",
    "The sample is a record of a clinical trial in phase 2 for the treatment of HIV infection using a drug called apricitabine. The trial has eligibility criteria for inclusion and exclusion, which includes having completed a previous protocol, having a low level of HIV RNA in the plasma, and having a certain level of CD4 cells. Pregnant or breastfeeding females are excluded from the trial, as well as those who have withdrawn from a previous protocol. The diseases and icd-10 codes associated with the trial are also listed.",
    "The sample is a phase 2 clinical trial for patients with inoperable stage III non-small cell lung cancer. The trial is testing the effectiveness of chemotherapy following concurrent chemoradiotherapy. The eligibility criteria include being 18 years or older, having no prior treatment for lung cancer, having an ECOG performance status of 0-1, and having adequate organ function. Exclusion criteria include having had prior treatment for lung cancer, having uncontrolled intercurrent illness, being pregnant or lactating, having documented or symptoms of peripheral neuropathy, and having any condition that would hamper ability to give informed consent or ability to comply with study protocol.",
    "The sample is a phase 2 clinical trial for patients with invasive breast cancer that has spread to other parts of the body. The trial is testing the effectiveness of a combination of two drugs, lapatinib and vinorelbine. The eligibility criteria include having a life expectancy of at least 12 weeks, having confirmed amplification of ErbB2, having received no more than one prior chemotherapy regimen in the metastatic setting, and having normal organ and marrow function. The trial also requires that participants have measurable disease, be able to swallow and retain oral medication, and have a cardiac ejection fraction of at least 50%. The exclusion criteria include having prior therapy with lapatinib or vinorelbine, having more than one line of therapy for treatment of metastatic breast cancer, and having concurrent anticancer or concomitant radiotherapy treatment.",
    "The sample is a phase 2 trial for the treatment of multiple myeloma. The eligibility criteria include written informed consent, age over 18, ECOG performance status of 2 or less, life expectancy of at least 3 months, previous diagnosis of MM, measurable disease, recovery from non-hematological toxicity, and specific laboratory values within 14 days before day 1, cycle 1. Exclusion criteria include prior therapy with Aplidin\u00ae, pregnancy or lactation, history of another neoplastic disease, and other relevant diseases or adverse clinical conditions. The trial drug is Plitidepsin.",
    "The sample is a clinical trial for patients with end stage renal disease, in which they will receive mycophenolate sodium delayed release tablets or mycophenolate mofetil. The trial is a combination of phase 2 and phase 3. The eligibility criteria include being between 18-75 years old, having a negative standard crossmatch for T cells, and having a primary or secondary renal allograft from a living or deceased donor. Patients must also be willing to follow study procedures for 12 months and have signed an informed consent form. Exclusion criteria include having received an organ transplant other than a kidney, having a current malignancy or a history of malignancy within the past 5 years, and having uncontrolled infections or unstable medical conditions. Patients must also be able to take medications orally or via nasogastric tube by the morning of the second day following completion of the transplant procedure.",
    "This sample is for a phase 2 clinical trial for the treatment of schizophrenia. The trial includes the drugs ly2140023, olanzapine, and a placebo. The eligibility criteria for the trial require participants to meet the DSM-IV criteria for schizophrenia as confirmed by modified SCID. However, participants who meet the full syndromal criteria for other Axis I disorder, have taken any depot antipsychotic within 4 weeks before screening, or are taking mood-stabilizing agents are excluded from the trial. The icd-10 codes associated with the disease are also provided.",
    "This is a sample from a clinical trial table. The trial is in phase 2 and is focused on Fabry disease. The eligibility criteria for participants include being female between 18 and 65 years old, having a confirmed diagnosis of Fabry disease with a documented missense gene mutation, having enhanceable enzyme activity based on in vitro tests, being na\u00efve to enzyme replacement therapy (ERT) and other therapies, except for palliative therapies for the signs and symptoms of Fabry disease, or stopped ERT for at least 18 weeks, having end organ dysfunction, even minimal, demonstrated by abnormal electrocardiogram (ECG) or evidence of left ventricular hypertrophy documented by echocardiogram or by cardiac biopsy; or renal insufficiency documented by common clinical assessments such as creatinine and glomerular filtration rate or by renal biopsy; or brain tissue dysfunction as documented by evidence of stroke (clinically or imaging); or peripheral nervous tissue dysfunction documented by complaints of intolerance to heat or cold, decreased vibratory sense and proprioception, decreased ability to perspire, or acroparesthesia. Participants must also be willing to undergo 2 renal and 3 skin biopsies, agree to be sexually abstinent or practice an effective method of contraception when engaging in sexual activity during the course of the study and for a period of 30 days following their completion of the study for women of childbearing potential, and be willing and able to provide written informed consent. Exclusion criteria include being pregnant or lactating, having a history of organ transplant, having a history of significant disease other than Fabry disease, having serum creatinine >176 micromoles/liter on Day -2, having a screening 12-lead ECG demonstrating corrected QT interval >450 milliseconds, having a pacemaker or other contraindication for magnetic resonance imaging scanning, taking a medication prohibited by the protocol, participating in a previous clinical trial in the last 30 days, or having any other condition which, in the opinion of the investigator, would jeopardize the safety of the participant or impact the validity of the study results.",
    "The sample is a phase 2 clinical trial for the treatment of iron deficiency and iron deficiency anemia in patients with stage III to V chronic kidney disease. The trial involves the use of ferric citrate and a placebo drug. The eligibility criteria include specific ranges for serum phosphorus and ferritin levels, as well as transferrin saturation. Patients must also have a hemoglobin level between 9.0 and 12.0 g/dL and consume at least two meals per day. Exclusion criteria include recent parathyroidectomy, gastrointestinal bleed or inflammatory bowel disease, kidney injury or requirement for dialysis, and certain medication requirements. Patients with a history of hemochromatosis, malignancy in the last 5 years, or allergies to iron products are also excluded.",
    "The sample is a phase 2 clinical trial for patients with non-small cell lung cancer who have previously undergone surgery or radiotherapy for their initial disease and have failed one prior platinum-containing chemotherapy regimen for advanced or metastatic disease. The trial is testing the effectiveness of the drug epothilone d. The eligibility criteria include specific disease characteristics, patient characteristics such as age and performance status, and various medical conditions that would preclude study participation. The sample also includes information on prior concurrent therapies that are allowed or not allowed during the trial.",
    "The sample is a phase 2 trial for the treatment of primary open angle glaucoma, ocular hypertension, pigmentary glaucoma, and pseudoexfoliative glaucoma. The trial involves two drugs, pf-03187207 and latanoprost, and their respective vehicles. The eligibility criteria for the trial include a diagnosis of one of the specified eye conditions and the absence of certain exclusion criteria, such as a history of acute angle closure in either eye. The icd-10 codes for the diseases are also provided.",
    "The sample is a phase 2 clinical trial for the treatment of small cell lung cancer using the drugs carboplatin and irinotecan hydrochloride. The eligibility criteria include having histologically or cytologically confirmed extensive stage small cell lung cancer, being newly diagnosed and treatment-naive, having at least one measurable lesion, and meeting certain medical requirements such as normal creatinine levels and no serious cardiovascular disease. Prior concurrent therapy is not specified, and patients must have recovered from any prior surgeries at least two weeks prior to the trial.",
    "The sample is a phase 2 clinical trial for the treatment of diabetic macular edema. The trial includes patients with a confirmed diagnosis of diabetes mellitus and retinal thickening involving the center of the fovea. The study eye must have a foveal thickness of greater than 250, and a best corrected visual acuity score of 20/40 to 20/320 inclusive. The trial will use the drug ranibizumab, and patients must meet certain inclusion and exclusion criteria to participate. Inclusion criteria include signed informed consent, age greater than 18 years, and a diagnosis of diabetic macular edema confirmed by OCT images. Exclusion criteria include previous participation in a study and receipt of anti-angiogenic drugs within 2 months of study entry, and uncontrolled diabetes mellitus.",
    "The sample is a phase 2 clinical trial for patients with coronary disease. The trial involves the use of drugs such as placebo and dabigatran etexilate. The eligibility criteria for the trial include having acute coronary syndromes with at least one additional risk factor for cardiovascular complications. However, patients who have been on long-term treatment with any other oral anticoagulant, have had a severe/disabling stroke within the last 6 months, have conditions associated with increased bleeding risk, anaemia or thrombocytopenia, severe renal impairment, liver disease, or a positive pregnancy test are excluded from the trial. The icd-10 codes associated with the disease are also provided.",
    "The sample is a phase 2 clinical trial for rectal cancer. The trial includes patients with histologically confirmed adenocarcinoma of the rectum that begins within 15cm of the anal verge, with no evidence of distant metastatic disease. The patients must have a clinical stage of T3 or T4 or lymph node positive rectal adenocarcinoma, and their tumor must be K-ras wildtype. The trial involves the use of cetuximab and 5-fluorouracil drugs. The eligibility criteria include having an Eastern Cooperative Oncology Group Performance Score (ECOG PS) less than or equal to 2, being 18 years of age or older, having no evidence of metastatic disease, and having adequate bone marrow, renal, and hepatic function. The patients must also be evaluated by a surgeon and considered a candidate for definitive surgery. The exclusion criteria include prior treatment for this malignancy, prior history of pelvic radiation therapy, prior history of 5-FU based or EGFR receptor inhibitor therapy, prior history of an allergic reaction to a monoclonal antibody, uncontrolled serious medical or psychiatric illness, significant history of uncontrolled cardiac disease, sexually active women of childbearing potential who are unwilling to use an effective method of birth control during the course of the study, and patients who are unwilling to agree to pre and post-cetuximab sigmoidoscopy and biopsy.",
    "The sample is a phase 2 clinical trial for patients with severe sickle hemoglobinopathy, specifically those with Hb SC disease. The trial is open to both male and female patients of all races who are able to swallow the Mg pidolate preparation and have had at least one prior painful crisis. The trial involves the use of two drugs, Mg pidolate and placebo. The eligibility criteria include not having been transfused within 90 days of study entry, not having elevated BUN, creatinine, or liver function tests, not taking magnesium-containing medication on a regular basis, not having progressive neuromuscular disease or being treated with a calcium channel blocker, and not being pregnant.",
    "The sample is a phase 2 clinical trial for the treatment of stable plaque psoriasis using desoximetasone 0.25% spray. The trial includes patients with a definite clinical diagnosis of stable plaque psoriasis with a certain extent of body surface area affected. Patients must also have a Physicians Global Assessment score of 3 or 4 for overall disease severity and normal cortisol response test results. The trial has various exclusion criteria, including pregnancy, other types of psoriasis, unresponsiveness to topical corticosteroid therapy, and other dermatological conditions that may interfere with the assessment of psoriasis symptoms. Patients must not have a history of adverse reactions to corticosteroids or other drugs, and must not have undergone certain types of therapy within a certain timeframe prior to the trial.",
    "The sample is a phase 2 trial for the treatment of advanced renal cell carcinoma. The trial includes patients with clear cell histology and measurable disease. The trial excludes patients who have received prior systemic therapy for advanced renal cell cancer, have a history of brain metastases, or have uncontrolled hypertension. The trial involves the use of two drugs, sunitinib malate continuous daily dosing and sunitinib malate schedule 4/2. The diseases being studied are limited to carcinoma, renal cell. The icd-10 codes associated with the disease are also provided.",
    "The sample is a phase 2 clinical trial for small cell lung carcinoma. The trial includes patients who have had no more than two prior chemotherapy treatments and have progressed after their last treatment. Patients must be between the ages of 18 and 75 and have a life expectancy of at least 3 months. They must also have an ECOG Performance Status of 0-1 and at least one measurable lesion according to modified RECIST criteria. The trial excludes patients who have progressed while on previous chemotherapy, have an active infection, or a known history of HIV positivity. Patients must also have adequate liver and renal functions, and fertile patients must use effective contraception during and for at least 6 weeks after completion of study therapy. The trial also excludes patients with impaired cardiac function, including those with a history of cardiac disease causing LVEF < 45%. Patients with symptomatic or progressive brain metastases, an active bleeding diathesis, or who are pregnant or lactating are also excluded.",
    "The sample is a phase 2 clinical trial for patients with metastatic breast cancer who have previously received chemotherapy with an anthracycline or taxane. The trial is testing the effectiveness of the drug imatinib mesylate in treating the disease. The eligibility criteria include having measurable lesions, adequate tumor tissue available for evaluation, and no known brain metastases. Patients must also meet certain health requirements, such as having normal bilirubin and creatinine levels, and no ongoing or active infections. Additionally, patients must not have any other concurrent anticancer therapy or be taking certain foods or drinks.",
    "The sample is a phase 2 clinical trial for asthma. The eligibility criteria include being 12 years or older, having a diagnosis of asthma as defined by the National Institutes of Health, and having a best forced expiratory volume in one second (FEV1) of 40%-85% of the predicted normal value during the Screening Visit. The trial also requires subjects to be on a short-acting \u03b22 agonist and inhaled corticosteroid for a minimum of 8 weeks before the Screening Visit and have been maintained on a stable dose of inhaled corticosteroids for four weeks prior to the Screening Visit. The exclusion criteria include having a history of life-threatening asthma, any asthma exacerbation requiring oral corticosteroids within 1 month of the Screening Visit, and having any of the following conditions that might cause participation in this study to be detrimental to the subject, including, but not limited to: cardiovascular, hepatic, renal, hematological, neuropsychological, endocrine, gastrointestinal, or pulmonary diseases. The trial also excludes subjects with a history of a positive test for HIV, hepatitis B or hepatitis C infection, and those with a history of severe allergy to milk protein.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on the disease of atrial fibrillation and includes a list of ICD-10 codes associated with the disease. The trial involves two drugs, ym150 and warfarin. The eligibility criteria for the trial are listed, including requirements for the subject's age, INR levels, and aPTT levels. The exclusion criteria are also listed, including a history of heart valve disorders, rheumatic fever, stroke, and other conditions that may increase the risk of bleeding. The sample also includes a section on written informed consent.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on the disease of asthma and includes a list of ICD-10 codes associated with the disease. The trial involves the use of several drugs, including amg 827 and a placebo. The eligibility criteria for the trial include being between the ages of 18 and 65, having a certain level of lung function, and ongoing asthma symptoms. The exclusion criteria include recent respiratory infections, other chronic pulmonary conditions, and uncontrolled systemic diseases.",
    "The sample is a phase 2 clinical trial for the treatment of medullary thyroid carcinoma. The trial includes patients who are 18 years or older and have confirmed medullary thyroid carcinoma with recurrent or persistent local disease and/or distant metastases. Patients must have had no more than one prior line of systemic therapy and must be receiving the best available supportive care to control symptoms. The trial also requires patients to meet certain criteria, including having at least one defined lesion in CT or MRI evaluable for Response Evaluation Criteria in Solid Tumors (RECIST v1.1), or at least one defined lesion in CT or MRI not evaluable by RECIST in combination with elevated tumour markers. Patients must also have had progression within the previous 12 months and meet certain health criteria, such as having a hemoglobin level above 8g/dl and sufficient renal function. The trial has exclusion criteria, such as patients with unresolved toxicity attributed to any prior therapy higher than National Cancer Institute-Common Toxicity Criteria for Adverse Effects (NCI-CTCAE version 4) Grade 2, patients with significant cardiovascular disease, and pregnant or breastfeeding patients.",
    "The sample is a phase 2 clinical trial for patients with metastatic breast cancer. The trial involves the drug trastuzumab emtansine (kadcyla) and has specific eligibility criteria that include having HER2-positive disease, disease progression on the last chemotherapy regimen received in the metastatic setting, and prior treatment with at least two lines of therapy in the metastatic setting. The trial also has exclusion criteria, such as recent chemotherapy or hormone therapy, history of intolerance to trastuzumab or murine proteins, and current pregnancy or lactation. The sample includes a detailed list of inclusion and exclusion criteria for the trial.",
    "The sample is a phase 2 clinical trial for lupus nephritis, a disease affecting the kidneys in patients with systemic lupus erythematosus (SLE). The trial is testing the effectiveness of cyclophosphamide, a drug used to suppress the immune system, in treating lupus nephritis. The eligibility criteria for the trial include patients who are between 16 and 65 years old, have a SLEDAI score greater than 8 or a BILAG score of A/B, and have newly diagnosed WHO Class III or IV Lupus Nephritis. Exclusion criteria include pregnant or nursing women, those who have participated in any research involving an investigational product within 30 days prior to screening, and those with certain medical conditions or disabilities that would interfere with treatment or assessment.",
    "The sample is a phase 2 clinical trial for patients with kidney cancer that is metastatic or unresectable. The trial is testing the effectiveness of the drug sorafenib. Patients must have a confirmed diagnosis of renal cell carcinoma with a component of conventional clear cell RCC. They must also meet certain eligibility criteria, including having a Karnofsky performance status of 70-100%, no evidence of CNS metastases, and meeting certain laboratory values. Patients must not have had more than one prior systemic therapy for RCC and no prior vascular endothelial growth factor receptor agents. They must also not be receiving concurrent full-dose oral or parenteral anticoagulation or hormonal therapy or chemotherapy.",
    "The sample is a clinical trial for patients with various types of indolent B-cell non-Hodgkin lymphoma, including marginal zone lymphoma, lymphoplasmacytic lymphoma, follicular lymphoma, and mantle cell lymphoma. The trial is in phase 1/phase 2 and involves the use of two drugs, bendamustine hydrochloride and obatoclax mesylate. The eligibility criteria include having received at least one prior therapy, having a certain level of blood counts and liver and kidney function, and not having certain medical conditions or taking certain medications. Patients with HIV are allowed to participate if they meet certain criteria. The trial also allows patients who have relapsed after stem cell transplantation.",
    "The sample is a clinical trial for patients with non-small-cell lung carcinoma. The trial is in phase 1/phase 2 and involves the use of drugs such as pemetrexed, carboplatin, and sorafenib. The eligibility criteria include having confirmed NSCLC, no prior systemic chemotherapy, and adequate bone marrow, renal, and hepatic function. Patients must also have measurable disease and be at least 18 years old with an ECOG performance score of 0-1. Exclusion criteria include any prior systemic anticancer therapy, cardiac disease, uncontrolled hypertension, and known HIV infection or chronic hepatitis B or C. Patients must also be willing to use adequate contraception and sign informed consent prior to any study-specific procedures.",
    "The sample is a phase 2 clinical trial for the treatment of diabetic macular edema. The trial involves the use of two drugs, dexamethasone and sham injection. The eligibility criteria for the trial include being 18 years or older with diabetic macular edema, a decrease in visual acuity in at least one eye as a result of macular edema (20/50 or worse), and visual acuity in the other eye no worse than 20/200. The exclusion criteria include a known anticipated need for ocular surgery within the next 12 months, a history of glaucoma or current high eye pressure requiring more than 1 medication, uncontrolled systemic disease, known steroid-responder, use of systemic steroids, and use of Warfarin/Heparin.",
    "The sample is a phase 2 trial for the treatment of Clostridium Difficile-associated diarrhea (CDAD). The trial includes patients who are at least 18 years old and have been diagnosed with CDAD for the first time or have experienced a first recurrence. The trial involves the use of drugs such as cadazolid, vancomycin, and placebo-matching cadazolid and vancomycin. The eligibility criteria include being male or female and not having any concurrent life-threatening conditions or being immunocompromised. Additionally, patients cannot be receiving concomitant antimicrobial treatment for CDAD and must be able to fully participate in the study and comply with the protocol.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on gallbladder cancer and the icd-10 codes associated with it. The drug being tested is irinotecan hydrochloride. The eligibility criteria for participants include having a histologically or cytologically proven gallbladder or bile duct carcinoma with metastatic or recurrent disease deemed unresectable and not considered a candidate for potentially curative therapy. Participants must also have measurable or evaluable disease and meet certain health criteria such as having a certain level of neutrophils and platelets, as well as no active CNS disease. The sample also includes information on prior concurrent therapy and other medical conditions that may affect eligibility.",
    "The sample is a clinical trial for patients with moderate-severe chronic obstructive pulmonary disease (COPD). The trial is in phase 1/phase 2 and involves the use of drugs such as glycopyrrolate, tiotropium, and placebo. The eligibility criteria include being between the ages of 40-75, having a smoking history of at least 10 pack-years, and having a post bronchodilator FEV1 between 40% and 80% predicted values. The trial also has exclusion criteria such as a history of chronic or seasonal allergy, significant lung diseases, and intolerance/hypersensitivity to the treatment. The trial requires written informed consent and the use of an acceptable method of contraception for female or male subjects.",
    "The sample is a phase 2 clinical trial for obesity. The eligibility criteria include being between 18 and 60 years old, having a body mass index of 30 or higher, and having a Binge Eating Scale score of 19 or higher. Participants must also be right-handed and have certain liver function test results within normal limits. Exclusion criteria include a history of eating disorders, certain psychiatric disorders, substance abuse, and certain medical conditions. Participants must not be pregnant or lactating, and must not have certain medical devices or metal foreign bodies in their body. They must also not have certain dietary requirements or be planning to start a calorie-controlled diet or major exercise routine.",
    "The sample is a clinical trial for a drug called idx719 and a placebo for the treatment of chronic hepatitis C. The trial is in phase 1/phase 2 and the participants must have documented GT1, GT2, or GT3 chronic HCV infection. The eligibility criteria include being in good general health, agreeing to use double-barrier method of birth control for at least 90 days after the last dose of study drugs, and not being pregnant or breastfeeding. Exclusion criteria include having received prior HCV treatment and being co-infected with hepatitis B virus (HBV) and/or human immunodeficiency virus (HIV). The diseases and their corresponding ICD-10 codes are listed as well.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on the disease of functional dyspepsia, which is identified by the ICD-10 code K30. The trial involves the use of the drugs rabeprazole and placebo. The eligibility criteria for the trial include a diagnosis of functional dyspepsia according to Rome III criteria, while exclusion criteria include neuropsychiatric disorders, irritable bowel syndrome, inflammatory bowel disease, and serious constipation.",
    "The sample is a phase 2 clinical trial for patients with squamous cell carcinoma of the head and neck or human papilloma virus. The trial involves the use of drugs such as docetaxel, cisplatin, 5-fu, cetuximab, and carboplatin. The eligibility criteria include having stage 3 or 4 disease without evidence of distant metastases, being 18 years or older, having no previous surgery, radiation therapy or chemotherapy for SSCHN, having an ECOG Performance Status of 0 or 1, and having adequate bone marrow, hepatic and renal function. Exclusion criteria include being pregnant or breastfeeding, having previous or current malignancies at other sites, experiencing an involuntary weight loss of more than 25% of their body weight in the 2 months preceding study entry, and participating in an investigational trial within 30 days of study entry.",
    "The sample is a phase 2 clinical trial for the treatment of type 1 diabetes mellitus. The trial involves the use of the drug dapagliflozin and a placebo that matches dapagliflozin. The eligibility criteria for the trial include having type 1 diabetes with a central lab Glycosylated hemoglobin (A1C) level between 7.0% and 10.0%, using insulin for at least 12 months, having a stable method of insulin administration for at least 3 months, having a stable basal insulin dose for at least 2 weeks, being between the ages of 18 and 65, having a central laboratory C-peptide value of less than 0.7 ng/mL, and having a body mass index (BMI) between 18.5 and 35.0 kg/m2. The exclusion criteria include having a history of type 2 diabetes mellitus (T2DM), maturity onset diabetes of young (MODY), pancreatic surgery, or chronic pancreatitis, taking oral hypoglycemic agents, having a history of diabetes ketoacidosis (DKA) within 24 weeks, having a history of hospital admission for glycemic control within 6 months, experiencing frequent episodes of hypoglycemia or hypoglycemic unawareness, having abnormal liver function tests or abnormal thyroid function tests, having an estimated glomerular filtration rate (eGFR) of less than or equal to 60 mL/min/1.73m2, or having cardiovascular or vascular diseases within 6 months.",
    "The sample is a phase 2 trial for various myeloid malignancies, including chronic myelogenous leukemia, acute myeloid leukemia, myelodysplastic syndromes, and other myeloproliferative disorders. The trial requires a matched related or unrelated donor with specific HLA markers. Patients must meet certain criteria, including no severe life-limiting diseases, normal AST and creatinine levels, no cardiac or coronary artery disease, and adequate oxygen levels. Patients must also be HIV negative, not pregnant or nursing, and use effective contraception if fertile. The trial involves the use of busulfan, fludarabine phosphate, methotrexate, and tacrolimus, and excludes the use of post-transplantation growth factors during methotrexate administration.",
    "The sample is a phase 2 clinical trial for patients with unresectable and/or metastatic, measurable predominantly clear cell renal cell carcinoma. The trial is testing the effectiveness of the drug regorafenib (also known as stivarga or bay73-4506) on previously untreated patients with advanced disease. The eligibility criteria include being male or female patients over 18 years of age, having at least one measurable lesion by CT-scan or MRI, having an Eastern Co-operative Oncology Group (ECOG) performance status of 0 or 1, and having adequate bone marrow, renal and hepatic function. Exclusion criteria include having received prior systemic treatment regimens for RCC, uncontrolled/unstable cardiac disease, uncontrolled hypertension, active clinically serious infections, history of HIV infection or chronic hepatitis B or C, known history or symptomatic metastatic brain or meningeal tumors, seizure disorder requiring medication, evidence or history of bleeding diathesis, and being pregnant or breast-feeding.",
    "The sample is a phase 2 clinical trial for patients with recurrent small cell lung cancer. The trial involves the use of two drugs, 13-cis-retinoic acid and paclitaxel. The eligibility criteria include confirmation of the disease, age over 18, specific blood counts and liver function, prior chemotherapy treatment for SCLC, and the use of contraception for sexually active patients. Exclusion criteria include a history of other neoplasms, pregnancy or nursing, severe depression, recent use of certain drugs, prior paclitaxel or interferon therapy, recent radiation or chemotherapy treatment, and recent use of GM-CSF or G-CSF.",
    "The sample is a phase 2 clinical trial for the treatment of chronic hepatitis C. The trial involves the use of drugs such as vaniprevir, pegylated interferon, ribavirin, and placebo. The eligibility criteria for the trial include having chronic HCV genotype 1 infection, being treatment-experienced, and having a liver biopsy without evidence of cirrhosis and hepatocellular carcinoma for the non-cirrhotic population, or having a liver biopsy with evidence of cirrhosis and without evidence of hepatocellular carcinoma for the cirrhotic population. Exclusion criteria include not tolerating previous courses of peg-IFN and RBV, being co-infected with HIV and/or hepatitis B, consuming excessive amounts of alcohol, having a history of drug or alcohol abuse, being pregnant or breastfeeding if female, having been in a clinical trial with an investigational drug in the last 30 days, and having used IFN/Peg-IFN and RBV in the last 3 months.",
    "The sample is a phase 2 clinical trial for patients with type 2 diabetes mellitus who have been on stable metformin treatment for at least 3 months. The trial includes a placebo and three different doses of taspoglutide as drugs. The eligibility criteria include being male or post-menopausal/surgically sterilized female between the ages of 18-75, having an HbA1c level between 7.0% and 9.5% at screening, and having a stable weight for at least 3 months prior to screening. Exclusion criteria include having type 1 diabetes, clinically significant gastrointestinal disease, using any anti-hyperglycemic medication other than metformin monotherapy in the last 3 months, using weight-lowering medications in the last 3 months, having uncontrolled hypertension, or having previous exposure to GLP-1 or GLP-1 analogues.",
    "The sample is a clinical trial for Huntington's disease, in which the phase is a combination of phase 2 and phase 3. The trial involves testing the effectiveness of three different doses of a drug called ACR16 (10mg, 22.5mg, and 45mg) on patients with Huntington's disease. The eligibility criteria for the trial include having clinical features of Huntington's disease, a positive family history and/or the presence of \u2265 36 CAG repeats in the Huntington gene, being male or female age \u2265 30 years, being able to take oral medication and comply with study procedures, being ambulatory and able to travel to the assessment center, having a caregiver or family member to accompany the subject to two visits, and having a sum of \u2265 10 points on the mMS at the screening visit. The exclusion criteria include treatment with certain medications, use of investigational products, certain medical conditions, and previous participation in a clinical study with ACR16.",
    "The sample is a record of a clinical trial that is in phase 2/phase 3. The trial is focused on macular edema associated with diabetes mellitus. The icd-10 codes associated with the disease are listed. The trial involves the use of two drugs, standard of care and macugen. The eligibility criteria for the trial are also listed, including inclusion criteria such as having macular edema associated with diabetes and a visual acuity between 20/50 and 20/200, and exclusion criteria such as recent laser therapy in the eye, recent signs of uncontrolled diabetes, blood pressure worse than 160/100, and severe cardiac disease.",
    "The sample is a clinical trial for impetigo, a skin infection. The trial is in phase 2/phase 3 and involves testing experimental and placebo topical gels containing cd07223. The eligibility criteria for participants include having a clinical diagnosis of primary impetigo, having at least one and no more than ten lesions, and having a Skin Infection Rating Scale (SIRS) total score of the Target Lesion of at least 4. Exclusion criteria include having other active skin diseases, requiring oral antibiotic treatment, having signs and symptoms of another current infection requiring antibiotic treatment, and having a history of Hepatitis B or C, HIV/AIDS, or other immunodeficiency disease. Participants must not have used systemic antibiotics or systemic steroids within 14 days prior to study entry, and must not have used topical antibiotics, topical antibacterials, topical antifungals or topical steroids within 14 days prior to study entry on any skin lesion. They must not have participated in any other clinical study or used any investigational drugs or investigational device within 30 days prior to enrollment.",
    "The sample is a record from a clinical trial table that includes information about the phase of the trial (phase 2/phase 3), a list of diseases (in this case, only one disease is listed - benign prostatic hypertrophy), a list of ICD-10 codes associated with the disease, a list of drugs being tested (ozarelix/placebo and placebo), and eligibility criteria for participants. The eligibility criteria include questions related to age, symptoms, urinary flow rate, and willingness to avoid other BPH treatments during the study. Exclusion criteria include a history of prostate cancer or high PSA levels, prior surgeries or radiation, and certain medication use.",
    "The sample is a clinical trial for patients with schizophrenia and cognitive effects. The trial is in phase 2/phase 3 and involves the drugs cyp-1020 and risperidone. The eligibility criteria include being between 18-50 years old, exhibiting symptoms of schizophrenia for at least one year but not more than 20 years, and currently experiencing an acute exacerbation of schizophrenia. The trial also requires a sufficient clinical response to at least one previous course of an anti-psychotic agent prescribed at a generally recognized therapeutic dose. The exclusion criteria include being pregnant or breastfeeding, having symptoms of schizophrenia for more than 20 years, and having a history of neuroleptic malignant syndrome. The trial also excludes patients with certain medical conditions or allergies to the drugs being tested.",
    "The sample is a record of a clinical trial with a phase 2/phase 3 designation. The trial is focused on breast cancer and includes a list of ICD-10 codes for related diseases. The trial involves the use of two drugs, capecitabine and hormonal treatment (tamoxifen, exemestane, anastrozole or letrozole). The eligibility criteria for the trial include having infiltrating breast cancer with distant metastases or inoperable locally advanced disease, a positive estrogen receptor, and having experienced progressive disease during first line hormonal therapy or recurrence of disease during adjuvant hormonal therapy. The sample also includes exclusion criteria such as having other malignancies, being pregnant or breastfeeding, having contra-indications to the use of capecitabine, and having known CNS metastases.",
    "The sample is a clinical trial for patients with acute myelogenous leukemia in either first or subsequent complete remission. The trial is in phase 2/phase 3 and the drug being tested is decitabine. The eligibility criteria include having unfavorable risk cytogenetics, a performance status of 0-2, and adequate organ function. Patients who have received any appropriate salvage regimen before achieving complete remission may also be included. Exclusion criteria include being pregnant or lactating, having active and uncontrolled disease/infection, and having received other investigational therapy within the past 14 days.",
    "The sample is a record of a clinical trial for the treatment of glaucoma. The trial is in phase 2/phase 3 and the disease being studied is glaucoma. The icd-10 codes associated with the disease are listed. The drugs being tested are ranibizumab and mitomycin (mmc). The eligibility criteria for the trial are listed, including age, previous surgeries, and current infections or inflammation. The sample also includes exclusion criteria, such as being enrolled in another investigational study or having an abnormality preventing reliable applanation tonometry in each eye.",
    "The sample is a clinical trial for metastatic colorectal cancer patients in phase 2/phase 3. The trial involves the use of three drugs, mitomycin c, capecitabine, and bevacizumab. The eligibility criteria include having a histological diagnosis of colorectal cancer, having metastatic disease that is not resectable, being over 18 years old, having measurable and/or non-measurable disease as assessed by CT scan, and having an ECOG performance status of 0, 1, or 2. Patients must also meet certain requirements for bone marrow, renal, and hepatic function, and have a life expectancy of at least 12 weeks. Exclusion criteria include having certain medical or psychiatric conditions, uncontrolled hypertension, active bleeding disorders, and recent major surgical procedures. Women and partners of women of childbearing potential must agree to use adequate contraception, and written informed consent is required.",
    "The sample is a clinical trial for a drug called tipranavir, which is being tested on individuals with HIV infections. The trial is in phase 2/phase 3 and the eligibility criteria include being 18 years or older, having completed a previous tipranavir/ritonavir trial or having confirmed virologic failure in previous trials, and having acceptable screening laboratory values indicating adequate baseline organ function. The exclusion criteria include being pregnant or breastfeeding, actively using injection drugs or other substance abuse, having any medical condition that would interfere with participation in the trial, having a history of illness or drug allergy that might confound the results of the study, and having active use of certain medications or herbal medications.",
    "The sample is a clinical trial for the treatment of hepatocellular carcinoma, a type of liver cancer. The trial is in phase 2/phase 3 and involves the use of the drugs menatetrenone and placebo. The eligibility criteria include being 20 years or older, having a performance status score of 0-2, and having a diagnosis of hepatocellular carcinoma confirmed through imaging or biopsy. Patients must also have undergone local therapy or surgical treatment within 90 days prior to registration and meet certain liver function criteria. Exclusion criteria include having extrahepatic metastasis or portal invasion, being unable to receive oral administration, and having a history of drug allergy to the study drugs. Women who are pregnant, lactating, or of childbearing potential are also excluded.",
    "The sample is a record from a clinical trial table that includes information about the phase of the trial, diseases being studied, icd-10 codes of the diseases, drugs being tested, and eligibility criteria for participants. In this particular sample, the trial is in phase 2/phase 3 and is studying early Parkinson's disease. The icd-10 code for Parkinson's disease is \"G20\". The drugs being tested are \"spm 962\" and \"placebo\". The eligibility criteria for participants include being diagnosed with Parkinson's disease, being between the ages of 30 and 80, having a Hoehn & Yahr stage of 1-3, and having a total sum score of UPDRS Part 2 and 3 over 10 at screening. There are also exclusion criteria, such as having previously participated in a trial with SPM 962, being on L-dopa treatment for over 6 months, having psychiatric symptoms, and having a history of epilepsy or serious cardiac disorder/arrhythmia.",
    "The sample is a clinical trial for a drug treatment for chronic obstructive pulmonary disease (COPD) in adults aged 40 years and above. The trial is in phase 2/phase 3 and involves several drugs, including indacaterol, formoterol, tiotropium, and placebos. The trial has inclusion criteria such as a smoking history of at least 20 pack years, post-bronchodilator FEV1 < 80% and \u2265 30% of the predicted normal value, and post-bronchodilator FEV1/FVC < 70%. Exclusion criteria include pregnancy or lactation, hospitalization for a COPD exacerbation in the 6 weeks prior to the trial, and a history of asthma or Type I or uncontrolled Type II diabetes. Other protocol-defined inclusion/exclusion criteria may also apply."
]